0001603756-22-000031.txt : 20220506 0001603756-22-000031.hdr.sgml : 20220506 20220505163217 ACCESSION NUMBER: 0001603756-22-000031 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220505 DATE AS OF CHANGE: 20220505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Axonics, Inc. CENTRAL INDEX KEY: 0001603756 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 454744083 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38721 FILM NUMBER: 22896920 BUSINESS ADDRESS: STREET 1: 26 TECHNOLOGY DRIVE CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-396-6322 MAIL ADDRESS: STREET 1: 26 TECHNOLOGY DRIVE CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: Axonics Modulation Technologies, Inc. DATE OF NAME CHANGE: 20140326 10-Q 1 axnx-20220331.htm 10-Q axnx-20220331
false2022Q10001603756December 31P3YP3YP3Y000016037562022-01-012022-03-3100016037562022-05-03xbrli:shares00016037562022-03-31iso4217:USD00016037562021-12-31iso4217:USDxbrli:shares00016037562021-01-012021-03-310001603756us-gaap:CommonStockMember2021-12-310001603756us-gaap:AdditionalPaidInCapitalMember2021-12-310001603756us-gaap:RetainedEarningsMember2021-12-310001603756us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001603756us-gaap:CommonStockMember2022-01-012022-03-310001603756us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001603756us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001603756us-gaap:RetainedEarningsMember2022-01-012022-03-310001603756us-gaap:CommonStockMember2022-03-310001603756us-gaap:AdditionalPaidInCapitalMember2022-03-310001603756us-gaap:RetainedEarningsMember2022-03-310001603756us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001603756us-gaap:CommonStockMember2020-12-310001603756us-gaap:AdditionalPaidInCapitalMember2020-12-310001603756us-gaap:RetainedEarningsMember2020-12-310001603756us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100016037562020-12-310001603756us-gaap:CommonStockMember2021-01-012021-03-310001603756us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001603756us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001603756us-gaap:RetainedEarningsMember2021-01-012021-03-310001603756us-gaap:CommonStockMember2021-03-310001603756us-gaap:AdditionalPaidInCapitalMember2021-03-310001603756us-gaap:RetainedEarningsMember2021-03-310001603756us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100016037562021-03-310001603756axnx:FollowonOfferingMember2021-05-142021-05-140001603756axnx:FollowonOfferingMember2021-05-140001603756us-gaap:OverAllotmentOptionMember2021-05-142021-05-140001603756axnx:SacralNeuromodulationMembercountry:US2022-01-012022-03-310001603756axnx:SacralNeuromodulationMembercountry:US2021-01-012021-03-310001603756us-gaap:NonUsMemberaxnx:SacralNeuromodulationMember2022-01-012022-03-310001603756us-gaap:NonUsMemberaxnx:SacralNeuromodulationMember2021-01-012021-03-310001603756axnx:SacralNeuromodulationMember2022-01-012022-03-310001603756axnx:SacralNeuromodulationMember2021-01-012021-03-310001603756axnx:BulkamidMembercountry:US2022-01-012022-03-310001603756axnx:BulkamidMembercountry:US2021-01-012021-03-310001603756axnx:BulkamidMemberus-gaap:NonUsMember2022-01-012022-03-310001603756axnx:BulkamidMemberus-gaap:NonUsMember2021-01-012021-03-310001603756axnx:BulkamidMember2022-01-012022-03-310001603756axnx:BulkamidMember2021-01-012021-03-310001603756axnx:ConturaLimitedMemberaxnx:ContingentConsiderationLiabilityMember2022-03-310001603756axnx:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001603756axnx:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001603756axnx:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-03-310001603756axnx:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-03-310001603756axnx:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001603756axnx:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001603756srt:MinimumMember2022-01-012022-03-310001603756srt:MaximumMember2022-01-012022-03-310001603756us-gaap:PreferredStockMemberus-gaap:PatentsMember2013-01-012013-12-310001603756us-gaap:PatentsMember2013-01-012013-12-310001603756us-gaap:PatentsMember2022-01-012022-03-310001603756us-gaap:CommonStockMemberaxnx:ExclusiveLicenseAssetMember2021-03-022021-03-020001603756axnx:ExclusiveLicenseAssetMember2021-03-022021-03-020001603756axnx:ExclusiveLicenseAssetMember2021-03-020001603756axnx:ExclusiveLicenseAssetMember2022-01-012022-03-310001603756axnx:ExclusiveLicenseAssetMember2021-01-012021-03-310001603756axnx:ConturaLimitedMember2022-01-012022-03-310001603756axnx:ConturaLimitedMember2021-01-012021-03-310001603756axnx:EmployeeStockOptionandRestrictedStockBasedAwardsMembersrt:MinimumMember2022-01-012022-03-310001603756srt:MaximumMemberaxnx:EmployeeStockOptionandRestrictedStockBasedAwardsMember2022-01-012022-03-310001603756us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-31axnx:segment0001603756us-gaap:EquipmentMember2022-03-310001603756us-gaap:EquipmentMember2021-12-310001603756us-gaap:ComputerEquipmentMember2022-03-310001603756us-gaap:ComputerEquipmentMember2021-12-310001603756us-gaap:ToolsDiesAndMoldsMember2022-03-310001603756us-gaap:ToolsDiesAndMoldsMember2021-12-310001603756us-gaap:LeaseholdImprovementsMember2022-03-310001603756us-gaap:LeaseholdImprovementsMember2021-12-310001603756us-gaap:FurnitureAndFixturesMember2022-03-310001603756us-gaap:FurnitureAndFixturesMember2021-12-310001603756us-gaap:ConstructionInProgressMember2022-03-310001603756us-gaap:ConstructionInProgressMember2021-12-310001603756us-gaap:PropertyPlantAndEquipmentMember2022-01-012022-03-310001603756us-gaap:PropertyPlantAndEquipmentMember2021-01-012021-03-310001603756axnx:Lease1Member2014-08-31utr:sqft0001603756axnx:Lease2Member2017-11-300001603756axnx:Lease3Member2019-06-300001603756axnx:Lease4Member2020-08-31xbrli:pure0001603756srt:MaximumMember2022-03-310001603756axnx:MedtronicLitigationMember2020-03-162020-03-16axnx:petition0001603756axnx:MedtronicLitigationMember2020-09-302020-09-300001603756us-gaap:LoansPayableMemberaxnx:TermLoanTwoMember2021-06-300001603756us-gaap:LoansPayableMemberaxnx:TermLoanTwoMember2021-06-012021-06-300001603756axnx:TermLoanOneMemberus-gaap:LoansPayableMember2021-01-310001603756axnx:TermLoanOneMemberus-gaap:LoansPayableMember2021-01-012021-01-310001603756us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001603756us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001603756us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001603756us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-310001603756us-gaap:SellingAndMarketingExpenseMember2022-01-012022-03-310001603756us-gaap:SellingAndMarketingExpenseMember2021-01-012021-03-310001603756srt:MinimumMember2021-01-012021-03-310001603756srt:MaximumMember2021-01-012021-03-310001603756us-gaap:EmployeeStockOptionMember2022-03-310001603756us-gaap:EmployeeStockOptionMember2021-12-310001603756us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001603756us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001603756us-gaap:RestrictedStockMember2022-03-310001603756us-gaap:RestrictedStockMember2021-12-310001603756us-gaap:RestrictedStockMember2022-01-012022-03-310001603756us-gaap:RestrictedStockMember2021-01-012021-12-310001603756us-gaap:RestrictedStockUnitsRSUMember2022-03-310001603756us-gaap:RestrictedStockUnitsRSUMember2021-12-310001603756us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001603756us-gaap:DomesticCountryMember2021-12-310001603756us-gaap:ForeignCountryMember2021-12-310001603756us-gaap:StateAndLocalJurisdictionMember2021-12-310001603756us-gaap:PatentsMember2022-03-310001603756axnx:ExclusiveLicenseAssetMember2022-03-310001603756us-gaap:TechnologyBasedIntangibleAssetsMember2022-01-012022-03-310001603756us-gaap:TechnologyBasedIntangibleAssetsMember2022-03-310001603756us-gaap:TrademarksAndTradeNamesMember2022-03-310001603756us-gaap:CustomerRelationshipsMember2022-01-012022-03-310001603756us-gaap:CustomerRelationshipsMember2022-03-310001603756us-gaap:PatentsMember2021-01-012021-12-310001603756us-gaap:PatentsMember2021-12-310001603756axnx:ExclusiveLicenseAssetMember2021-01-012021-12-310001603756axnx:ExclusiveLicenseAssetMember2021-12-310001603756us-gaap:TechnologyBasedIntangibleAssetsMember2021-01-012021-12-310001603756us-gaap:TechnologyBasedIntangibleAssetsMember2021-12-310001603756us-gaap:TrademarksAndTradeNamesMember2021-12-310001603756us-gaap:CustomerRelationshipsMember2021-01-012021-12-310001603756us-gaap:CustomerRelationshipsMember2021-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________________________________
FORM 10-Q
_________________________________________________________________
(Mark One)
        QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2022
or
        TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to ___________
Commission File Number: 001-38721
_________________________________________________________________
Axonics, Inc.
(Exact name of registrant as specified in its charter)
_________________________________________________________________
Delaware45-4744083
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
26 Technology Drive
Irvine,California92618
(Address of principal executive offices)(Zip Code)
(949)396-6322
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of classTrading symbolName of exchange on which registered
Common stock, par value $0.0001 per shareAXNXNasdaq Global Select Market
    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes      No 
    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes     No 
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes   No 
As of May 3, 2022, 47,070,097 shares of the registrant’s common stock, par value $0.0001 per share, were outstanding.



TABLE OF CONTENTS
Page


Special Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), that involve risks and uncertainties, including statements based on our current expectations, assumptions, estimates and projections about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, or other comparable terms intended to identify statements about the future. Forward-looking statements include, but are not limited to, statements about:
unanticipated safety concerns related to the use of our products;
U.S. Food and Drug Administration (FDA) or other U.S. or foreign regulatory or legal actions or changes affecting us or our industry;
the results of any ongoing or future legal proceedings, including but not limited to intellectual property, product liability or other litigation against us, our third-party manufacturers or other parties on which we rely or litigation against our general industry;
any termination or loss of intellectual property rights;
any voluntary or regulatory mandated product recalls;
adverse developments concerning our manufacturers or suppliers or any future strategic partnerships;
introductions and announcements of new technologies by us, any commercialization partners or our competitors, and the timing of these introductions and announcements;
successful integration of acquired operations into our ongoing business;
announcements of regulatory approval or disapproval of our products and any future enhancements to our products;
adverse results from or delays in clinical studies of our products;
variations in our financial results or those of companies that are perceived to be similar to us;
success or failure of competitive products or therapies in the markets in which we do business;
changes in the structure of healthcare payment of our products;
announcements by us or our competitors of significant acquisitions, licenses, strategic partnerships, joint ventures or capital commitments;
economic and market conditions in general and in the medical technology industry, specifically, including the size and growth, if any, of the market, and issuance of securities analysts’ reports or recommendations;
rumors and market speculation involving us or other companies in our industry;
sales of substantial amounts of our stock by directors, officers or significant stockholders, or the expectation that such sales might occur;
additions or departures of key personnel;
changes in our capital structure, such as future issuances of securities and the incurrence of additional debt;
the continued impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government and consumers on our business, financial condition and results of operations; and
reduction or interruption in our supply chain.


The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control. As such, our actual results may differ significantly from those expressed in any forward-looking statements. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of Part I and Item 1A “Risk Factors” of Part II of this Quarterly Report on Form 10-Q. Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission (SEC). In light of the significant risks and uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should read this Quarterly Report on Form 10-Q and the documents we file with the SEC, with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.
Unless the context indicates otherwise, as used in this Quarterly Report on Form 10-Q, the terms “Axonics,” “our company,” “we,” “us” and “our” refer to Axonics, Inc. and our consolidated subsidiaries.
This Quarterly Report on Form 10-Q includes our trademarks and trade names, including, without limitation, r-SNM®, Axonics SNM System® and Bulkamid®, which are our property and are protected under applicable intellectual property laws. This Quarterly Report on Form 10-Q also includes trademarks and trade names that are the property of other organizations. Solely for convenience, trademarks and trade names referred to in this Quarterly Report on Form 10-Q appear without the ® and ™ symbols, but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.


Part IFinancial Information
Item 1.    Condensed Consolidated Financial Statements (unaudited)
Axonics, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
March 31,December 31,
20222021
(unaudited)
ASSETS
Current assets
Cash and cash equivalents$213,180 $220,878 
Accounts receivable, net of allowance for credit losses of $316 and $355 at March 31, 2022 and December 31, 2021, respectively
27,425 29,044 
Inventory, net61,876 64,946 
Prepaid expenses and other current assets4,952 6,449 
Total current assets307,433 321,317 
Property and equipment, net6,907 6,915 
Intangible assets, net101,179 106,469 
Other assets7,494 7,734 
Goodwill102,558 105,510 
Total assets$525,571 $547,945 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable$10,390 $7,654 
Accrued liabilities6,246 5,435 
Accrued compensation and benefits7,480 12,413 
Operating lease liability, current portion1,403 1,366 
Total current liabilities25,519 26,868 
Operating lease liability, net of current portion8,686 9,052 
Deferred tax liabilities, net17,564 19,217 
Other long-term liabilities10,370 10,370 
Total liabilities62,139 65,507 
Commitments and contingencies (Note 3)
Stockholders’ equity
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2022 and December 31, 2021
  
Common stock, par value $0.0001, 50,000,000 shares authorized at March 31, 2022 and December 31, 2021; 47,002,862 and 46,330,167 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively
5 5 
Additional paid-in capital812,141 803,559 
Accumulated deficit(337,234)(314,566)
Accumulated other comprehensive loss(11,480)(6,560)
Total stockholders’ equity463,432 482,438 
Total liabilities and stockholders’ equity$525,571 $547,945 
See accompanying notes to unaudited condensed consolidated financial statements.
1

Axonics, Inc.
Condensed Consolidated Statements of Comprehensive Loss
(in thousands, except share and per share data)
(unaudited)
Three Months Ended
March 31,
20222021
Net revenue$48,420 $34,373 
Cost of goods sold15,178 13,974 
Gross profit33,242 20,399 
Operating expenses
Research and development11,236 9,369 
General and administrative10,013 6,626 
Sales and marketing33,063 20,928 
Amortization of intangible assets2,463 678 
Acquisition-related costs 4,414 
Total operating expenses56,775 42,015 
Loss from operations(23,533)(21,616)
Other income (expense)
Interest income43 8 
Interest and other expense(289)(1,450)
Other expense, net(246)(1,442)
Loss before income tax benefit(23,779)(23,058)
Income tax benefit(1,111)(555)
Net loss(22,668)(22,503)
Foreign currency translation adjustment(4,920)(2,202)
Comprehensive loss$(27,588)$(24,705)
Net loss per share, basic and diluted (see Note 1)$(0.50)$(0.57)
Weighted-average shares used to compute basic and diluted net loss per share (see Note 1)45,139,038 39,613,964 
See accompanying notes to unaudited condensed consolidated financial statements.
2

Axonics, Inc.
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share and per share data)
(unaudited)
Accumulated
AdditionalOther
Common StockPaid-inAccumulatedComprehensive
SharesAmountCapitalDeficitLossTotal
Balance at December 31, 2021
46,330,167 $5 $803,559 $(314,566)$(6,560)$482,438 
Issuance of common stock for employee stock option exercises for cash91,286 — 1,444 — — 1,444 
Restricted Shares Award (RSA) issuances and forfeitures for terminations, net and stock-based compensation312,479 — 5,633 — — 5,633 
Issuance of common stock for vesting of Restricted Stock Units (RSU) and stock-based compensation268,930 — 1,505 — — 1,505 
Foreign currency translation adjustment— — — — (4,920)(4,920)
Net loss— — — (22,668)— (22,668)
Balance at March 31, 2022
47,002,862 $5 $812,141 $(337,234)$(11,480)$463,432 
Accumulated
AdditionalOther
Common StockPaid-inAccumulatedComprehensive
SharesAmountCapitalDeficitLossTotal
Balance at December 31, 2020
39,931,030 $4 $522,296 $(234,499)$(431)$287,370 
Issuance of common stock for employee stock option exercises for cash206,507 — 2,821 — — 2,821 
RSA issuances and forfeitures for terminations, net and stock-based compensation358,300 — 3,809 — — 3,809 
Issuance of common stock for vesting of RSU and stock-based compensation169,054 — 1,494 — — 1,494 
Issuance of common stock for acquisition of Contura Limited1,096,583 — 55,728 — — 55,728 
Issuance of common stock for exclusive license asset65,594 — 3,637 — — 3,637 
Foreign currency translation adjustment— — — — (2,202)(2,202)
Net loss— — — (22,503)— (22,503)
Balance at March 31, 2021
41,827,068 $4 $589,785 $(257,002)$(2,633)$330,154 
See accompanying notes to unaudited condensed consolidated financial statements.
3

Axonics, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
Three Months Ended
March 31,
20222021
Cash Flows from Operating Activities
Net loss$(22,668)$(22,503)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization3,029 1,133 
Stock-based compensation7,138 5,303 
Amortization of debt issuance costs 567 
Reversal of allowance of credit losses(39)(65)
Deferred income taxes and other items, net(1,210)(577)
Changes in operating assets and liabilities, net of business acquisition
Accounts receivable1,595 (1,480)
Inventory3,015 (7,193)
Prepaid expenses and other current assets1,474 860 
Other assets(25)(100)
Accounts payable2,529 914 
Accrued liabilities900 (1,569)
Accrued compensation and benefits(4,925)(915)
Lease liability20 42 
Net cash used in operating activities(9,167)(25,583)
Cash Flows from Investing Activities
Purchases of property and equipment(291)(123)
Acquisition of a business, net of cash acquired (140,741)
Net cash used in investing activities(291)(140,864)
Cash Flows from Financing Activities
Payment of debt issuance costs (106)
Proceeds from debt 75,000 
Repayment of debt (21,500)
Proceeds from exercise of stock options1,444 2,821 
Net cash provided by financing activities1,444 56,215 
Effect of exchange rate changes on cash and cash equivalents316 13 
Net decrease in cash and cash equivalents(7,698)(110,219)
Cash and cash equivalents, beginning of year220,878 241,181 
Cash and cash equivalents, end of period$213,180 $130,962 
Supplemental Disclosure of Cash Flow Information
Cash paid for interest$1 $170 
Cash paid for taxes$ $ 
Noncash Investing and Financing Activities
Change in property and equipment acquired but not yet paid$267 $ 
Common stock issuance for business acquisition$ $55,728 
Contingent consideration for business acquisition$ $6,750 
Common stock issuance for exclusive license asset$ $3,637 
Accrued loan fees as debt issuance costs$ $4,500 
See accompanying notes to unaudited condensed consolidated financial statements.
4

AXONICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)


Note 1. Nature of Operations and Summary of Significant Accounting Policies
Nature of Operations
Axonics, Inc. (the Company) was incorporated in the state of Delaware on March 2, 2012 under the name American Restorative Medicine, Inc. In August 2013, the Company changed its name to Axonics Modulation Technologies, Inc. In March 2021, the Company changed its name to Axonics, Inc. The Company had no operations until October 1, 2013, when the license agreement between Alfred E. Mann Foundation for Scientific Research (AMF) and the Company (the License Agreement) was entered into. The Company is a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction. The Company has designed and developed the rechargeable sacral neuromodulation (SNM) system (r-SNM System), which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The r-SNM System is protected by intellectual property based on Company-generated innovations and patents and other intellectual property licensed from AMF. The Company has marketing approvals in the United States, Europe, Canada, and Australia for all relevant clinical indications. The premarket approval (PMA) application for the r-SNM System for the treatment of FI was approved by the U.S. Food and Drug Administration (FDA) on September 6, 2019, and the PMA application for the r-SNM System for the treatment of OAB and UR was approved by the FDA on November 13, 2019. Accordingly, the Company began U.S. commercialization of its r-SNM System in the fourth quarter of 2019. Prior to the fourth quarter of 2019, the Company derived revenue only from its international operations in select markets including England, the Netherlands and Canada, and its activities had consisted primarily of developing the r-SNM System, conducting its RELAX-OAB post-market clinical follow-up study in Europe, its ARTISAN-SNM pivotal clinical study in the United States and hiring and training its U.S. commercial team in preparation for the launch of the r-SNM System in the United States. Beginning in February 2021 with the acquisition of Contura Limited, the Company also markets Bulkamid, a urethral bulking agent to treat female stress urinary incontinence (SUI). For more information, see Note 8.
May 2021 Follow-On Offering
On May 14, 2021, the Company completed a follow-on offering by issuing 4,025,000 shares of common stock, at an offering price of $50.00 per share, inclusive of 525,000 shares of the Company’s common stock issued upon the exercise by the underwriters of their option to purchase additional shares. The net proceeds to the Company were approximately $190.0 million, after deducting underwriting discounts, commissions and offering expenses payable by the Company.
Principles of Consolidation
The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company; its wholly-owned subsidiaries, Axonics Europe, S.A.S., Axonics Modulation Technologies U.K. Limited, Axonics Modulation Technologies Australia Pty Ltd, Axonics Women’s Health Limited, Bulkamid SARL, Axonics GmbH, and Contura, Inc. Intercompany accounts and transactions have been eliminated in consolidation.
Basis of Presentation and Liquidity
Interim Financial Statements
The interim condensed consolidated financial statements and related footnote disclosures as of and for the three months ended March 31, 2022 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The unaudited interim condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three months ended March 31, 2022 in accordance with United States (U.S.) generally accepted accounting principles (GAAP), however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (SEC) rules and regulations relating to interim financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated
5

financial statements and notes thereto included within the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (filed with the SEC on March 1, 2022).
Liquidity
The Company only began full-scale commercialization of the r-SNM System in late 2019. The Company has expended significant resources on research and development activities, growing its operations organization and building and training its sales organization.
The Company incurred net losses of $22.7 million and $22.5 million for the three months ended March 31, 2022 and 2021, respectively, and had an accumulated deficit of $337.2 million as of March 31, 2022 compared to $314.6 million at December 31, 2021. The Company expects to continue to spend a significant amount of its existing resources on sales and marketing activities as the Company continues to commercialize and market its products in the United States and internationally.
As of March 31, 2022, the Company had cash and cash equivalents of $213.2 million compared to $220.9 million at December 31, 2021. The Company expects that its cash and cash equivalents on hand will be sufficient to fund its operations through at least the next 12 months. The Company funds its operations through a combination of proceeds from public offerings of its common stock and cash receipts from sales of its products. As of March 31, 2022, the Company had no outstanding borrowings.
The Company may need to raise additional financing in the future to facilitate its business operations. If the Company raises additional funds by issuing equity securities, its stockholders could experience dilution. Debt financing, if available, may involve covenants further restricting its operations or its ability to incur additional debt. Any debt financing or additional equity that the Company raises may contain terms that are not favorable to the Company or its stockholders. Additional financing may not be available at all, or in amounts or on terms acceptable to the Company. If the Company is unable to obtain additional financing when needed to satisfy its liquidity requirements, the Company may be required to scale back its operations.
COVID-19
The recent COVID-19 outbreak, and the resulting restrictions intended to slow the spread of COVID-19, including stay-at-home orders, business shutdowns and other restrictions, has adversely affected the Company’s business in several ways. The primary impact on the Company’s business was the cancellation or delay of elective procedures in certain areas to allow health care facilities to prioritize the treatment of COVID-19 patients during the initial stages and resurgence periods of the pandemic or because patients are avoiding health care facilities that they feel are unsafe. These developments materially reduced the number of procedures using the Company’s r-SNM System. If governmental authorities recommend again in the future that it is deemed advisable for health care facilities to not perform outpatient elective procedures, as was the case at various times since the second quarter of 2020, the Company expects it would materially harm the Company’s revenues and potentially increase the Company’s operating loss. Even as efforts to contain the pandemic have made progress and some restrictions have relaxed, new variants of the virus may continue to cause additional outbreaks. These challenges will likely continue for the duration of the pandemic and could reduce our revenue and negatively impact our business, financial condition and results of operations while the pandemic continues. If these delays in procedures occur in the future, the Company may have to scale back its business, including reducing headcount, which could have a negative impact on the Company’s long-term operations. The Company could also experience other negative impacts of the COVID-19 outbreak such as the lack of availability of the Company’s key personnel, temporary closures of the Company’s office or the facilities of the Company’s business partners, customers, third party service providers or other vendors, and the interruption of the Company’s supply chain, distribution channels, liquidity and capital or financial markets.
Any disruption and volatility in the global capital markets as a result of the pandemic may increase the Company’s cost of capital and adversely affect the Company’s ability to access financing when and on terms that the Company desires. In addition, a recession resulting from the spread of COVID-19 could materially affect the Company’s business, especially if a recession results in higher unemployment causing potential patients to not have access to health insurance.
6

The ultimate extent to which the COVID-19 pandemic and its repercussions impact the Company’s business will depend on future developments, which are highly uncertain. However, the foregoing and other continued disruptions to the Company’s business as a result of COVID-19 could result in a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses, and related disclosure of contingent assets and liabilities. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. The results of this evaluation then form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates, and such differences may be material to the consolidated financial statements. Significant items subject to such estimates and assumptions include the useful lives of property and equipment and intangible assets, the valuation of deferred income tax assets and liabilities, the valuation of contingent consideration liability, the valuation of stock-based compensation, the product returns reserve, the inventory obsolescence reserve and accounts receivable allowance for credit losses.
Revenue Recognition
Revenue recognized during the three months ended March 31, 2022 and 2021 relates entirely to the sale of the Company’s products to its customers and distributors.
The Company has revenue arrangements that consist of a single performance obligation. The Company recognizes revenue at the point in time when it transfers control of promised goods to its customers. Revenue is measured as the amount of consideration it expects to receive in exchange for transferring goods. The amount of revenue that is recognized is based on the transaction price, which represents the invoiced amount and includes estimates of variable consideration such as discounts, where applicable. The Company also sells to distributors and applies the same policies as its revenue arrangements with customers, specifically that revenue is recognized at the point in time when it transfers control of promised goods to its distributors. The Company does not offer rights of return or price protection. The amount of variable consideration included in the transaction price may be constrained and is included only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Payment terms, typically less than three months, do not include a significant financing component. The Company extends credit to its customers and distributors based upon an evaluation of their financial condition and credit history and generally requires no collateral. The Company does not have any contract balances related to product sales. The Company also does not have significant contract acquisition costs related to product sales.
In accordance with Company policy and based on the Company’s historical experience, the allowance for product returns was $0.1 million and $0.2 million at March 31, 2022 and December 31, 2021, respectively, and is recorded as a reduction of gross revenue in its condensed consolidated statements of comprehensive loss. Damaged or defective products are replaced at no charge under the Company’s standard warranty. For the three months ended March 31, 2022 and 2021, the replacement costs were $0.1 million and $0.1 million, respectively, and are recorded within the sales and marketing expenses in its condensed consolidated statements of comprehensive loss.
The Company offers its standard warranty to all customers. The Company does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to sales and marketing expense. The warranty liability as of March 31, 2022 and December 31, 2021 were $0.1 million and $0.1 million, respectively.
Shipping and handling costs incurred for the delivery of goods to customers and distributors are included in cost of goods sold. Amounts billed to customers and distributors for shipping and handling are included in net revenue.
7

The following table provides additional information pertaining to net revenue disaggregated by product and geographic market for the three months ended March 31, 2022 and 2021 (in thousands):
Three Months Ended
March 31,
20222021
SNM net revenue
United States$37,715 $31,745 
International markets1,355 1,158 
$39,070 $32,903 
Bulkamid net revenue(1)
United States$6,569 $578 
International markets2,781 892 
$9,350 $1,470 
Total net revenue$48,420 $34,373 
_____________________________________________
(1)    The acquisition of Bulkamid was completed on February 25, 2021. Reported revenue includes sales from February 26, 2021 onwards.
Allowance for Credit Losses
The Company makes estimates of the collectability of accounts receivable in accordance with Accounting Standards Update (ASU) 2016-13. The Company’s estimate of future credit losses is made by management based upon historical bad debts, customer receivable balances, age of customer receivable balances, customers’ financial conditions and reasonable forecasted economic trends. Despite the Company’s efforts to minimize credit risk exposure, customers could be adversely affected if future economic and industry trends, including those related to COVID-19, change in such a manner as to negatively impact their cash flows. The full effects of COVID-19 on the Company’s customers are highly uncertain and cannot be predicted. As a result, the Company’s future collection experience can differ significantly from historical collection trends. If the Company’s customers experience a negative impact on their cash flows, it could have a material adverse effect on the Company’s results of operations and financial condition.
The following table summarizes the changes in our allowance for credit losses (in thousands):
Three Months Ended
March 31,
20222021
Balance at beginning of period$355 $465 
Write-offs 12 
Bad debt recoveries(39)(65)
Balance at end of period$316 $412 
Cash and Cash Equivalents
Cash equivalents consist of short-term, highly liquid investments purchased with an original maturity of three months or less. Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. At times, the cash and cash equivalent balances may exceed federally insured limits. The Company does not believe that this results in any significant credit risk as the Company’s policy is to place its cash and cash equivalents in highly-rated financial institutions. The Company also holds cash in foreign banks that are not federally insured. The Company has not experienced any losses on its deposits of cash and cash equivalents.
8

Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2: Inputs are quoted prices for similar assets and liabilities in active markets or quoted prices for identical or similar instruments in markets that are not active and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.
Level 3: Inputs are unobservable inputs based on the Company’s assumptions and valuation techniques used to measure assets and liabilities at fair value. The inputs require significant management judgment or estimation.
The Company’s assessment of the significance of an input to the fair value measurement requires judgment, which may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels. The carrying amounts reported in the condensed consolidated financial statements approximate the fair value for cash and cash equivalents, accounts receivable, accounts payables, and accrued expenses due to their short-term nature. The carrying amount of the Company’s term loan, which is described below, approximates fair value, considering the interest rates are based on the prime interest rate.
The purchase price of business acquisitions is primarily allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition date, with the excess recorded as goodwill.
Contingent consideration represents contingent milestone, performance and revenue-sharing payment obligations related to acquisitions and is measured at fair value, based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration is estimated using a binary option-based approach with assumptions the Company believes would be made by a market participant. Significant inputs include projected revenues, discount rates, volatility factors and risk-free rates. The Company assesses these assumptions on an ongoing basis as additional data impacting the assumptions is obtained and any change in fair value of the contingent consideration is recorded within the general and administrative expenses in the consolidated statements of comprehensive loss. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. Generally, a change in the assumption used for the projected revenues would result in a directionally similar change to the overall estimate of the contingent consideration. The fair value of contingent consideration of $10.4 million at
9

March 31, 2022 is reflected in other long-term liabilities in the Company’s condensed consolidated balance sheets.
The following table summarizes the changes in the fair value of recurring Level 3 fair value measurements during the three months ended March 31, 2022 and 2021 (in thousands):
Three Months Ended
March 31,
20222021
Liabilities
Contingent consideration:
Balance at beginning of period$10,370 $ 
February 25, 2021 Acquisition 6,750 
Balance at end of period$10,370 $6,750 
There were no transfers between Levels 1, 2 or 3 for the periods presented.
Investment Securities
Those investments in debt securities with maturities less than 12 months at the date of purchase are considered short-term investments. Those investments in debt securities with maturities greater than 12 months at the date of purchase are considered long-term investments. The Company’s investment securities classified as available-for-sale are recorded at fair value based on the fair value hierarchy (Level 1 and Level 2 inputs in the fair value hierarchy), and consists primarily of commercial paper, corporate notes and U.S. government and agency securities. Unrealized gains or losses, deemed temporary in nature, are reported as other comprehensive income within the condensed consolidated statements of comprehensive loss. There were no unrealized gains or losses during the three months ended March 31, 2022 and 2021.
A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to net income (loss) and the corresponding establishment of a new cost basis for the security. Premiums (discounts) are amortized (accreted) over the life of the related security as an adjustment to yield using the straight-line interest method. Dividend and interest income are recognized when earned. Realized gains or losses are included in net loss and are derived using the specific identification method for determining the cost of securities sold.
The Company had no outstanding investment securities as of March 31, 2022 and December 31, 2021.
Foreign Currency Translation
The functional currencies of the Company’s subsidiaries are currencies other than the U.S. dollar. The Company translates assets and liabilities of the foreign subsidiaries into U.S. dollars at the exchange rate in effect on the balance sheet date. Revenue and expenses of the subsidiaries are translated into U.S. dollars at the average exchange rate during the period. Gains or losses from these translation adjustments are reported as a separate component of stockholders’ equity in accumulated other comprehensive gain or loss until there is a sale or complete or substantially complete liquidation of the Company’s investment in the foreign subsidiary at which time the gains or losses will be realized and included in net income (loss). As of March 31, 2022 and December 31, 2021, all foreign currency translation gains (losses) have been unrealized and included in accumulated other comprehensive loss. Accumulated other comprehensive loss consists entirely of losses or gains from translation of foreign subsidiaries at March 31, 2022 and December 31, 2021.
Inventory, Net
Inventories are stated at the lower of cost or net realizable value, with cost computed on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors.
The Company capitalizes inventory produced for commercial sale. The Company capitalizes manufacturing costs as inventory following both the receipt of regulatory approval from regulatory bodies and the Company’s
10

intent to commercialize. Costs associated with developmental products prior to satisfying the Company’s inventory capitalization criteria are charged to research and development expenses as incurred.
Products that have been approved by certain regulatory authorities may also be used in clinical programs to assess the safety and efficacy of the products for usage that have not been approved by the FDA or other regulatory authorities. The form of product utilized for both commercial and certain clinical programs that are identical are included as inventory with an “alternative future use” as defined in authoritative guidance. Component materials and purchased products associated with clinical development programs are included in inventory and charged to research and development expenses when the product enters the research and development process and no longer can be used for commercial purposes and, therefore, does not have an “alternative future use.”
For products that are under development and have not yet been approved by regulatory authorities, purchased component materials are charged to research and development expenses when the inventory ownership transfers to the Company.
The Company analyzes inventory levels to identify inventory that may expire prior to sale, inventory that has a cost basis in excess of its net realizable value, or inventory in excess of expected sales requirements. Although the manufacturing of the r-SNM System is subject to strict quality control, certain batches or units of product may no longer meet quality specifications or may expire, which would require adjustments to the Company’s inventory values. The Company also applies judgment related to the results of quality tests that are performed throughout the production process, as well as the understanding of regulatory guidelines, to determine if it is probable that inventory will be saleable. These quality tests are performed throughout the pre- and post-production processes, and the Company continually gathers information regarding product quality for periods after the manufacturing date. The Company’s products currently have a maximum estimated shelf life range of 12 to 36 months and, based on sales forecasts, the Company expects to realize the carrying value of the product inventory. In the future, reduced demand, quality issues, or excess supply beyond those anticipated by management may result in a material adjustment to inventory levels, which would be recorded as an increase to cost of sales.
The determination of whether inventory costs will be realizable or not requires estimates by the Company’s management. A critical input in this determination is future expected inventory requirements based on internal sales forecasts. Management then compares these requirements to the expiry dates of inventory on hand. To the extent that inventory is expected to expire prior to being sold, management will write down the value of inventory.
As of March 31, 2022, the Company had $44.3 million, $3.0 million and $14.6 million of finished goods inventory, work-in-process inventory and raw materials inventory, respectively, net of reserves of $0.1 million. As of December 31, 2021, the Company had $46.8 million, $2.8 million and $15.3 million of finished goods inventory, work-in-process inventory and raw materials inventory, respectively, net of reserves of $0.2 million.
Customer and Vendor Concentration
As of March 31, 2022 and December 31, 2021, there were no customers who accounted for over 10% of the Company’s consolidated accounts receivable. As of March 31, 2022 and December 31, 2021, there were two vendors and no vendor, respectively, who accounted for over 10% of the Company’s consolidated accounts payable. As of March 31, 2022 and December 31, 2021, there were no customers who accounted for over 10% of the Company’s consolidated net revenue. As of March 31, 2022 and December 31, 2021, there were three vendors and one vendor, respectively, who accounted for over 10% of the Company’s inventory-related purchases.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and seven years. Leasehold improvements are amortized over the lesser of the life of the lease or the useful life of the improvements. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations.
11

Goodwill
Goodwill represents the excess purchase price over the fair values of the identifiable assets acquired less the liabilities assumed. Goodwill is tested for impairment at the reporting unit level by comparing the reporting unit’s carrying amount to the fair value of the reporting unit. The fair values are estimated using an income and discounted cash flow approach. The Company evaluates its goodwill on an annual basis in the fourth quarter or more frequently if it believes indicators of impairment exist. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount or performs an annual impairment test. When tested quantitatively, the Company compares the fair value of the applicable reporting unit with its carrying value. In making this assessment, management relies on a number of factors, including expected future operating results, business plans, economic projections, anticipated future cash flows, business trends and declines in the Company’s market capitalization. The Company estimates the fair values of its reporting unit using a combination of the discounted cash flow and income approaches. If the carrying amount of a reporting unit exceeds the reporting unit’s fair value, the amount by which the carrying value exceeds the fair value is recognized as an impairment loss. During the three months ended March 31, 2022, the Company did not record any impairment charges related to goodwill.
Intangible Assets
Patent license asset
The intangible asset represents exclusive rights to an additional field-of-use on the patent suite within the License Agreement with AMF. The additional field-of-use was provided in exchange for 50,000 shares of Series A preferred stock, the fair value of which was $1.0 million in 2013. The intangible asset was recorded at its fair value of $1.0 million at the date contributed. In connection with the initial public offering, such shares of Series A preferred stock were converted into common stock. Amortization of this asset is recorded over the shorter of the patent or legal life on a straight-line basis. The weighted-average amortization period is 8.71 years. The Company recorded minimal expenses for the amortization of the patent license asset during the three months ended March 31, 2022 and 2021. The Company will review the intangible asset for impairment whenever an impairment indicator exists. There have been no intangible asset impairment charges to date. For additional information, see Note 8.
Exclusive license asset
The intangible asset represents exclusive rights of existing technologies and development services from MST entered into on March 2, 2021. The agreement was provided in exchange for 65,594 shares of common stock, $0.0001 par value, the fair value of which was $3.6 million upon transfer. The intangible asset was recorded at its fair value of $3.3 million at the date of the agreement, with the difference of $0.3 million recorded as a vendor credit in accounts payable in the condensed consolidated balance sheets. Amortization of this asset is recorded over the four-year term of the agreement on a straight-line basis. The Company recorded expense for the amortization of the exclusive license asset of $0.2 million during the three months ended March 31, 2022. There was no amortization of this intangible asset recorded during the three months ended March 31, 2021. The Company will review the intangible asset for impairment whenever an impairment indicator exists. There have been no intangible asset impairment charges to date. For additional information, see Note 8.
Contura acquisition
The intangible assets represent technology, trade names and trademarks, and customer relationships acquired from Contura on February 25, 2021. The straight-line method over the period of estimated benefit is used to amortize finite-lived intangible assets except for customer relationships. Accounting Standards Codification (ASC) 350-30-35-3 states that customer relationships generally dissipate at a more rapid rate in the earlier periods following a company’s succession to these relationships, with the rate of attrition declining over time. As such, the accelerated method is used to amortize customer relationships. The Company recorded expense for the amortization of Contura acquisition intangible assets of $2.2 million and $0.6 million during the three months ended March 31, 2022 and 2021, respectively. For additional information, see Note 8.
12

Impairment of Long-Lived Assets
The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net cash flows that the assets are expected to generate. If said assets are considered to be impaired, the impairment that would be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There have been minimal impairments of long-lived assets to date.
Leases
In accordance with ASU No. 2016-02, “Leases (Topic 842)”, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only. Topic 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the bright line thresholds referenced in Topic 842 to assist in evaluating leases for appropriate classification between operating and finance leases. The aforementioned bright lines are applied consistently to the Company’s entire portfolio of leases.
Operating lease ROU asset and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate, which is the rate for a fully collateralized amortizing loan with the same maturity as the lease term, based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
Research and Development
Research and development costs are charged to operations as incurred. Research and development costs include salary and personnel-related costs, costs of clinical studies and testing, supplies and materials, and outside consultant costs.
Advertising Expense
The Company expenses advertising costs as they are incurred. During the three months ended March 31, 2022 and 2021, advertising expense totaled $3.2 million and $1.4 million, respectively, and are recorded within the sales and marketing expenses in its condensed consolidated statements of comprehensive loss.
Income Taxes
The Company accounts for income taxes using the asset and liability method to compute the difference between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. The Company has net deferred tax assets in certain jurisdictions. The realization of these deferred tax assets is dependent upon the Company’s ability to generate sufficient taxable income in future years. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company evaluates the recoverability of the deferred tax assets annually, and maintains a full valuation allowance on its U.S. net deferred tax assets. The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company is subject to transfer pricing and other tax regulations designed to ensure that appropriate levels of income are reported as earned by the Company’s U.S. and foreign entities and are taxed accordingly. In the normal course of business, the Company is audited by federal, state
13

and foreign tax authorities, and subject to inquiries from those tax authorities regarding the amount of taxes due. These inquiries may relate to the timing and amount of deductions and the allocation of income among various tax jurisdictions. The Company’s policy is to recognize interest and penalties related to unrecognized tax benefits, if any, in income tax expense.
Stock-Based Compensation
The Company measures the cost of employee and non-employee services in exchange for an award of equity instruments based on the grant-date fair value of the award and recognizes compensation cost over the requisite service period (typically the vesting period), generally three or four years. Forfeitures are estimated at the time of the grant and revised in subsequent periods to reflect differences between the estimates and the number of shares that actually become exercisable.
The Company uses the Black-Scholes option pricing model to determine the fair value of stock options (as of the date of grant) that have service conditions for vesting. Stock options and restricted shares awards vest based on service conditions, typically over three or four years.
The Company also grants shares of performance-based restricted stock units that typically vest after one year only if the Company has also achieved certain performance objectives as defined and approved by the Company’s board of directors. The fair value of performance awards are determined based on the Company’s stock price at the date of grant and expensed over the performance period based on the probability of achieving the performance objectives. In addition, the Company also grants market-based restricted stock units that have combined market conditions and service conditions for vesting, for which the Company uses the Monte Carlo valuation model to value equity awards (as of the date of grant).
Net Loss per Share of Common Stock
Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options, unvested RSAs and RSUs are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, diluted net loss per share of common stock is the same as basic net loss per share of common stock for those periods.
For the three months ended March 31, 2022 and 2021, there were 2,416,373 and 2,488,284 potentially dilutive weighted-average shares, respectively, that were not included in the computation of diluted weighted-average shares of common stock and common stock equivalent shares outstanding because their effect would have been antidilutive given the Company’s net loss.
Segment Reporting
Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company has determined it operates in one segment, the development and commercialization of innovative and minimally invasive products to treat bladder and bowel dysfunction. Geographically, the Company sells over 90% to hospitals in the United States. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance.
Recently Adopted Accounting Pronouncements
In December 2019, the Financial Accounting Standards Board (FASB) issued ASU 2019-12, “Income Taxes—Simplifying the Accounting for Income Taxes,” which simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step-up in the tax basis of goodwill and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. This guidance is effective for annual periods beginning after December 15, 2020, which
14

was the Company’s first quarter of fiscal year 2021, with early adoption permitted. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or related disclosures.
Recent Accounting Pronouncements
We have reviewed and considered all recent accounting pronouncements that have not yet been adopted and believe there are none that could potentially have a material impact on our business practices, financial condition, results of operations, or disclosures.
Note 2. Property and Equipment
Property and equipment, net consists of the following (in thousands) at:
March 31,December 31,
20222021
Equipment$2,611 $2,429 
Computer hardware and software2,595 2,450 
Tools and molds1,626 1,579 
Leasehold improvements4,449 4,372 
Furniture and fixtures1,515 1,502 
Construction in progress198 127 
12,994 12,459 
Less: accumulated depreciation and amortization(6,087)(5,544)
$6,907 $6,915 
Depreciation and amortization expense of property and equipment was $0.6 million and $0.5 million for the three months ended March 31, 2022 and 2021, respectively.
Note 3. Commitments and Contingencies
Operating Leases
In August 2014, the Company entered into a five-year operating lease for approximately 12,215 square feet of office space beginning on November 1, 2014, and expiring on October 31, 2019. In June 2019, the lease was amended to extend the expiration date to October 31, 2020. In September 2020, the lease was amended to extend the expiration date to July 31, 2022, and in December 2021, the lease was amended to extend the expiration date to January 31, 2028. Upon the execution of the amendments, which were deemed to be a lease modification, the Company reassessed the lease liability using the incremental borrowing rate for a collateralized asset of the same remaining term at the modification date and recorded ROU assets for the same amount. The Company also reassessed the lease classification and concluded that the lease continues to be an operating lease. Under the terms of the lease, the Company is responsible for taxes, insurance, and maintenance expense. The lease contains certain scheduled rent increases. Rent expense is recognized on a straight-line basis over the expected lease term.
In November 2017, the Company entered into a seven-year operating lease for approximately 25,548 square feet of office space beginning on August 1, 2018, and expiring on August 31, 2025. In June 2019, the lease was amended to extend the expiration date to October 31, 2027. Upon the execution of the amendments, which were deemed to be a lease modification, the Company reassessed the lease liability using the incremental borrowing rate for a collateralized asset of the same remaining term at the modification date and recorded ROU assets for the same amount. The Company also reassessed the lease classification and concluded that the lease continues to be an operating lease. Under the terms of the lease, the Company is responsible for taxes, insurance, and maintenance expense. The lease contains certain scheduled rent increases. Rent expense is recognized on a straight-line basis over the expected lease term. The Company has a renewal option to extend the term of the lease for a period of five years beyond the initial term. Under the terms of the lease, the base rent payable with respect to each renewal term will be equal to the prevailing market rental rent as of the commencement of the applicable renewal term. In the event of a default of certain of the Company’s obligations under the lease, the Company’s landlord would have the right to
15

terminate the lease.
In June 2019, the Company entered into an eight-year operating lease for approximately 32,621 square feet of office space beginning on January 15, 2020 and expiring on January 31, 2028. The Company uses these premises as its new principal executive offices and for general office space. The Company intends to utilize its other currently-leased spaces through the lease expiration dates to conduct the training of its sales team and for manufacturing purposes. Under the terms of the lease, the Company is responsible for taxes, insurance, and maintenance expense. The lease contains certain scheduled rent increases. Rent expense is recognized on a straight-line basis over the expected lease term. The Company has a renewal option to extend the term of the lease for a period of five years beyond the initial term. Under the terms of the lease, the base rent payable with respect to each renewal term will be equal to the prevailing market rental rent as of the commencement of the applicable renewal term. In the event of a default of certain of the Company’s obligations under the lease, the Company’s landlord would have the right to terminate the lease.
In August 2020, the Company entered into a 38-month operating lease for approximately 5,693 square feet of warehouse space beginning on October 15, 2020 and expiring on December 31, 2023. The Company uses these premises for general warehouse space.
During the three months ended March 31, 2022 and 2021, ROU assets obtained in exchange for new operating lease liabilities were none and $0.1 million, respectively. As of March 31, 2022 and December 31, 2021, the ROU asset has a balance of $6.8 million and $7.1 million, respectively. The operating lease ROU asset is included within the Company’s non-current other assets, and lease liabilities are included in current or noncurrent liabilities in the Company’s condensed consolidated balance sheets. During the three months ended March 31, 2022 and 2021, cash paid for amounts included in operating lease liabilities was $0.5 million and $0.5 million, respectively. Amortization of the ROU asset was $0.2 million and $0.3 million for the three months ended March 31, 2022 and 2021, respectively.
As of March 31, 2022 and December 31, 2021, the weighted-average remaining lease term for the Company’s operating leases were 5.7 years and 5.9 years, respectively. The weighted-average incremental borrowing rate for a collateralized asset of the same remaining term used to determine the present value of the Company’s operating leases’ future payments was 7.1% and 7.1% as of March 31, 2022 and December 31, 2021, respectively.
Total lease cost for the three months ended March 31, 2022 and 2021 are as follows (in thousands):
Three Months Ended
March 31,
20222021
Lease cost
Operating lease cost$524 $525 
Short-term lease cost21 23 
Variable lease cost35 47 
Total lease cost$580 $595 
License Agreement
In October 2013, the Company entered into the License Agreement, pursuant to which AMF, a Company stockholder, licensed the Company certain patents and know-how (collectively, the AMF IP) relating to, in relevant part, an implantable pulse generator and related system components in development by AMF as of that date, in addition to any peripheral or auxiliary devices, including all components, that when assembled, comprise such device, excluding certain implantable pulse generators (collectively, the AMF Licensed Products). Under the License Agreement, for each calendar year beginning in 2018, the Company is obligated to pay AMF a royalty on an AMF Licensed Product-by-AMF Licensed Product basis if one of the following conditions applies: (i) one or more valid claims within any of the patents licensed to the Company by AMF covers such AMF Licensed Products or the manufacture of such AMF Licensed Products or (ii) for a period of 12 years from the first commercial sale anywhere
16

in the world of such AMF Licensed Product, in each case. The foregoing royalty is calculated as the greater of (a) 4% of all net revenue derived from the AMF Licensed Products, and (b) the Minimum Royalty, payable quarterly. The Minimum Royalty automatically increases each year after 2018, subject to a maximum amount of $200,000 per year. The Company generated net SNM revenue of $39.1 million and $32.9 million during the three months ended March 31, 2022 and 2021, respectively, and recorded related royalties of $1.6 million and $1.3 million during the three months ended March 31, 2022 and 2021, respectively. Royalty expense is included in operating expenses in the condensed consolidated statements of comprehensive loss. Accrued royalty of $1.6 million and $1.8 million as of March 31, 2022 and December 31, 2021, respectively, is included within accrued liabilities in the Company’s condensed consolidated balance sheets.
Legal Matters
On November 4, 2019, Medtronic, Inc., Medtronic Puerto Rico Operations Co., Medtronic Logistics LLC and Medtronic USA, Inc. (collectively, the Medtronic Affiliates) filed a complaint against the Company in the United States District Court for the Central District of California, Case No. 8:19-cv-2115, and amended the complaint on November 26, 2019. The Company refers to this matter as the Medtronic Litigation. The complaint asserts that the Company’s r-SNM System infringes U.S. Patent Nos. 8,036,756, 8,626,314, 9,463,324 and 9,821,112 held by the Medtronic Affiliates, and the amended complaint further includes the additional patents 8,738,148; 8,457,758; and 7,774,069 (collectively, the Medtronic Patents). The Medtronic Litigation requests customary remedies for patent infringement, including (i) a judgment that the Company has infringed and is infringing the Medtronic Patents, (ii) damages, including treble damages for willful infringement, (iii) a permanent injunction preventing the Company from infringing the Medtronic Patents, (iv) attorneys’ fees, and (v) costs and expenses. The Company believes the allegations are without merit and is vigorously defending itself against them. Given the early stage of the Medtronic Litigation, the Company is unable to predict the likelihood of success of the claims of the Medtronic Affiliates against the Company or to quantify any risk of loss. The Medtronic Litigation could last for an extended period of time and require the Company to dedicate significant financial resources and management resources to its defense. An adverse ruling against the Company could materially and adversely affect its business, financial position, results of operations or cash flows and could also result in reputational harm. Even if the Company is successful in defending against these claims, the Medtronic Litigation could result in significant costs, delays in future product developments, reputational harm or other collateral consequences.
On March 16, 2020, the Company filed seven petitions before the United States Patent and Trademark Office (USPTO) requesting inter partes review (IPR) to contest the validity of each of the Medtronic patents that Medtronic has alleged are being infringed by the Company. In September 2020, the USPTO decided that it will accept or “institute” the IPR process for six of the seven patents, finding that the Company had demonstrated a reasonable likelihood that at least one, if not all, of the claims of these six patents are invalid. The USPTO issued decisions on the IPR petitions in September 2021. The USPTO invalidated several claims in the Medtronic patents but declined to invalidate the majority of asserted claims. The Company appealed the decisions on the claims that were not invalidated. Following these IPR decisions, the judge presiding over the litigation in the United States District Court for the Central District of California lifted the stay on litigation proceedings. The Company is currently engaged in discovery in the Medtronic Litigation.
In addition to the Medtronic Litigation, the Company is and may continue to be involved in claims, legal proceedings, and investigations arising out of its operations in the normal course of business.
Note 4. Long-Term Debt
In June 2021, the principal amount, accrued interest, accrued loan fees, and prepayment fees related to the term loan under the Loan and Security Agreement with Silicon Valley Bank entered into in February 2021, were paid in full. The unamortized debt issuance costs of $4.4 million were expensed and recognized as interest expense.
In January 2021, the principal amount, accrued interest, accrued loan fees, and prepayment fees related to the term loan under the Loan and Security Agreement with Silicon Valley Bank entered into in February 2018, were paid in full. The unamortized debt issuance costs of $0.4 million were expensed and recognized as interest expense.
17

Note 5. Stock-based Compensation
Stock-based compensation expense included in the Company’s unaudited condensed consolidated statements of comprehensive loss is allocated as follows (in thousands):
Three Months Ended
March 31,
20222021
Research and development$1,510 $1,329 
General and administrative1,937 1,685 
Sales and marketing3,691 2,289 
$7,138 $5,303 
Stock Option Activity
The option awards issued under the 2014 Stock Option Plan (the 2014 Plan) and the 2018 Omnibus Incentive Plan (the 2018 Plan) were measured based on fair value. The Company’s fair value calculations were made using the Black-Scholes option pricing model with the following assumptions:
Three Months Ended
March 31,
20222021
Expected term (in years)
5.46 - 6.00
Stock volatility
63.49%
Risk-free interest rate
0.53% - 1.16%
Dividend rate
The Company used the simplified method of determining the expected term of stock options as the Company believes this represents the best estimate of the expected term of a new option. The expected stock price volatility assumption was determined by examining the historical volatilities for industry peers, as the Company did not have sufficient trading history for the Company’s common stock. The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical data for the Company’s common stock becomes available. The risk-free interest rate assumption is based on the U.S. Treasury instruments, whose term was consistent with the expected term of the Company’s stock options. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The assumptions regarding the expected term of the options and the expected volatility of the stock price are subjective, and these assumptions have a significant effect on the estimated fair value amounts. There were no stock option grants for the three months ended March 31, 2022. The weighted-average grant date fair value of options granted was $32.89 for the three months ended March 31, 2021.
As of March 31, 2022 and December 31, 2021, there was $5.3 million and $6.7 million, respectively, of total unrecognized compensation cost related to unvested stock options that is expected to be recognized over a weighted-average period of approximately 1.4 years and 1.6 years, respectively.
18

The following table summarizes stock option activity for the three months ended March 31, 2022 under the 2014 and 2018 Plans (in thousands, except share and per share data):
Number of OptionsWeighted-Average Exercise Price Per ShareAggregate Intrinsic Value
Outstanding at December 31, 2021
1,427,892 $18.13 
Options exercised(91,286)15.53 $3,486 (1)
Options forfeited(8,500)33.88 
Outstanding at March 31, 2022
1,328,106 $18.20 $58,963 (2)
_____________________________________________
(1)    Represents the total difference between the Company’s closing stock price at the time of exercise and the stock option exercise price, multiplied by the number of options exercised.
(2)    Represents the total difference between the Company’s closing stock price on the last trading day of the first quarter of 2022 and the stock option exercise price, multiplied by the number of in-the-money options as of March 31, 2022. The amount of intrinsic value will change based on the fair market value of the Company’s stock.
The weighted-average remaining contractual term of options outstanding and exercisable is 6.8 years and 6.9 years at March 31, 2022 and December 31, 2021, respectively.
Restricted Shares Awards Activity
As of March 31, 2022 and December 31, 2021, there was $52.8 million and $42.5 million, respectively, of total unrecognized compensation cost related to unvested restricted shares awards that is expected to be recognized over a weighted-average period of approximately 2.8 years and 3.0 years, respectively.
19

The following table summarizes restricted shares awards activity for the three months ended March 31, 2022:
Number of Restricted Shares AwardsWeighted-Average Fair Value Per Share at Grant Date
Outstanding at December 31, 20211,102,034 $46.07 
Restricted shares awards granted352,204 48.14 
Restricted shares awards vested(169,110)37.55 
Restricted shares awards forfeited(39,725)56.85 
Outstanding at March 31, 20221,245,403 $47.47 
Restricted Stock Units Activity
As of March 31, 2022 and December 31, 2021, there was $5.8 million and $1.9 million, respectively, of total unrecognized compensation cost related to unvested restricted stock units that is expected to be recognized over a weighted-average period of approximately 1.1 years and 0.9 years, respectively.
The following table summarizes restricted stock units activity for the three months ended March 31, 2022:
Number of Restricted Stock UnitsWeighted-Average Fair Value Per Share at Grant Date
Outstanding at December 31, 2021250,464 $42.99 
Restricted stock units granted201,884 38.75 
Restricted stock units vested(268,930)35.88 
Outstanding at March 31, 2022183,418 $48.74 
Note 6. Income Taxes
The following table presents details of the provision for income taxes and effective tax rates (in thousands, except percentages):
Three Months Ended
March 31,
20222021
Income tax benefit$(1,111)$(555)
Effective tax rate4.67%2.41%
The Company accounts for income taxes according to ASC 740. The Company periodically evaluates whether a portion or all of its deferred tax assets will be recovered. The Company records a valuation allowance against deferred tax assets if and to the extent it is more likely than not that they will not be recovered. In evaluating the need for a valuation allowance, the Company weighs all relevant positive and negative evidence, including among other factors, historical financial performance, forecasts of income over the applicable carryforward periods, and the market environment, with each consideration weighted based on its reliability. The Company continues to maintain a full valuation allowance against its otherwise recognizable U.S. net deferred income tax assets as of March 31, 2022 and December 31, 2021.
The effective tax rate differs from the statutory U.S. income tax rate due to differing tax rates imposed on income earned in foreign jurisdictions, losses in foreign jurisdictions, and certain nondeductible expenses. The effective tax rate could change significantly from quarter to quarter because of recurring and nonrecurring factors.
20

The provision for income taxes for the three months ended March 31, 2022 was primarily the result of losses benefited in certain foreign jurisdictions.
At December 31, 2021, the Company had U.S. federal and foreign net operating loss (NOL) carryforwards of approximately $258.2 million and $16.4 million, respectively. U.S. federal NOLs in the amount of $51.5 million will expire between 2033 and 2037 while the remainder will carryover indefinitely. The foreign net operating loss carryforwards have an indefinite carryforward period. The Company had U.S. state NOLs of $245.6 million, which will expire between 2033 and 2041.
Pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Internal Revenue Code), use of the Company’s NOL carryforwards may be limited if the Company experiences a cumulative change in ownership of greater than 50% in a rolling three-year period. The Company performed an analysis of changes in ownership for purposes of these Internal Revenue Code sections. Based on the study performed in 2020, the Company determined that an ownership change occurred in 2014, 2018 and 2019. Based on the study performed in 2021, the Company determined that an ownership change did not occur in 2021.
Note 7. Employee Benefit Plan
The Company sponsors a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan covers all employees who meet minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pre- or post-tax basis. Contributions to the plan by the Company may be made at the discretion of the board of directors. During the three months ended March 31, 2022 and 2021, the Company contributions to the plan amounted to $0.5 million and $0.4 million, respectively.
21

Note 8. Goodwill and Intangible Assets
The change in the carrying amount of goodwill during the three months ended March 31, 2022 included the following (in thousands):
December 31, 2021$105,510 
Foreign currency translation adjustment(2,952)
March 31, 2022$102,558 
Intangible assets as of March 31, 2022 included the following (in thousands):
March 31, 2022
Weighted-Average Amortization PeriodGross Carrying AmountAccumulated AmortizationForeign currency translation adjustmentIntangible Assets, Net
Patent license asset8.71 years$1,000 (947) $53 
Exclusive license asset4 years$3,300 (880) $2,420 
Technology12 years$81,100 (7,362)(3,490)$70,248 
Trade names and trademarksIndefinite$19,700 — (906)$18,794 
Customer relationships12 years$11,400 (1,320)(416)$9,664 
$116,500 $(10,509)$(4,812)$101,179 
Intangible asset as of December 31, 2021 included the following (in thousands):
December 31, 2021
Weighted-Average Amortization PeriodGross Carrying AmountAccumulated AmortizationForeign currency translation adjustmentIntangible Asset, Net
Patent license asset8.71 years$1,000 (919) $81 
Exclusive license asset4 years$3,300 (660) 2,640 
Technology12 years$81,100 (5,668)(1,424)74,008 
Trade names and trademarksIndefinite$19,700 — (365)19,335 
Customer relationships12 years$11,400 (799)(196)10,405 
$116,500 $(8,046)$(1,985)$106,469 
Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes to those statements included elsewhere in this Quarterly Report on Form 10-Q, as well as the audited consolidated financial statements and the related notes thereto, and the discussion under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 1, 2022.
Overview
We are a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction, including: (i) implantable rechargeable sacral neuromodulation (SNM) systems to treat urinary urge incontinence (UUI) and urinary urgency frequency (UUF), together referred to as overactive bladder (OAB), as well as fecal incontinence (FI), and non-obstructive urinary retention (UR); and (ii) a urethral bulking agent to treat female stress urinary incontinence (SUI).
22

OAB affects an estimated 87 million adults in the United States and Europe, with an additional 40 million adults estimated to suffer from FI. SUI affects an estimated 29 million women in the United States alone.
SNM therapy is an effective and durable treatment for UUI, UUF, UR and FI that has been widely used and reimbursed in Europe and the United States for the past two decades. Bulkamid is also an effective and durable treatment for SUI. Bulkamid was approved by the FDA for use in the United States in early 2020 and is widely reimbursed in the United States and most international markets.
SNM is the only OAB treatment with proven clinical superiority to standard medical therapy and OAB patients who receive SNM report significantly higher quality of life than patients undergoing drug treatment.
We estimate the U.S. SNM market is now approximately $750 million and believe it is a growing market. Until we entered the market, it was serviced by Medtronic as a single participant.
We believe our proprietary rechargeable SNM system (r-SNM System), the first to be marketed worldwide, offers significant advantages, and is well positioned to capture market share and grow the market for SNM therapy. Our r-SNM System is designed to last 15 or more years in the human body, is only 5cc in volume, offers broad MRI access, ease of use, intuitive programmers, and the longest interval between recharging among rechargeable SNM systems.
We have marketing approvals in the United States, Europe, Canada, and Australia for all relevant clinical indications and initiated limited commercial efforts in England, the Netherlands and Canada in late 2018 and subsequently in Germany and Switzerland. SNM revenue during the three months ended March 31, 2022 from international operations in the Netherlands, England, Canada, Switzerland, and Germany, was approximately $1.4 million.
We are primarily focused on commercializing our products in the United States, which accounts for the vast majority of sales worldwide. We have established a significant commercial infrastructure, with approximately 290 sales and clinical support personnel in the United States. We continue to make significant investments to build our commercial organization to market and support our products. When making hiring decisions for these roles, we prioritize individuals with strong sales backgrounds who also have existing relationships with urologists and urogynecologists.
In February 2021, the FDA approved a third-generation INS for our r-SNM System under a PMA supplement. The third-generation INS upgrades the embedded software in the INS and the functionality of the patient remote control. These modifications give patients the ability to make broader stimulation parameter adjustments at home, including selecting a second therapy program that was set post-operatively based on interoperative findings. We intend to continue to make investments in research and development efforts to develop enhancements to our r-SNM System.
On February 25, 2021, we acquired Contura Limited (Contura) and its Bulkamid product, a urethral bulking agent indicated for the treatment of female SUI. In consideration for the acquisition, we paid approximately $141.3 million in cash and issued 1,096,583 shares of our common stock. We may pay an additional $35 million in the event Bulkamid sales in any consecutive 12-month period exceed $50 million before December 31, 2024. As part of the transaction, we entered into a supply agreement with Contura International A/S (Contura International) to manufacture Bulkamid for us (Manufacturing and Supply Agreement). We have a right to a technology transfer after June 30, 2022 that would enable us to insource the manufacturing of Bulkamid. Bulkamid received a CE Mark in 2003 and a PMA from the FDA in 2020 and is sold through a combination of a direct sales force in the United States and certain European countries and distributors in certain international markets. The acquisition of Contura has expanded our international operations.
In March 2022, the FDA approved our newly developed, long-lived, non-rechargeable SNM system. The non-rechargeable INS utilizes a primary cell battery with an expected life of 15 years at typical stimulation parameters and over 20 years at low amplitude parameters. The non-rechargeable INS is approximately 10cc in volume, utilizes constant current stimulation and a recharge-free patient remote control, and is MRI compatible with 1.5T and 3.0T scanners.
Our ability to generate revenue and become profitable will depend on our ability to continue to successfully commercialize our products and any product enhancements we may advance in the future. We expect to derive future revenue by increasing patient and physician awareness of our products. If we are unable to accomplish any of
23

these objectives, it could have a significant negative impact on our future revenue. If we fail to generate sufficient revenue in the future, our business, results of operations, financial condition, cash flows, and future prospects would be materially and adversely affected.
In the United States, the cost required to treat each patient is reimbursed through various third-party payors, such as commercial payors and government agencies. Most large insurers have established coverage policies in place to cover SNM therapy. Certain commercial payors have a patient-by-patient prior authorization process that must be followed before they will provide reimbursement for SNM therapy. Outside the United States, reimbursement levels vary significantly by country, particularly if that country maintains a single-payor system. SNM therapy is eligible for reimbursement in Canada, Australia, and certain countries in Europe, such as Germany and the United Kingdom. Annual healthcare budgets generally determine the number of SNM systems that will be paid for by the payor in these single-payor system countries.
We currently outsource the manufacture of certain implantable components of our r-SNM System. Our contract manufacturers are all recognized in their field for their competency to manufacture the respective portions of our r-SNM System and have quality systems established that meet FDA requirements. We believe the manufacturers we currently utilize have sufficient capacity to meet our requirements and are able to scale up their capacity relatively quickly with limited capital investment.
Prior to obtaining FDA approval, we devoted substantially all of our resources to research and development activities related to our r-SNM System, including clinical and regulatory initiatives to obtain marketing approvals. We spend a significant amount of our resources on sales and marketing activities to commercialize and market our r-SNM System in the United States.
We incurred net losses of $22.7 million and $22.5 million for the three months ended March 31, 2022 and 2021, respectively, and had an accumulated deficit of $337.2 million as of March 31, 2022 compared to $314.6 million at December 31, 2021. As of March 31, 2022, we had available cash and cash equivalents of approximately $213.2 million, current liabilities of approximately $25.5 million, and long-term liabilities of approximately $36.6 million.
May 2021 Follow-On Offering
On May 14, 2021, we completed a follow-on offering by issuing 4,025,000 shares of common stock, at an offering price of $50.00 per share, inclusive of 525,000 shares of our common stock issued upon the exercise by the underwriters of their option to purchase additional shares. The gross proceeds to us from this follow-on offering were $201.3 million and the net proceeds were approximately $190.0 million, after deducting underwriting discounts, commissions and offering expenses payable by us.
Impact of COVID-19
The COVID-19 pandemic negatively impacted our sales, starting in the second quarter of 2020, by significantly decreasing and delaying the number of procedures performed using our r-SNM System, and we expect that the pandemic could negatively impact our business, financial condition and results of operations. Similar to the general trend in elective and other surgical procedures, the number of procedures performed using our r-SNM System decreased significantly as healthcare organizations in the United States and globally, including in Europe and Canada, have prioritized the treatment of patients with COVID-19 or have altered their operations to prepare for and respond to the pandemic. Specifically, substantially all of the procedures using our r-SNM System were postponed or cancelled from middle of March 2020 through May 2020, but order flow began a gradual recovery in May 2020 and continued to improve in the second half of 2020 through the second quarter of 2021. During the second half of 2021 and through the first quarter of 2022, certain outpatient elective procedures were again postponed or cancelled related to the COVID-19 pandemic and specifically the Delta and Omicron variants, which adversely affected our business during the second half of 2021 and through the first quarter of 2022.
To protect the health of our employees, their families, and our communities, we have restricted access to our offices to personnel who must perform critical activities that must be completed on-site, limited the number of such personnel that can be present at our facilities at any one time, requested that many of our employees work remotely, and implemented strict travel restrictions. These restrictions and precautionary measures have not adversely affected our operations. Even as efforts to contain the pandemic have made progress and some restrictions
24

have relaxed, new variants of the virus may continue to cause additional outbreaks. The full extent of COVID-19’s effect on our operational and financial performance will depend on future developments, including the duration, spread and intensity of the pandemic, and additional protective measures implemented by the governmental authorities, all of which are uncertain and difficult to predict considering the rapidly evolving landscape. However, if the pandemic continues to evolve into a long-term severe worldwide health crisis, there could be a material adverse effect on our business, results of operations, financial condition, and cash flows.
AMF License Agreement
On October 1, 2013, we entered into a license agreement (the License Agreement) with the Alfred E. Mann Foundation for Scientific Research (AMF), pursuant to which AMF licensed us certain patents and know-how (AMF IP), relating to, in relevant part, an implantable pulse generator and related system components in development by AMF as of that date, in addition to any peripheral or auxiliary devices, including all components, that when assembled, comprise such device, excluding certain implantable pulse generators (AMF Licensed Products).
Under the License Agreement, for each calendar year beginning in 2018, we are obligated to pay AMF a royalty on an AMF Licensed Product-by-AMF Licensed Product basis if one of the following conditions applies: (i) one or more valid claims within any of the patents licensed to us by AMF covers such AMF Licensed Products or the manufacture of such AMF Licensed Products or (ii) for a period of 12 years from the first commercial sale anywhere in the world of such AMF Licensed Product, in each case. The foregoing royalty is calculated as the greater of (a) 4% of all net revenue derived from the AMF Licensed Products, and (b) a minimum annual royalty (the Minimum Royalty), payable quarterly. The Minimum Royalty automatically increases each year, subject to a maximum amount of $200,000 per year. During the three months ended March 31, 2022 and 2021, we have recorded royalties of $1.6 million and $1.3 million, respectively. We have 60 days to pay AMF the royalty amount due under the License Agreement, and if we fail to pay AMF within such 60-day period, AMF may, at its election, convert the exclusive license to a non-exclusive license or terminate the License Agreement.
Components of Our Results of Operations
Net Revenue
Revenue during the three months ended March 31, 2022 and 2021 are as follows (in thousands):

Three Months Ended
March 31,
20222021
SNM net revenue
United States$37,715 $31,745 
International markets1,355 1,158 
$39,070 $32,903 
Bulkamid net revenue(1)
United States$6,569 $578 
International markets2,781 892 
$9,350 $1,470 
Total net revenue$48,420 $34,373 
_____________________________________________
(1)    The acquisition of Bulkamid was completed on February 25, 2021. Reported revenue includes sales from February 26, 2021 onwards.
Cost of Goods Sold and Gross Margin
Cost of goods sold consists primarily of costs of the components of our r-SNM System, third-party contract labor costs, overhead costs, Bulkamid product costs, as well as distribution-related expenses such as logistics and
25

shipping costs. The overhead costs include the cost of material procurement and operations supervision and management personnel. We expect overhead costs as a percentage of revenue to decrease as our sales volume increases. Cost of goods sold also include other expenses such as scrap and inventory obsolescence. We expect cost of goods sold to increase in absolute dollars primarily as, and to the extent, our revenue grows. We expect gross margin to vary based on manufacturing costs, regional differences in pricing, and discounts negotiated by customers.
We calculate gross margin as gross profit divided by revenue. We expect future gross margin will be affected by a variety of factors, including manufacturing costs, the average selling price of our products, the implementation of cost-reduction strategies, inventory obsolescence costs, which may occur when new generations of our r-SNM System are introduced, and to a lesser extent, the sales mix between the United States, Canada, Europe and Australia as our average selling price in the United States is expected to be higher than in Canada, Europe and Australia and foreign currency exchange rates. Our gross margin may increase over the long term to the extent our production volumes increase and we receive discounts on the costs charged by our contract manufacturers, thereby reducing our per unit costs. Additionally, our gross margin may fluctuate from quarter to quarter due to seasonality.
Research and Development Expenses
Research and development expenses consist primarily of employee compensation, including stock-based compensation, product development, including testing and engineering, royalty expense, and clinical studies to develop and support our r-SNM System, including clinical study and registry management and monitoring, payments to clinical investigators, and data management. Other research and development expenses include consulting and advisory fees, royalty expense, travel expenses, and equipment-related expenses and other miscellaneous office and facilities expenses related to research and development programs. Research and development costs are expensed as incurred. We expect to continue incurring research and development expenses in the future as we develop next generation versions of our r-SNM System and expand to new markets. We expect research and development expenses as a percentage of revenue to vary over time depending on the level and timing of initiating new product development efforts and new clinical development activities.
The following table summarizes our research and development expenses by functional area for the three months ended March 31, 2022 and 2021 (in thousands):
 Three Months Ended
March 31,
 20222021
Personnel related$5,137 $4,878 
Clinical development268104 
Contract R&D and manufacturing3,9562,833 
Royalty expense1,5551,308 
Other R&D expenses320246 
Total R&D expenses$11,236 $9,369 
General and Administrative Expenses
General and administrative expenses consist primarily of employee compensation, including stock-based compensation, and spending related to finance, information technology, human resource functions, consulting, legal, and professional service fees. Other general and administrative expenses include director and officer insurance premiums, investor relations costs, changes in fair value of the contingent consideration, office-related expenses, facilities and equipment rentals, bad debt expense, and travel expenses. We expect our general and administrative expenses will significantly increase in absolute dollars as we increase our headcount and expand administrative personnel to support our growth and operations as a public company including finance personnel and information technology services. Additionally, we anticipate increased legal expenses associated with our patent infringement litigation with Medtronic. We expect general and administrative expenses to decrease as a percentage of revenue primarily as, and to the extent, our revenue grows.
26

Sales and Marketing Expenses
Sales and marketing expenses consist primarily of employee compensation, including sales personnel commissions and stock-based compensation, trade shows, booth exhibition costs, and the related travel for these events. Other sales and marketing expenses include direct-to-consumer promotional programs, consulting, and advisory fees. We expect sales and marketing expenses to continue to increase in absolute dollars as we expand our commercial infrastructure to both drive and support our expected growth in revenue. However, we expect sales and marketing expenses to decrease as a percentage of revenue in the long term primarily as, and to the extent, our revenue grows.
Amortization of Intangible Assets
Amortization of intangible assets consist primarily of amortization expense on patent license asset, manufacturing license asset, technology, and customer relationships. We amortize finite lived intangible assets over the period of estimated benefit using the straight-line method. Indefinite lived intangible assets are tested for impairment annually or whenever events or circumstances indicate that the carrying amount of the asset (asset group) may not be recoverable. If impairment is indicated, we measure the amount of the impairment loss as the amount by which the carrying amount exceeds the fair value of the asset. Fair value is generally determined using a discounted future cash flow analysis.
Acquisition-Related Costs
Acquisition-related costs consist of expenses incurred related to the Contura acquisition.
Other Income (Expense), Net
Other income (expense), net consists primarily of interest expense payable under the Loan Agreement with Silicon Valley Bank and other debt arrangements, gains and losses on foreign currency transactions, net of interest income earned on cash equivalents.
Income Tax Expense (Benefit)
Income tax expense (benefit) primarily consists of losses benefited in certain foreign jurisdictions. We maintain a full valuation allowance for deferred tax assets in our domestic operations, including net operating loss carryforwards and research and development credits.
27

Results of Operations
The following table shows our results of operations for the three months ended March 31, 2022 and 2021 (in thousands, except percentages):
 Three Months Ended March 31,
Period to Period Change
 20222021 
Net revenue$48,420 $34,373 $14,047 
Cost of goods sold15,178 13,974 1,204 
Gross profit33,242 20,399 12,843 
Gross Margin68.7 %59.3 % 
Operating expenses   
Research and development11,236 9,369 1,867 
General and administrative10,013 6,626 3,387 
Sales and marketing33,063 20,928 12,135 
Amortization of intangible assets2,463 678 1,785 
Acquisition-related costs— 4,414 (4,414)
Total operating expenses56,775 42,015 14,760 
Loss from operations(23,533)(21,616)(1,917)
Other income (expense) 
Interest income43 35 
Interest and other expense(289)(1,450)1,161 
Other expense, net(246)(1,442)1,196 
Loss before income tax benefit(23,779)(23,058)(721)
Income tax benefit(1,111)(555)(556)
Net loss(22,668)(22,503)(165)
Foreign currency translation adjustment(4,920)(2,202)(2,718)
Comprehensive loss$(27,588)$(24,705)$(2,883)
 
Comparison of the Three Months Ended March 31, 2022 and 2021
Net Revenue
Net revenue was $48.4 million for the three months ended March 31, 2022 and was primarily derived from the sale of our products to customers in the United States and certain international markets. Net revenue was $34.4 million for the three months ended March 31, 2021 and was primarily derived from the sale of our r-SNM System to customers in the United States, Europe and Canada. The increase in net revenue is primarily due to increased sales of our products as we expanded our customer base in the U.S. and international markets and increased sales with our existing customer base.
Cost of Goods Sold and Gross Margin
We incurred $15.2 million of cost of goods sold for the three months ended March 31, 2022. We incurred $14.0 million of cost of goods sold for the three months ended March 31, 2021. Gross margin was 68.7% in the three months ended March 31, 2022, compared to 59.3% for the three months ended March 31, 2021. The increase in gross margin is primarily due to higher sales volumes and increased efficiencies resulting in higher absorption rates.
28

Research and Development Expenses
Research and development expenses increased $1.9 million, or 19.9%, to $11.2 million in the three months ended March 31, 2022, compared to $9.4 million in the three months ended March 31, 2021. The increase in research and development expenses was primarily attributable to an increase of $1.1 million in contract R&D and manufacturing costs, an increase of $0.3 million in personnel costs including salaries and wages, stock-based compensation and other employee-related benefits, and an increase of $0.2 million in royalty expense.
General and Administrative Expenses
General and administrative expenses increased $3.4 million, or 51.1%, to $10.0 million in the three months ended March 31, 2022, compared to $6.6 million in the three months ended March 31, 2021, primarily as a result of an increase of $2.7 million in legal costs.
Sales and Marketing Expenses
Sales and marketing expenses increased $12.1 million, or 58.0%, to $33.1 million in the three months ended March 31, 2022, compared to $20.9 million in the three months ended March 31, 2021. The increase in sales and marketing expenses was primarily due to an increase of $7.4 million related to personnel costs including salaries, wages, sales personnel commissions, stock-based compensation and other employee-related benefits, an increase of $2.2 million related to travel expenses, and an increase of $1.9 million related to direct-to-consumer programs and other advertising expenses.
Amortization of Intangible Assets
Amortization of intangible assets increased to $2.5 million in the three months ended March 31, 2022, compared to $0.7 million in the three months ended March 31, 2021. The increase in amortization of intangible assets was primarily due to an increase of technology and customer relationships acquired related to the Contura acquisition.
Acquisition-Related Costs
There were no acquisition-related costs in the three months ended March 31, 2022. Acquisition-related costs were $4.4 million in the three months ended March 31, 2021 related to the Contura acquisition.
Other Expense, Net
Other expense, net was $0.2 million in the three months ended March 31, 2022 consisting primarily of losses on foreign currency transactions. Other expense, net was $1.4 million in the three months ended March 31, 2021 consisting primarily of interest expense incurred related to the Loan Agreement with Silicon Valley Bank. The decrease in other expense, net primarily relates to interest on higher outstanding debt balances during the three months ended March 31, 2021 and the related write-off of unamortized debt issuance costs.
Income Tax Benefit
Income tax benefit was $1.1 million for the three months ended March 31, 2022 primarily related to losses in certain foreign jurisdictions. Income tax benefit was $0.6 million for the three months ended March 31, 2021 primarily related to deferred tax assets generated in our foreign operations related to the Contura acquisition.
Liquidity and Capital Resources
We only began full-scale commercialization of our r-SNM System in late 2019. We have expended significant resources on research and development activities, growing our operations organization and building and training our sales organization.
We incurred net losses of $22.7 million and $22.5 million for the three months ended March 31, 2022 and 2021, respectively, and had an accumulated deficit of $337.2 million as of March 31, 2022 compared to $314.6 million at December 31, 2021. We expect to continue to spend a significant amount of our existing resources on sales and marketing activities as we continue to commercialize and market our products in the United States and internationally.
As of March 31, 2022, we had cash and cash equivalents of $213.2 million compared to $220.9 million at
29

December 31, 2021. We expect that our cash and cash equivalents on hand will be sufficient to fund our operations through at least the next 12 months. We fund our operations through a combination of proceeds from public offerings of our common stock and cash receipts from sales of our products. As of March 31, 2022, we had no outstanding borrowings.
We may need to raise additional financing in the future to facilitate our business operations. If we raise additional funds by issuing equity securities, our stockholders could experience dilution. Debt financing, if available, may involve covenants further restricting our operations or our ability to incur additional debt. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. Additional financing may not be available at all, or in amounts or on terms acceptable to us. If we are unable to obtain additional financing when needed to satisfy our liquidity requirements, we may be required to scale back our operations.
Cash Flows
The following table presents a summary of our cash flow for the periods indicated (in thousands):
 Three Months Ended
March 31,
 20222021
Net cash provided by (used in)  
Operating activities$(9,167)$(25,583)
Investing activities(291)(140,864)
Financing activities1,444 56,215 
Effect of exchange rate changes on cash and cash equivalents316 13 
Net decrease in cash and cash equivalents$(7,698)$(110,219)
Net cash used in operating activities
Net cash used in operating activities was $9.2 million for the three months ended March 31, 2022 and consisted primarily of a net loss of $22.7 million, partially offset by non-cash charges of $8.9 million and an increase from changes in net operating assets of $4.6 million. Net operating assets consisted primarily of inventory and accounts receivable due to the commercial growth of our r-SNM System in the United States and the addition of Bulkamid sales. Non-cash charges consisted primarily of stock-based compensation and depreciation and amortization.
Net cash used in operating activities was $25.6 million for the three months ended March 31, 2021 and consisted primarily of a net loss of $22.5 million and a decrease from changes in net operating assets of $9.4 million, partially offset by non-cash charges of $6.4 million. Net operating assets consisted primarily of inventory due to the commercial growth of our r-SNM System in the United States. Non-cash charges consisted primarily of stock-based compensation.
Net cash used in investing activities
Net cash used in investing activities was $0.3 million for the three months ended March 31, 2022 and consisted of purchases of property and equipment.
Net cash used in investing activities was $140.9 million for the three months ended March 31, 2021 and consisted primarily of the $140.7 million paid for the acquisition of Contura.
Net cash provided by financing activities
Net cash provided by financing activities was $1.4 million for the three months ended March 31, 2022 and consisted of proceeds from exercise of stock options.
Net cash provided by financing activities was $56.2 million for the three months ended March 31, 2021 and consisted primarily of $75 million in net proceeds received in the Loan Agreement with Silicon Valley Bank in
30

connection with the Contura acquisition, partially offset by the pay down of $21.5 million of the prior Loan Agreement with Silicon Valley Bank.
Indebtedness
In June 2021, the principal amount, accrued interest, accrued loan fees, and prepayment fees related to the term loan under the Loan and Security Agreement with Silicon Valley Bank entered into in February 2021, were paid in full. The unamortized debt issuance costs of $4.4 million were expensed and recognized as interest expense.
In January 2021, the principal amount, accrued interest, accrued loan fees, and prepayment fees related to the term loan under the Loan and Security Agreement with Silicon Valley Bank entered into in February 2018, were paid in full. The unamortized debt issuance costs of $0.4 million were expensed and recognized as interest expense.
We have no further indebtedness arrangements.
Critical Accounting Policies and Estimates
Our critical accounting policies and estimates are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 1, 2022. We have reviewed and determined that those critical accounting policies and estimates remain our critical accounting policies and estimates as of and for the three months ended March 31, 2022.
Recent Accounting Pronouncements
We have reviewed all recently issued standards and have determined that, other than as disclosed in Note 1 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, such standards will not have a significant impact on our condensed consolidated financial statements or do not otherwise apply to our operations.
Item 3.    Quantitative and Qualitative Disclosures About Market Risk.
We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate risk, foreign currency exchange rate risk and inflation risk as follows:
Interest Rate Risk
We had cash and cash equivalents of $213.2 million as of March 31, 2022, which came from public offerings of our common stock and cash receipts from our product sales. The goals of our investment policy are liquidity and capital preservation and we do not enter into investments for trading or speculative purposes. We believe that we do not have any material exposure to changes in the fair value of these assets as a result of changes in interest rates due to the short term nature of our cash and cash equivalents. A hypothetical 10% relative change in interest rates during any of the periods presented would not have had a material impact on our consolidated financial statements. We do not currently engage in hedging transactions to manage our exposure to interest rate risk.
Foreign Currency Exchange Rate Risk
As we expand internationally our results of operations and cash flows may become increasingly subject to fluctuations due to changes in foreign currency exchange rates. All of our revenue is denominated in U.S. dollars. Our expenses are generally denominated in the currencies in which our operations are located, which is primarily in the United States. The effect of a 10% adverse change in exchange rates on foreign denominated cash, receivables and payables would not have been material for the periods presented. As our operations in countries outside of the United States grow, our results of operations and cash flows may be subject to fluctuations due to changes in foreign currency exchange rates, which could harm our business in the future. To date, we have not entered into any material foreign currency hedging contracts although we may do so in the future.
Inflation Risk
Inflationary factors, such as increases in our cost of goods sold and selling and operating expenses, may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, a high rate of inflation in the future may have an adverse effect on
31

our ability to maintain and increase our gross margin and sales and marketing and operating expenses as a percentage of our revenue if the selling prices of our products do not increase as much as or more than these increased costs.
Item 4.    Controls and Procedures.
Limitations on effectiveness of controls and procedures
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Evaluation of disclosure controls and procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of March 31, 2022 due to the material weakness in internal control over financial reporting, as described below.
Material Weakness in Internal Control Over Financial Reporting
In connection with the audit of our financial statements as of and for the year ended December 31, 2021, we identified a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.
We determined that a material weakness exists relating to the determination of the fair values of identifiable intangible assets and contingent consideration liability related to business combination. This control deficiency creates a reasonable possibility that a material misstatement to the consolidated financial statements will not be prevented or detected on a timely basis.
Notwithstanding such material weakness in internal control over financial reporting, our management, including our Principal Executive Officer and our Chief Financial Officer, has concluded that our consolidated financial statements present fairly, in all material respects, our financial position, results of our operations and our cash flows for the periods presented in this Quarterly Report, in conformity with GAAP.
Remediation Plan
We have identified steps as further described below, to remediate the material weakness described in this Item 4 and to enhance our overall control environment. We are committed to ensuring that our internal controls over financial reporting are designed and operating effectively. Our remediation process includes, but is not limited to:
Enhancing the design of controls, including the precision of the management review controls relating to key methodologies, assumptions and inputs used in the determination of the fair value of identifiable intangibles and a contingent consideration liability;
Implementing a valuation review checklist that includes specific review attributes to ensure sufficient evidence of an effective review is documented and maintained to support management’s conclusions; and
Expanding personnel with appropriate experience to devote sufficient time and resources to our internal controls over fair value measurements.
32

We believe that these actions will remediate the material weakness. The weakness will not be considered remediated, however, until the applicable controls operate and management has concluded, through testing, that these controls are operating effectively.
As we continue to evaluate and test the remediation plan outlined above, we may also identify additional measures to address the material weakness or modify certain of the remediation procedures described above. Management, with the oversight of the Audit Committee, will continue to take steps necessary to remedy the material weakness to reinforce the overall design and capability of our control environment.
Changes in internal control over financial reporting
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
33

PART IIOTHER INFORMATION
Item 1.    Legal Proceedings.
There have been no material developments in the litigation matters disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 1, 2022, during the quarter ended March 31, 2022.
Item 1A. Risk Factors.
You should carefully consider the information described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 1, 2022. There have been no material changes from the risk factors disclosed in our recent SEC filings, including our most recently filed Form 10-K, as referenced above.
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3.    Defaults Upon Senior Securities.
None.
Item 4.    Mine Safety Disclosures.
Not applicable.
Item 5.    Other Information.
None.
34

Item 6.     Exhibits.
EXHIBIT INDEX
Exhibit Number
Exhibit Title 
31.1
31.2
32.1#
32.2#
101.INS**Inline XBRL Instance Document.
101.SCH**Inline XBRL Taxonomy Extension Schema Document.
101.CAL**Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF**Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB**Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE**Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101).
#The information in Exhibits 32.1 and 32.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report on Form 10-Q), unless the Company specifically incorporates the foregoing information into those documents by reference.
**In accordance with Rule 402 of Regulation S-T, this interactive data file is deemed not filed or part of this Quarterly Report on Form 10-Q for purposes of Sections 11 or 12 of the Securities Act or Section 18 of the Exchange Act and otherwise is not subject to liability under these sections.
35

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 AXONICS, INC.
Date: May 5, 2022
By: /s/ Raymond W. Cohen
   
Raymond W. Cohen
   Chief Executive Officer and Director
   (Principal Executive Officer)
Date: May 5, 2022By:/s/ Dan L. Dearen
Dan L. Dearen
President and Chief Financial Officer
(Principal Financial and Accounting Officer)
36
EX-31.1 2 a03312022-exhibit311.htm EX-31.1 Document

Exhibit 31.1
I, Raymond W. Cohen, certify that:
1.    I have reviewed this Quarterly Report on Form 10-Q of Axonics, Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 5, 2022By: /s/ Raymond W. Cohen
   
Raymond W. Cohen
   Chief Executive Officer and Director
   (Principal Executive Officer)


EX-31.2 3 a03312022-exhibit312.htm EX-31.2 Document

Exhibit 31.2
I, Dan L. Dearen, certify that:
1.    I have reviewed this Quarterly Report on Form 10-Q of Axonics, Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 5, 2022By: /s/ Dan L. Dearen
   
Dan L. Dearen
   
President and Chief Financial Officer
   
(Principal Financial Officer)


EX-32.1 4 a03312022-exhibit321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Axonics, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 5, 2022By: /s/ Raymond W. Cohen
   
Raymond W. Cohen
   Chief Executive Officer and Director
   (Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to Axonics, Inc. and will be retained by Axonics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 a03312022-exhibit322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Axonics, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 5, 2022By: /s/ Dan L. Dearen
   
Dan L. Dearen
   
President and Chief Financial Officer
   
(Principal Financial Officer)

A signed original of this written statement required by Section 906 has been provided to Axonics, Inc. and will be retained by Axonics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.


EX-101.SCH 6 axnx-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Schedule of Revenue Disaggregated by Geographic Market (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2108102 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Property and Equipment - Schedule of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Property and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2112103 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2313303 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2415408 - Disclosure - Commitments and Contingencies - Schedule of Total Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2116104 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 2417409 - Disclosure - Long-Term Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2118105 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 2319304 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2420410 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2421411 - Disclosure - Stock-based Compensation - Schedule of Option Awards Fair Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2422412 - Disclosure - Stock-based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2423413 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2424414 - Disclosure - Stock-based Compensation - Schedule of Restricted Shares Awards Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2425415 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2126106 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2327305 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2428416 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes and Effective Tax Rates (Details) link:presentationLink link:calculationLink link:definitionLink 2429417 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2130107 - Disclosure - Employee Benefit Plan link:presentationLink link:calculationLink link:definitionLink 2431418 - Disclosure - Employee Benefit Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2132108 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2333306 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2434419 - Disclosure - Goodwill and Intangible Assets - Schedule of Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2435420 - Disclosure - Goodwill and Intangible Assets - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2435420 - Disclosure - Goodwill and Intangible Assets - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 axnx-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 axnx-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 axnx-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Net Loss per Share of Common Stock Earnings Per Share, Policy [Policy Text Block] Trade names and trademarks Trademarks and Trade Names [Member] Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Leasehold improvements Leasehold Improvements [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net loss Net loss Net Income (Loss) Attributable to Parent Right-of-use asset Operating Lease, Right-of-Use Asset Preferred stock outstanding (in shares) Preferred Stock, Shares Outstanding Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Schedule of Finite-Lived and Indefinite-Lived Intangible Assets [Table Text Block] Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Accrued compensation and benefits Employee-related Liabilities, Current Income Statement Location [Axis] Income Statement Location [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Statistical Measurement [Domain] Statistical Measurement [Domain] Acquisition-related costs Business Combination, Acquisition Related Costs Advertising Expense: Marketing and Advertising Expense [Abstract] Number of petitions accepted by the United States Patent and Trademark Office Loss Contingency, New Claims Filed, Number Accepted by Court Loss Contingency, New Claims Filed, Number Accepted by Court Segment Reporting Segment Reporting, Policy [Policy Text Block] Vendor credit in accounts payable Accounts Payable, Vendor Credit Accounts Payable, Vendor Credit Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Forfeited (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Options forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Weighted-average remaining lease terms for operating leases Operating Lease, Weighted Average Remaining Lease Term Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Other assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Dividend rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Retirement Benefits [Abstract] Retirement Benefits [Abstract] Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity File Number Entity File Number Intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Fourth Lease Lease 4 [Member] Lease 4 Restricted Shares Award (RSA) issuances and forfeitures for terminations, net and stock-based compensation APIC, Share-based Payment Arrangement, Restricted Stock Award, Increase for Cost Recognition APIC, Share-based Payment Arrangement, Restricted Stock Award, Increase for Cost Recognition Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization of intangible assets Amortization of Intangible Assets Finite-lived intangible assets, weighted-average amortization period Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Variable lease cost Variable Lease, Cost Weighted-average incremental borrowing rate for a collateralized asset of the same remaining term (as a percent) Operating Lease, Weighted Average Discount Rate, Percent Potentially dilutive weighted-average shares not included in computation of diluted weighted average shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Research and development Research and Development Expense [Member] Sale of Stock [Axis] Sale of Stock [Axis] Liability Class [Axis] Liability Class [Axis] Granted (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Business Acquisition [Axis] Business Acquisition [Axis] Schedule of Changes in Fair Value of Liabilities Measured on Recurring Basis Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Award Type [Domain] Award Type [Domain] Local Phone Number Local Phone Number ASSETS Assets [Abstract] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2022 and December 31, 2021 Preferred Stock, Value, Issued Finite-lived intangible asset acquired Finite-lived Intangible Assets Acquired Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Accumulated Deficit Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Advertising Expense Advertising Cost [Policy Text Block] Issuance of common stock for exclusive license asset (in shares) Stock issued for purchase of intangible asset (in shares) Stock Issued During Period, Shares, Purchase of Assets Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Term Loan Two Term Loan Two [Member] Term Loan Two Accounts receivable Increase (Decrease) in Accounts Receivable Change in property and equipment acquired but not yet paid Capital Expenditures Incurred but Not yet Paid Right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Interest income Investment Income, Nonoperating Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Number of operating segments Number of Operating Segments Net loss per share, basic (in USD per share) Earnings Per Share, Basic Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Schedule of Revenue Disaggregated by Product and Geographic Market Disaggregation of Revenue [Table Text Block] Contributions by employer Defined Contribution Plan, Cost Cash paid for operating lease liabilities Operating Lease, Payments Bad debt recoveries Accounts Receivable, Allowance for Credit Loss, Recovery Research and Development Research and Development Expense, Policy [Policy Text Block] Deferred income taxes and other items, net Deferred Income Tax Expense (Benefit) and Other Operating Activities, Cash Flow Statement Deferred Income Tax Expense (Benefit) and Other Operating Activities, Cash Flow Statement Reversal of allowance of credit losses Accounts Receivable, Credit Loss Expense (Reversal) Goodwill [Roll Forward] Goodwill [Roll Forward] Unrealized gain (loss) on investment securities Debt Securities, Unrealized Gain (Loss) Outstanding borrowings Long-term Debt Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Impairment charges related to goodwill Goodwill, Impairment Loss Operating loss carryforwards, subject to expiration Operating Loss Carryforwards, Subject To Expiration Operating Loss Carryforwards, Subject To Expiration Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Small Business Entity Small Business Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total liabilities and stockholders’ equity Liabilities and Equity Options exercised (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Additional paid-in capital Additional Paid in Capital Supplemental Disclosure of Cash Flow Information Supplemental Cash Flow Elements [Abstract] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Minimum number of claims by Medtronic that are invalid as determined by the United States Patent and Trademark Office Loss Contingency, New Claims Filed, Minimum Number of Patent Claims that are Invalid Loss Contingency, New Claims Filed, Minimum Number of Patent Claims that are Invalid Contingent consideration: Liability Measured At Fair Value, Recurring Basis [Roll Forward] Liability Measured At Fair Value, Recurring Basis Operating expenses Operating Expenses [Abstract] Entity Interactive Data Current Entity Interactive Data Current Minimum Minimum [Member] May 2021 Follow-On Offering: Class of Stock Disclosures [Abstract] Royalty commitments Royalty Guarantees, Commitments, Amount Gross profit Gross Profit Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Unamortized debt issuance costs Debt Issuance Costs, Net Net rentable area (square feet) Net Rentable Area Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Preferred stock authorized (in shares) Preferred Stock, Shares Authorized Income Tax Authority [Domain] Income Tax Authority [Domain] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Address, State or Province Entity Address, State or Province Follow-on Offering Follow-on Offering [Member] Follow-on Offering [Member] First Lease Lease 1 [Member] Lease #1 [Member] Issuance of common stock for acquisition of Contura Limited Common stock issuance for business acquisition Stock Issued During Period, Value, Acquisitions Current liabilities Liabilities, Current [Abstract] General and administrative General and Administrative Expense Acquisition of a business, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Long-Term Debt Debt Disclosure [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Leases Lessee, Leases [Policy Text Block] Accrued loan fees as debt issuance costs Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Weighted-average remaining contractual term of options outstanding and exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Document Transition Report Document Transition Report Period after first sale royalty is due Period After First Sale Royalty Is Due Period After First Sale Royalty Is Due Common stock, par value $0.0001, 50,000,000 shares authorized at March 31, 2022 and December 31, 2021; 47,002,862 and 46,330,167 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Other expense, net Nonoperating Income (Expense) Inventory: Inventory, Net [Abstract] Weighted-average period of recognition of compensation cost Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Outstanding at beginning of period (in USD per share) Outstanding at end of period (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Commitments and contingencies (Note 3) Commitments and Contingencies Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Emerging Growth Company Entity Emerging Growth Company Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Restricted Shares Awards Restricted Stock [Member] Payment of debt issuance costs Payments of Debt Issuance Costs Schedule of Option Awards Fair Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Restricted Stock Units Activity Share-based Payment Arrangement, Activity [Table Text Block] Investment Securities: Debt Securities [Abstract] Cover [Abstract] Cover [Abstract] Inventory shelf life Inventory, Shelf Life Inventory, Shelf Life Royalty expense Royalty Expense Second Lease Lease 2 [Member] Lease #2 [Member] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Income Tax Authority [Axis] Income Tax Authority [Axis] Net proceeds from sale of stock Sale of Stock, Consideration Received on Transaction Work-in-process inventory Inventory, Work in Process, Net of Reserves Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Lease liability Increase (Decrease) in Lease Liabilities Increase (Decrease) in Lease Liabilities Gross Carrying Amount Indefinite-lived Intangible Assets, Gross Indefinite-lived Intangible Assets, Gross Accrued liabilities Accrued Liabilities, Current Net revenue Revenues Revenue from Contract with Customer, Excluding Assessed Tax Finished goods inventory Inventory, Finished Goods, Net of Reserves Stock Options Share-based Payment Arrangement, Option [Member] Equity [Abstract] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Document Quarterly Report Document Quarterly Report Contingent Consideration Liability Contingent Consideration Liability [Member] Contingent Consideration Liability Third Lease Lease 3 [Member] Lease 3 [Member] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Common Stock Common Stock [Member] Other income (expense) Other Nonoperating Income (Expense) [Abstract] Loss from operations Operating Income (Loss) Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Operating lease liability, current portion Operating Lease, Liability, Current Nature of Operations and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Property and Equipment: Property, Plant and Equipment [Abstract] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Technology Technology-Based Intangible Assets [Member] Repayment of debt Repayments of Debt Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Accrued liabilities Increase (Decrease) in Accrued Liabilities Issuance of common stock for vesting of Restricted Stock Units (RSU) and stock-based compensation APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition Interest and other expense Other Nonoperating Income (Expense) Allowance for product returns Accounts Receivable, Allowance for Product Returns Accounts Receivable, Allowance for Product Returns Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Property and Equipment Property, Plant and Equipment [Member] Maximum Maximum [Member] Total liabilities Liabilities Intangible Assets, Net (Excluding Goodwill): Intangible Assets, Net (Excluding Goodwill) [Abstract] Raw materials inventory Inventory, Raw Materials, Net of Reserves Award Type [Axis] Award Type [Axis] Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Intrinsic value of options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Total stockholders’ equity Balance at beginning of period Balance at end of period Stockholders' Equity Attributable to Parent Operating loss carryforwards Operating Loss Carryforwards Common stock issued (in shares) Common Stock, Shares, Issued Preferred stock issued (in shares) Preferred Stock, Shares Issued City Area Code City Area Code Foreign currency translation adjustment Finite-Lived Intangible Assets, Foreign Exchange Adjustment Finite-Lived Intangible Assets, Foreign Exchange Adjustment Issuance of common stock for exclusive license asset Fair value of shares issued for purchase of intangible asset Stock Issued During Period, Value, Purchase of Assets Goodwill and Intangible Assets Disclosure [Abstract] Entity Address, City or Town Entity Address, City or Town Property and equipment useful life Property, Plant and Equipment, Useful Life Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Noncash Investing and Financing Activities Noncash Investing and Financing Items [Abstract] Stock-Based Compensation: Share-based Payment Arrangement, Noncash Expense [Abstract] Risk-free interest rate, minimum (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Measurement Frequency [Domain] Measurement Frequency [Domain] Interest expense Interest Expense Accrued compensation and benefits Increase (Decrease) in Employee Related Liabilities Stock volatility, maximum (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Replacement costs Replacement of Damaged or Defective Products Cost Replacement of Damaged or Defective Products Cost Accumulated deficit Retained Earnings (Accumulated Deficit) Term of operating lease contract Lessee, Operating Lease, Term of Contract Litigation Case [Domain] Litigation Case [Domain] Restricted Stock Units Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Entity Filer Category Entity Filer Category Schedule of Restricted Shares Awards Activity Share-based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block] Entity Registrant Name Entity Registrant Name Asset Class [Domain] Asset Class [Domain] Intangible Assets, Net Indefinite-lived Intangible Assets (Excluding Goodwill) Proceeds from exercise of stock options Proceeds from Stock Options Exercised Issuance of common stock for vesting of Restricted Stock Units (RSU) and stock-based compensation (in shares) Shares Issued, Restricted Stock Units, Shares, Share-based Payment Arrangement, after Forfeiture Shares Issued, Restricted Stock Units, Shares, Share-based Payment Arrangement, after Forfeiture Options forfeited (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax benefit Income tax benefit Income Tax Expense (Benefit) Accounts receivable, net of allowance for credit losses of $316 and $355 at March 31, 2022 and December 31, 2021, respectively Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Proceeds from debt Proceeds from Issuance of Long-term Debt Equity Components [Axis] Equity Components [Axis] Entity Tax Identification Number Entity Tax Identification Number Fair Value of Financial Instruments Fair Value Disclosures [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Sales and marketing Selling and Marketing Expense [Member] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Sale of Stock [Domain] Sale of Stock [Domain] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Inventory, net Inventory, Net Tools and molds Tools, Dies and Molds [Member] Stock-Based Compensation Share-based Payment Arrangement [Policy Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Unrecognized compensation cost related to unvested stock options Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Product and Service [Axis] Product and Service [Axis] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share February 25, 2021 Acquisition Business Combination, Contingent Consideration, Liability, Acquired During Period Business Combination, Contingent Consideration, Liability, Acquired During Period Weighted-average grant date fair value of options granted (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Short-term lease cost Short-term Lease, Cost Sales and marketing Selling and Marketing Expense Foreign currency translation adjustment Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Statement [Line Items] Statement [Line Items] Litigation Case [Axis] Litigation Case [Axis] Issuance of common stock for acquisition of Contura Limited (in shares) Stock Issued During Period, Shares, Acquisitions Impairment of finite-lived intangible asset Impairment of Intangible Assets, Finite-lived Weighted-Average Exercise Price Per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Contingent consideration for business acquisition Noncash or Part Noncash Acquisition, Contingent Consideration Noncash or Part Noncash Acquisition, Contingent Consideration Domestic Tax Authority Domestic Tax Authority [Member] Stock Option and Restricted Stock-Based Awards Employee Stock Option and Restricted Stock-Based Awards [Member] Employee Stock Option and Restricted Stock-Based Awards [Member] Foreign currency translation adjustment Indefinite-lived Intangible Assets, Foreign Currency Translation Adjustment Indefinite-lived Intangible Assets, Foreign Currency Translation Adjustment Revenue Recognition Revenue Recognition [Abstract] Outstanding investment securities Debt Securities, Available-for-sale Gross Carrying Amount Intangible Assets, Gross (Excluding Goodwill) Debt Disclosure [Abstract] Debt Disclosure [Abstract] Issuance of common stock for employee stock option exercises for cash (in shares) Share-Based Compensation Arrangement By Share-based Payment Award, Options, Exercises In Period, Cash Share-based Compensation Arrangement By Share-based Payment Award, Options, Exercises In Period, Cash Allowance for Credit Losses Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Loss before income tax benefit Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Segment Reporting [Abstract] Segment Reporting [Abstract] Weighted-Average Amortization Period Finite-Lived Intangible Asset, Useful Life Employee Benefit Plan Retirement Benefits [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Asset Class [Axis] Asset Class [Axis] Schedule of Stock-based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Title of 12(b) Security Title of 12(b) Security Total assets Assets Common stock authorized (in shares) Common Stock, Shares Authorized Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Geographical [Domain] Geographical [Domain] Document Type Document Type Product and Service [Domain] Product and Service [Domain] Research and development Research and Development Expense Renewal term of operating lease Lessee, Operating Lease, Renewal Term Medtronic Litigation Medtronic Litigation [Member] Medtronic Litigation Contingent consideration at fair value Balance at beginning of period Balance at end of period Business Combination, Contingent Consideration, Liability Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Furniture and fixtures Furniture and Fixtures [Member] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Total Lease Cost Lease, Cost [Table Text Block] Geographical [Axis] Geographical [Axis] Weighted-average shares used to compute basic net loss per share (in shares) Weighted Average Number of Shares Outstanding, Basic Net loss per share, diluted (in USD per share) Earnings Per Share, Diluted State and Local Jurisdiction State and Local Jurisdiction [Member] Amortization of the ROU asset Operating Lease, Right-of-Use Asset, Amortization Expense Sale of stock, price per share (in USD per share) Sale of Stock, Price Per Share Cash paid for taxes Income Taxes Paid, Net International markets Non-US [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Intangible assets, net Intangible Assets, Net Intangible Assets, Net (Excluding Goodwill) Exclusive license asset Exclusive License Asset [Member] Exclusive License Asset Investment Securities Investment, Policy [Policy Text Block] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Indefinite-lived Intangible Assets: Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract] Deferred tax liabilities, net Deferred Income Tax Liabilities, Net Term Loans Loans Payable [Member] Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Schedule of Provision for Income Taxes and Effective Tax Rates Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Accounts payable Accounts Payable, Current Depreciation and amortization Depreciation and amortization expense Depreciation, Depletion and Amortization Foreign Tax Authority Foreign Tax Authority [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Inventory Increase (Decrease) in Inventories Accrued royalty expense Accrued Royalties, Current Common stock outstanding (in shares) Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Outstanding Cost of goods sold Cost of Goods and Services Sold Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Document Period End Date Document Period End Date Restricted Shares Award (RSA) issuances and forfeitures for terminations, net and stock-based compensation (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Entity Central Index Key Entity Central Index Key Issuance of common stock for employee stock option exercises for cash Stock Issued During Period, Value, Stock Options Exercised, Cash Stock Issued During Period, Value, Stock Options Exercised, Cash Number of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Total lease cost Lease, Cost Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Customer relationships Customer Relationships [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Total operating expenses Operating Expenses Stock-based Compensation Shareholders' Equity and Share-based Payments [Text Block] Other long-term liabilities Other Liabilities, Noncurrent Debt Instrument [Line Items] Debt Instrument [Line Items] Trading Symbol Trading Symbol Net Loss per Share of Common Stock: Earnings Per Share [Abstract] Property and equipment, gross Property, Plant and Equipment, Gross Balance at beginning of period Balance at end of period Accounts Receivable, Allowance for Credit Loss Other assets Increase (Decrease) in Other Operating Assets Equipment Equipment [Member] Outstanding at beginning of period (in USD per share) Outstanding at end of period (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Patent license asset Patents [Member] Share-based compensation expense Share-based Payment Arrangement, Expense Bulkamid net revenue Bulkamid [Member] Bulkamid Entity Current Reporting Status Entity Current Reporting Status Weighted-Average Fair Value Per Share at Grant Date Weighted-Average Fair Value Per Share at Grant Date Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Stock volatility, minimum (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Effective tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest SNM net revenue Sacral Neuromodulation [Member] Sacral Neuromodulation Amortization of debt issuance costs Amortization of Debt Issuance Costs Inventory reserves Inventory Valuation Reserves Construction in progress Construction in Progress [Member] Cash and cash equivalents, beginning of year Cash and cash equivalents, end of period Cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents United States UNITED STATES Stock issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Risk-free interest rate, maximum (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Current assets Assets, Current [Abstract] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Intangible Asset: Finite-Lived Intangible Assets, Net: Finite-Lived Intangible Assets, Net [Abstract] Income Taxes Income Tax, Policy [Policy Text Block] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] [Line Items] for Summary Of Significant Accounting Policies [Table] Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Options exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Weighted-average shares used to compute diluted net loss per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Fair Value, Recurring Fair Value, Recurring [Member] Income Taxes Income Tax Disclosure [Text Block] Requisite service period of recognition of compensation cost Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Exercise of Underwriters Option Over-Allotment Option [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Schedule of Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Goodwill: Goodwill, Impaired [Abstract] Write-offs Accounts Receivable, Allowance for Credit Loss, Writeoff Net revenue due as royalty (as a percent) Percentage of Net Revenue Due As Royalty Percentage of Net Revenue Due as Royalty Contura Contura Limited [Member] Contura Limited Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Entity Address, Address Line One Entity Address, Address Line One Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Changes in operating assets and liabilities, net of business acquisition Increase (Decrease) in Operating Capital [Abstract] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Vested (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value General and administrative General and Administrative Expense [Member] Principles of Consolidation Consolidation, Policy [Policy Text Block] Entity Shell Company Entity Shell Company Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Foreign currency translation adjustment Goodwill, Foreign Currency Translation Gain (Loss) Loss Contingencies [Table] Loss Contingencies [Table] Term Loan One Term Loan One [Member] Term Loan One Current Fiscal Year End Date Current Fiscal Year End Date Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Statement [Table] Statement [Table] Number of Restricted Shares Awards Number of Restricted Stock Units Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Advertising expense Advertising Expense Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Unrecognized compensation cost related to unvested RSAs or RSUs Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Number of petitions filed with the United States Patent and Trademark Office Loss Contingency, New Claims Filed, Number Statistical Measurement [Axis] Statistical Measurement [Axis] Basis of Presentation and Liquidity [Abstract] Basis Of Presentation And Liquidity [Abstract] Basis Of Presentation And Liquidity Preferred Stock Preferred Stock [Member] Intangible Assets, Net Finite-Lived Intangible Assets, Net Goodwill Balance at beginning of period Balance at end of period Goodwill Warranty liability Standard Product Warranty Accrual Inventory, Net Inventory, Policy [Policy Text Block] Schedule of Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Common stock issuance for exclusive license asset Stock Issued During Period, Value, Exclusive License Asset Stock Issued During Period, Value, Exclusive License Asset Operating lease cost Operating Lease, Cost Computer hardware and software Computer Equipment [Member] Schedule of Changes in Allowance for Credit Losses Accounts Receivable, Allowance for Credit Loss [Table Text Block] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] EX-101.PRE 10 axnx-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - shares
3 Months Ended
Mar. 31, 2022
May 03, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2022  
Document Transition Report false  
Entity File Number 001-38721  
Entity Registrant Name Axonics, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 45-4744083  
Entity Address, Address Line One 26 Technology Drive  
Entity Address, City or Town Irvine,  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92618  
City Area Code (949)  
Local Phone Number 396-6322  
Title of 12(b) Security Common stock, par value $0.0001 per share  
Trading Symbol AXNX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   47,070,097
Amendment Flag false  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0001603756  
Current Fiscal Year End Date --12-31  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Current assets    
Cash and cash equivalents $ 213,180 $ 220,878
Accounts receivable, net of allowance for credit losses of $316 and $355 at March 31, 2022 and December 31, 2021, respectively 27,425 29,044
Inventory, net 61,876 64,946
Prepaid expenses and other current assets 4,952 6,449
Total current assets 307,433 321,317
Property and equipment, net 6,907 6,915
Intangible assets, net 101,179 106,469
Other assets 7,494 7,734
Goodwill 102,558 105,510
Total assets 525,571 547,945
Current liabilities    
Accounts payable 10,390 7,654
Accrued liabilities 6,246 5,435
Accrued compensation and benefits 7,480 12,413
Operating lease liability, current portion 1,403 1,366
Total current liabilities 25,519 26,868
Operating lease liability, net of current portion 8,686 9,052
Deferred tax liabilities, net 17,564 19,217
Other long-term liabilities 10,370 10,370
Total liabilities 62,139 65,507
Commitments and contingencies (Note 3)
Stockholders’ equity    
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2022 and December 31, 2021 0 0
Common stock, par value $0.0001, 50,000,000 shares authorized at March 31, 2022 and December 31, 2021; 47,002,862 and 46,330,167 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively 5 5
Additional paid-in capital 812,141 803,559
Accumulated deficit (337,234) (314,566)
Accumulated other comprehensive loss (11,480) (6,560)
Total stockholders’ equity 463,432 482,438
Total liabilities and stockholders’ equity $ 525,571 $ 547,945
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 316 $ 355
Preferred stock, par value (in USD per share) $ 0.0001 $ 0.0001
Preferred stock authorized (in shares) 10,000,000 10,000,000
Preferred stock issued (in shares) 0 0
Preferred stock outstanding (in shares) 0 0
Common stock, par value (in USD per share) $ 0.0001 $ 0.0001
Common stock authorized (in shares) 50,000,000 50,000,000
Common stock issued (in shares) 47,002,862 46,330,167
Common stock outstanding (in shares) 47,002,862 46,330,167
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Statement of Comprehensive Income [Abstract]    
Net revenue $ 48,420 $ 34,373
Cost of goods sold 15,178 13,974
Gross profit 33,242 20,399
Operating expenses    
Research and development 11,236 9,369
General and administrative 10,013 6,626
Sales and marketing 33,063 20,928
Amortization of intangible assets 2,463 678
Acquisition-related costs 0 4,414
Total operating expenses 56,775 42,015
Loss from operations (23,533) (21,616)
Other income (expense)    
Interest income 43 8
Interest and other expense (289) (1,450)
Other expense, net (246) (1,442)
Loss before income tax benefit (23,779) (23,058)
Income tax benefit (1,111) (555)
Net loss (22,668) (22,503)
Foreign currency translation adjustment (4,920) (2,202)
Comprehensive loss $ (27,588) $ (24,705)
Net loss per share, basic (in USD per share) $ (0.50) $ (0.57)
Net loss per share, diluted (in USD per share) $ (0.50) $ (0.57)
Weighted-average shares used to compute basic net loss per share (in shares) 45,139,038 39,613,964
Weighted-average shares used to compute diluted net loss per share (in shares) 45,139,038 39,613,964
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Balance at beginning of period (in shares) at Dec. 31, 2020   39,931,030      
Balance at beginning of period at Dec. 31, 2020 $ 287,370 $ 4 $ 522,296 $ (234,499) $ (431)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock for employee stock option exercises for cash (in shares)   206,507      
Issuance of common stock for employee stock option exercises for cash 2,821   2,821    
Restricted Shares Award (RSA) issuances and forfeitures for terminations, net and stock-based compensation (in shares)   358,300      
Restricted Shares Award (RSA) issuances and forfeitures for terminations, net and stock-based compensation 3,809   3,809    
Issuance of common stock for vesting of Restricted Stock Units (RSU) and stock-based compensation (in shares)   169,054      
Issuance of common stock for vesting of Restricted Stock Units (RSU) and stock-based compensation 1,494   1,494    
Issuance of common stock for acquisition of Contura Limited (in shares)   1,096,583      
Issuance of common stock for acquisition of Contura Limited 55,728   55,728    
Issuance of common stock for exclusive license asset (in shares)   65,594      
Issuance of common stock for exclusive license asset 3,637   3,637    
Foreign currency translation adjustment (2,202)       (2,202)
Net loss (22,503)     (22,503)  
Balance at end of period (in shares) at Mar. 31, 2021   41,827,068      
Balance at end of period at Mar. 31, 2021 $ 330,154 $ 4 589,785 (257,002) (2,633)
Balance at beginning of period (in shares) at Dec. 31, 2021 46,330,167 46,330,167      
Balance at beginning of period at Dec. 31, 2021 $ 482,438 $ 5 803,559 (314,566) (6,560)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock for employee stock option exercises for cash (in shares)   91,286      
Issuance of common stock for employee stock option exercises for cash 1,444   1,444    
Restricted Shares Award (RSA) issuances and forfeitures for terminations, net and stock-based compensation (in shares)   312,479      
Restricted Shares Award (RSA) issuances and forfeitures for terminations, net and stock-based compensation 5,633   5,633    
Issuance of common stock for vesting of Restricted Stock Units (RSU) and stock-based compensation (in shares)   268,930      
Issuance of common stock for vesting of Restricted Stock Units (RSU) and stock-based compensation 1,505   1,505    
Issuance of common stock for acquisition of Contura Limited 0        
Foreign currency translation adjustment (4,920)       (4,920)
Net loss $ (22,668)     (22,668)  
Balance at end of period (in shares) at Mar. 31, 2022 47,002,862 47,002,862      
Balance at end of period at Mar. 31, 2022 $ 463,432 $ 5 $ 812,141 $ (337,234) $ (11,480)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash Flows from Operating Activities    
Net loss $ (22,668) $ (22,503)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization 3,029 1,133
Stock-based compensation 7,138 5,303
Amortization of debt issuance costs 0 567
Reversal of allowance of credit losses (39) (65)
Deferred income taxes and other items, net (1,210) (577)
Changes in operating assets and liabilities, net of business acquisition    
Accounts receivable 1,595 (1,480)
Inventory 3,015 (7,193)
Prepaid expenses and other current assets 1,474 860
Other assets (25) (100)
Accounts payable 2,529 914
Accrued liabilities 900 (1,569)
Accrued compensation and benefits (4,925) (915)
Lease liability 20 42
Net cash used in operating activities (9,167) (25,583)
Cash Flows from Investing Activities    
Purchases of property and equipment (291) (123)
Acquisition of a business, net of cash acquired 0 (140,741)
Net cash used in investing activities (291) (140,864)
Cash Flows from Financing Activities    
Payment of debt issuance costs 0 (106)
Proceeds from debt 0 75,000
Repayment of debt 0 (21,500)
Proceeds from exercise of stock options 1,444 2,821
Net cash provided by financing activities 1,444 56,215
Effect of exchange rate changes on cash and cash equivalents 316 13
Net decrease in cash and cash equivalents (7,698) (110,219)
Cash and cash equivalents, beginning of year 220,878 241,181
Cash and cash equivalents, end of period 213,180 130,962
Supplemental Disclosure of Cash Flow Information    
Cash paid for interest 1 170
Cash paid for taxes 0 0
Noncash Investing and Financing Activities    
Change in property and equipment acquired but not yet paid 267 0
Common stock issuance for business acquisition 0 55,728
Contingent consideration for business acquisition 0 6,750
Common stock issuance for exclusive license asset 0 3,637
Accrued loan fees as debt issuance costs $ 0 $ 4,500
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Operations and Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Operations and Summary of Significant Accounting Policies Nature of Operations and Summary of Significant Accounting Policies
Nature of Operations
Axonics, Inc. (the Company) was incorporated in the state of Delaware on March 2, 2012 under the name American Restorative Medicine, Inc. In August 2013, the Company changed its name to Axonics Modulation Technologies, Inc. In March 2021, the Company changed its name to Axonics, Inc. The Company had no operations until October 1, 2013, when the license agreement between Alfred E. Mann Foundation for Scientific Research (AMF) and the Company (the License Agreement) was entered into. The Company is a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction. The Company has designed and developed the rechargeable sacral neuromodulation (SNM) system (r-SNM System), which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The r-SNM System is protected by intellectual property based on Company-generated innovations and patents and other intellectual property licensed from AMF. The Company has marketing approvals in the United States, Europe, Canada, and Australia for all relevant clinical indications. The premarket approval (PMA) application for the r-SNM System for the treatment of FI was approved by the U.S. Food and Drug Administration (FDA) on September 6, 2019, and the PMA application for the r-SNM System for the treatment of OAB and UR was approved by the FDA on November 13, 2019. Accordingly, the Company began U.S. commercialization of its r-SNM System in the fourth quarter of 2019. Prior to the fourth quarter of 2019, the Company derived revenue only from its international operations in select markets including England, the Netherlands and Canada, and its activities had consisted primarily of developing the r-SNM System, conducting its RELAX-OAB post-market clinical follow-up study in Europe, its ARTISAN-SNM pivotal clinical study in the United States and hiring and training its U.S. commercial team in preparation for the launch of the r-SNM System in the United States. Beginning in February 2021 with the acquisition of Contura Limited, the Company also markets Bulkamid, a urethral bulking agent to treat female stress urinary incontinence (SUI). For more information, see Note 8.
May 2021 Follow-On Offering
On May 14, 2021, the Company completed a follow-on offering by issuing 4,025,000 shares of common stock, at an offering price of $50.00 per share, inclusive of 525,000 shares of the Company’s common stock issued upon the exercise by the underwriters of their option to purchase additional shares. The net proceeds to the Company were approximately $190.0 million, after deducting underwriting discounts, commissions and offering expenses payable by the Company.
Principles of Consolidation
The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company; its wholly-owned subsidiaries, Axonics Europe, S.A.S., Axonics Modulation Technologies U.K. Limited, Axonics Modulation Technologies Australia Pty Ltd, Axonics Women’s Health Limited, Bulkamid SARL, Axonics GmbH, and Contura, Inc. Intercompany accounts and transactions have been eliminated in consolidation.
Basis of Presentation and Liquidity
Interim Financial Statements
The interim condensed consolidated financial statements and related footnote disclosures as of and for the three months ended March 31, 2022 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The unaudited interim condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three months ended March 31, 2022 in accordance with United States (U.S.) generally accepted accounting principles (GAAP), however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (SEC) rules and regulations relating to interim financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated
financial statements and notes thereto included within the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (filed with the SEC on March 1, 2022).
Liquidity
The Company only began full-scale commercialization of the r-SNM System in late 2019. The Company has expended significant resources on research and development activities, growing its operations organization and building and training its sales organization.
The Company incurred net losses of $22.7 million and $22.5 million for the three months ended March 31, 2022 and 2021, respectively, and had an accumulated deficit of $337.2 million as of March 31, 2022 compared to $314.6 million at December 31, 2021. The Company expects to continue to spend a significant amount of its existing resources on sales and marketing activities as the Company continues to commercialize and market its products in the United States and internationally.
As of March 31, 2022, the Company had cash and cash equivalents of $213.2 million compared to $220.9 million at December 31, 2021. The Company expects that its cash and cash equivalents on hand will be sufficient to fund its operations through at least the next 12 months. The Company funds its operations through a combination of proceeds from public offerings of its common stock and cash receipts from sales of its products. As of March 31, 2022, the Company had no outstanding borrowings.
The Company may need to raise additional financing in the future to facilitate its business operations. If the Company raises additional funds by issuing equity securities, its stockholders could experience dilution. Debt financing, if available, may involve covenants further restricting its operations or its ability to incur additional debt. Any debt financing or additional equity that the Company raises may contain terms that are not favorable to the Company or its stockholders. Additional financing may not be available at all, or in amounts or on terms acceptable to the Company. If the Company is unable to obtain additional financing when needed to satisfy its liquidity requirements, the Company may be required to scale back its operations.
COVID-19
The recent COVID-19 outbreak, and the resulting restrictions intended to slow the spread of COVID-19, including stay-at-home orders, business shutdowns and other restrictions, has adversely affected the Company’s business in several ways. The primary impact on the Company’s business was the cancellation or delay of elective procedures in certain areas to allow health care facilities to prioritize the treatment of COVID-19 patients during the initial stages and resurgence periods of the pandemic or because patients are avoiding health care facilities that they feel are unsafe. These developments materially reduced the number of procedures using the Company’s r-SNM System. If governmental authorities recommend again in the future that it is deemed advisable for health care facilities to not perform outpatient elective procedures, as was the case at various times since the second quarter of 2020, the Company expects it would materially harm the Company’s revenues and potentially increase the Company’s operating loss. Even as efforts to contain the pandemic have made progress and some restrictions have relaxed, new variants of the virus may continue to cause additional outbreaks. These challenges will likely continue for the duration of the pandemic and could reduce our revenue and negatively impact our business, financial condition and results of operations while the pandemic continues. If these delays in procedures occur in the future, the Company may have to scale back its business, including reducing headcount, which could have a negative impact on the Company’s long-term operations. The Company could also experience other negative impacts of the COVID-19 outbreak such as the lack of availability of the Company’s key personnel, temporary closures of the Company’s office or the facilities of the Company’s business partners, customers, third party service providers or other vendors, and the interruption of the Company’s supply chain, distribution channels, liquidity and capital or financial markets.
Any disruption and volatility in the global capital markets as a result of the pandemic may increase the Company’s cost of capital and adversely affect the Company’s ability to access financing when and on terms that the Company desires. In addition, a recession resulting from the spread of COVID-19 could materially affect the Company’s business, especially if a recession results in higher unemployment causing potential patients to not have access to health insurance.
The ultimate extent to which the COVID-19 pandemic and its repercussions impact the Company’s business will depend on future developments, which are highly uncertain. However, the foregoing and other continued disruptions to the Company’s business as a result of COVID-19 could result in a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses, and related disclosure of contingent assets and liabilities. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. The results of this evaluation then form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates, and such differences may be material to the consolidated financial statements. Significant items subject to such estimates and assumptions include the useful lives of property and equipment and intangible assets, the valuation of deferred income tax assets and liabilities, the valuation of contingent consideration liability, the valuation of stock-based compensation, the product returns reserve, the inventory obsolescence reserve and accounts receivable allowance for credit losses.
Revenue Recognition
Revenue recognized during the three months ended March 31, 2022 and 2021 relates entirely to the sale of the Company’s products to its customers and distributors.
The Company has revenue arrangements that consist of a single performance obligation. The Company recognizes revenue at the point in time when it transfers control of promised goods to its customers. Revenue is measured as the amount of consideration it expects to receive in exchange for transferring goods. The amount of revenue that is recognized is based on the transaction price, which represents the invoiced amount and includes estimates of variable consideration such as discounts, where applicable. The Company also sells to distributors and applies the same policies as its revenue arrangements with customers, specifically that revenue is recognized at the point in time when it transfers control of promised goods to its distributors. The Company does not offer rights of return or price protection. The amount of variable consideration included in the transaction price may be constrained and is included only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Payment terms, typically less than three months, do not include a significant financing component. The Company extends credit to its customers and distributors based upon an evaluation of their financial condition and credit history and generally requires no collateral. The Company does not have any contract balances related to product sales. The Company also does not have significant contract acquisition costs related to product sales.
In accordance with Company policy and based on the Company’s historical experience, the allowance for product returns was $0.1 million and $0.2 million at March 31, 2022 and December 31, 2021, respectively, and is recorded as a reduction of gross revenue in its condensed consolidated statements of comprehensive loss. Damaged or defective products are replaced at no charge under the Company’s standard warranty. For the three months ended March 31, 2022 and 2021, the replacement costs were $0.1 million and $0.1 million, respectively, and are recorded within the sales and marketing expenses in its condensed consolidated statements of comprehensive loss.
The Company offers its standard warranty to all customers. The Company does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to sales and marketing expense. The warranty liability as of March 31, 2022 and December 31, 2021 were $0.1 million and $0.1 million, respectively.
Shipping and handling costs incurred for the delivery of goods to customers and distributors are included in cost of goods sold. Amounts billed to customers and distributors for shipping and handling are included in net revenue.
The following table provides additional information pertaining to net revenue disaggregated by product and geographic market for the three months ended March 31, 2022 and 2021 (in thousands):
Three Months Ended
March 31,
20222021
SNM net revenue
United States$37,715 $31,745 
International markets1,355 1,158 
$39,070 $32,903 
Bulkamid net revenue(1)
United States$6,569 $578 
International markets2,781 892 
$9,350 $1,470 
Total net revenue$48,420 $34,373 
_____________________________________________
(1)    The acquisition of Bulkamid was completed on February 25, 2021. Reported revenue includes sales from February 26, 2021 onwards.
Allowance for Credit Losses
The Company makes estimates of the collectability of accounts receivable in accordance with Accounting Standards Update (ASU) 2016-13. The Company’s estimate of future credit losses is made by management based upon historical bad debts, customer receivable balances, age of customer receivable balances, customers’ financial conditions and reasonable forecasted economic trends. Despite the Company’s efforts to minimize credit risk exposure, customers could be adversely affected if future economic and industry trends, including those related to COVID-19, change in such a manner as to negatively impact their cash flows. The full effects of COVID-19 on the Company’s customers are highly uncertain and cannot be predicted. As a result, the Company’s future collection experience can differ significantly from historical collection trends. If the Company’s customers experience a negative impact on their cash flows, it could have a material adverse effect on the Company’s results of operations and financial condition.
The following table summarizes the changes in our allowance for credit losses (in thousands):
Three Months Ended
March 31,
20222021
Balance at beginning of period$355 $465 
Write-offs— 12 
Bad debt recoveries(39)(65)
Balance at end of period$316 $412 
Cash and Cash Equivalents
Cash equivalents consist of short-term, highly liquid investments purchased with an original maturity of three months or less. Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. At times, the cash and cash equivalent balances may exceed federally insured limits. The Company does not believe that this results in any significant credit risk as the Company’s policy is to place its cash and cash equivalents in highly-rated financial institutions. The Company also holds cash in foreign banks that are not federally insured. The Company has not experienced any losses on its deposits of cash and cash equivalents.
Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2: Inputs are quoted prices for similar assets and liabilities in active markets or quoted prices for identical or similar instruments in markets that are not active and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.
Level 3: Inputs are unobservable inputs based on the Company’s assumptions and valuation techniques used to measure assets and liabilities at fair value. The inputs require significant management judgment or estimation.
The Company’s assessment of the significance of an input to the fair value measurement requires judgment, which may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels. The carrying amounts reported in the condensed consolidated financial statements approximate the fair value for cash and cash equivalents, accounts receivable, accounts payables, and accrued expenses due to their short-term nature. The carrying amount of the Company’s term loan, which is described below, approximates fair value, considering the interest rates are based on the prime interest rate.
The purchase price of business acquisitions is primarily allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition date, with the excess recorded as goodwill.
Contingent consideration represents contingent milestone, performance and revenue-sharing payment obligations related to acquisitions and is measured at fair value, based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration is estimated using a binary option-based approach with assumptions the Company believes would be made by a market participant. Significant inputs include projected revenues, discount rates, volatility factors and risk-free rates. The Company assesses these assumptions on an ongoing basis as additional data impacting the assumptions is obtained and any change in fair value of the contingent consideration is recorded within the general and administrative expenses in the consolidated statements of comprehensive loss. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. Generally, a change in the assumption used for the projected revenues would result in a directionally similar change to the overall estimate of the contingent consideration. The fair value of contingent consideration of $10.4 million at
March 31, 2022 is reflected in other long-term liabilities in the Company’s condensed consolidated balance sheets.
The following table summarizes the changes in the fair value of recurring Level 3 fair value measurements during the three months ended March 31, 2022 and 2021 (in thousands):
Three Months Ended
March 31,
20222021
Liabilities
Contingent consideration:
Balance at beginning of period$10,370 $— 
February 25, 2021 Acquisition— 6,750 
Balance at end of period$10,370 $6,750 
There were no transfers between Levels 1, 2 or 3 for the periods presented.
Investment Securities
Those investments in debt securities with maturities less than 12 months at the date of purchase are considered short-term investments. Those investments in debt securities with maturities greater than 12 months at the date of purchase are considered long-term investments. The Company’s investment securities classified as available-for-sale are recorded at fair value based on the fair value hierarchy (Level 1 and Level 2 inputs in the fair value hierarchy), and consists primarily of commercial paper, corporate notes and U.S. government and agency securities. Unrealized gains or losses, deemed temporary in nature, are reported as other comprehensive income within the condensed consolidated statements of comprehensive loss. There were no unrealized gains or losses during the three months ended March 31, 2022 and 2021.
A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to net income (loss) and the corresponding establishment of a new cost basis for the security. Premiums (discounts) are amortized (accreted) over the life of the related security as an adjustment to yield using the straight-line interest method. Dividend and interest income are recognized when earned. Realized gains or losses are included in net loss and are derived using the specific identification method for determining the cost of securities sold.
The Company had no outstanding investment securities as of March 31, 2022 and December 31, 2021.
Foreign Currency Translation
The functional currencies of the Company’s subsidiaries are currencies other than the U.S. dollar. The Company translates assets and liabilities of the foreign subsidiaries into U.S. dollars at the exchange rate in effect on the balance sheet date. Revenue and expenses of the subsidiaries are translated into U.S. dollars at the average exchange rate during the period. Gains or losses from these translation adjustments are reported as a separate component of stockholders’ equity in accumulated other comprehensive gain or loss until there is a sale or complete or substantially complete liquidation of the Company’s investment in the foreign subsidiary at which time the gains or losses will be realized and included in net income (loss). As of March 31, 2022 and December 31, 2021, all foreign currency translation gains (losses) have been unrealized and included in accumulated other comprehensive loss. Accumulated other comprehensive loss consists entirely of losses or gains from translation of foreign subsidiaries at March 31, 2022 and December 31, 2021.
Inventory, Net
Inventories are stated at the lower of cost or net realizable value, with cost computed on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors.
The Company capitalizes inventory produced for commercial sale. The Company capitalizes manufacturing costs as inventory following both the receipt of regulatory approval from regulatory bodies and the Company’s
intent to commercialize. Costs associated with developmental products prior to satisfying the Company’s inventory capitalization criteria are charged to research and development expenses as incurred.
Products that have been approved by certain regulatory authorities may also be used in clinical programs to assess the safety and efficacy of the products for usage that have not been approved by the FDA or other regulatory authorities. The form of product utilized for both commercial and certain clinical programs that are identical are included as inventory with an “alternative future use” as defined in authoritative guidance. Component materials and purchased products associated with clinical development programs are included in inventory and charged to research and development expenses when the product enters the research and development process and no longer can be used for commercial purposes and, therefore, does not have an “alternative future use.”
For products that are under development and have not yet been approved by regulatory authorities, purchased component materials are charged to research and development expenses when the inventory ownership transfers to the Company.
The Company analyzes inventory levels to identify inventory that may expire prior to sale, inventory that has a cost basis in excess of its net realizable value, or inventory in excess of expected sales requirements. Although the manufacturing of the r-SNM System is subject to strict quality control, certain batches or units of product may no longer meet quality specifications or may expire, which would require adjustments to the Company’s inventory values. The Company also applies judgment related to the results of quality tests that are performed throughout the production process, as well as the understanding of regulatory guidelines, to determine if it is probable that inventory will be saleable. These quality tests are performed throughout the pre- and post-production processes, and the Company continually gathers information regarding product quality for periods after the manufacturing date. The Company’s products currently have a maximum estimated shelf life range of 12 to 36 months and, based on sales forecasts, the Company expects to realize the carrying value of the product inventory. In the future, reduced demand, quality issues, or excess supply beyond those anticipated by management may result in a material adjustment to inventory levels, which would be recorded as an increase to cost of sales.
The determination of whether inventory costs will be realizable or not requires estimates by the Company’s management. A critical input in this determination is future expected inventory requirements based on internal sales forecasts. Management then compares these requirements to the expiry dates of inventory on hand. To the extent that inventory is expected to expire prior to being sold, management will write down the value of inventory.
As of March 31, 2022, the Company had $44.3 million, $3.0 million and $14.6 million of finished goods inventory, work-in-process inventory and raw materials inventory, respectively, net of reserves of $0.1 million. As of December 31, 2021, the Company had $46.8 million, $2.8 million and $15.3 million of finished goods inventory, work-in-process inventory and raw materials inventory, respectively, net of reserves of $0.2 million.
Customer and Vendor Concentration
As of March 31, 2022 and December 31, 2021, there were no customers who accounted for over 10% of the Company’s consolidated accounts receivable. As of March 31, 2022 and December 31, 2021, there were two vendors and no vendor, respectively, who accounted for over 10% of the Company’s consolidated accounts payable. As of March 31, 2022 and December 31, 2021, there were no customers who accounted for over 10% of the Company’s consolidated net revenue. As of March 31, 2022 and December 31, 2021, there were three vendors and one vendor, respectively, who accounted for over 10% of the Company’s inventory-related purchases.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and seven years. Leasehold improvements are amortized over the lesser of the life of the lease or the useful life of the improvements. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations.
Goodwill
Goodwill represents the excess purchase price over the fair values of the identifiable assets acquired less the liabilities assumed. Goodwill is tested for impairment at the reporting unit level by comparing the reporting unit’s carrying amount to the fair value of the reporting unit. The fair values are estimated using an income and discounted cash flow approach. The Company evaluates its goodwill on an annual basis in the fourth quarter or more frequently if it believes indicators of impairment exist. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount or performs an annual impairment test. When tested quantitatively, the Company compares the fair value of the applicable reporting unit with its carrying value. In making this assessment, management relies on a number of factors, including expected future operating results, business plans, economic projections, anticipated future cash flows, business trends and declines in the Company’s market capitalization. The Company estimates the fair values of its reporting unit using a combination of the discounted cash flow and income approaches. If the carrying amount of a reporting unit exceeds the reporting unit’s fair value, the amount by which the carrying value exceeds the fair value is recognized as an impairment loss. During the three months ended March 31, 2022, the Company did not record any impairment charges related to goodwill.
Intangible Assets
Patent license asset
The intangible asset represents exclusive rights to an additional field-of-use on the patent suite within the License Agreement with AMF. The additional field-of-use was provided in exchange for 50,000 shares of Series A preferred stock, the fair value of which was $1.0 million in 2013. The intangible asset was recorded at its fair value of $1.0 million at the date contributed. In connection with the initial public offering, such shares of Series A preferred stock were converted into common stock. Amortization of this asset is recorded over the shorter of the patent or legal life on a straight-line basis. The weighted-average amortization period is 8.71 years. The Company recorded minimal expenses for the amortization of the patent license asset during the three months ended March 31, 2022 and 2021. The Company will review the intangible asset for impairment whenever an impairment indicator exists. There have been no intangible asset impairment charges to date. For additional information, see Note 8.
Exclusive license asset
The intangible asset represents exclusive rights of existing technologies and development services from MST entered into on March 2, 2021. The agreement was provided in exchange for 65,594 shares of common stock, $0.0001 par value, the fair value of which was $3.6 million upon transfer. The intangible asset was recorded at its fair value of $3.3 million at the date of the agreement, with the difference of $0.3 million recorded as a vendor credit in accounts payable in the condensed consolidated balance sheets. Amortization of this asset is recorded over the four-year term of the agreement on a straight-line basis. The Company recorded expense for the amortization of the exclusive license asset of $0.2 million during the three months ended March 31, 2022. There was no amortization of this intangible asset recorded during the three months ended March 31, 2021. The Company will review the intangible asset for impairment whenever an impairment indicator exists. There have been no intangible asset impairment charges to date. For additional information, see Note 8.
Contura acquisition
The intangible assets represent technology, trade names and trademarks, and customer relationships acquired from Contura on February 25, 2021. The straight-line method over the period of estimated benefit is used to amortize finite-lived intangible assets except for customer relationships. Accounting Standards Codification (ASC) 350-30-35-3 states that customer relationships generally dissipate at a more rapid rate in the earlier periods following a company’s succession to these relationships, with the rate of attrition declining over time. As such, the accelerated method is used to amortize customer relationships. The Company recorded expense for the amortization of Contura acquisition intangible assets of $2.2 million and $0.6 million during the three months ended March 31, 2022 and 2021, respectively. For additional information, see Note 8.
Impairment of Long-Lived Assets
The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net cash flows that the assets are expected to generate. If said assets are considered to be impaired, the impairment that would be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There have been minimal impairments of long-lived assets to date.
Leases
In accordance with ASU No. 2016-02, “Leases (Topic 842)”, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only. Topic 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the bright line thresholds referenced in Topic 842 to assist in evaluating leases for appropriate classification between operating and finance leases. The aforementioned bright lines are applied consistently to the Company’s entire portfolio of leases.
Operating lease ROU asset and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate, which is the rate for a fully collateralized amortizing loan with the same maturity as the lease term, based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
Research and Development
Research and development costs are charged to operations as incurred. Research and development costs include salary and personnel-related costs, costs of clinical studies and testing, supplies and materials, and outside consultant costs.
Advertising Expense
The Company expenses advertising costs as they are incurred. During the three months ended March 31, 2022 and 2021, advertising expense totaled $3.2 million and $1.4 million, respectively, and are recorded within the sales and marketing expenses in its condensed consolidated statements of comprehensive loss.
Income Taxes
The Company accounts for income taxes using the asset and liability method to compute the difference between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. The Company has net deferred tax assets in certain jurisdictions. The realization of these deferred tax assets is dependent upon the Company’s ability to generate sufficient taxable income in future years. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company evaluates the recoverability of the deferred tax assets annually, and maintains a full valuation allowance on its U.S. net deferred tax assets. The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company is subject to transfer pricing and other tax regulations designed to ensure that appropriate levels of income are reported as earned by the Company’s U.S. and foreign entities and are taxed accordingly. In the normal course of business, the Company is audited by federal, state
and foreign tax authorities, and subject to inquiries from those tax authorities regarding the amount of taxes due. These inquiries may relate to the timing and amount of deductions and the allocation of income among various tax jurisdictions. The Company’s policy is to recognize interest and penalties related to unrecognized tax benefits, if any, in income tax expense.
Stock-Based Compensation
The Company measures the cost of employee and non-employee services in exchange for an award of equity instruments based on the grant-date fair value of the award and recognizes compensation cost over the requisite service period (typically the vesting period), generally three or four years. Forfeitures are estimated at the time of the grant and revised in subsequent periods to reflect differences between the estimates and the number of shares that actually become exercisable.
The Company uses the Black-Scholes option pricing model to determine the fair value of stock options (as of the date of grant) that have service conditions for vesting. Stock options and restricted shares awards vest based on service conditions, typically over three or four years.
The Company also grants shares of performance-based restricted stock units that typically vest after one year only if the Company has also achieved certain performance objectives as defined and approved by the Company’s board of directors. The fair value of performance awards are determined based on the Company’s stock price at the date of grant and expensed over the performance period based on the probability of achieving the performance objectives. In addition, the Company also grants market-based restricted stock units that have combined market conditions and service conditions for vesting, for which the Company uses the Monte Carlo valuation model to value equity awards (as of the date of grant).
Net Loss per Share of Common Stock
Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options, unvested RSAs and RSUs are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, diluted net loss per share of common stock is the same as basic net loss per share of common stock for those periods.
For the three months ended March 31, 2022 and 2021, there were 2,416,373 and 2,488,284 potentially dilutive weighted-average shares, respectively, that were not included in the computation of diluted weighted-average shares of common stock and common stock equivalent shares outstanding because their effect would have been antidilutive given the Company’s net loss.
Segment Reporting
Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company has determined it operates in one segment, the development and commercialization of innovative and minimally invasive products to treat bladder and bowel dysfunction. Geographically, the Company sells over 90% to hospitals in the United States. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance.
Recently Adopted Accounting Pronouncements
In December 2019, the Financial Accounting Standards Board (FASB) issued ASU 2019-12, “Income Taxes—Simplifying the Accounting for Income Taxes,” which simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step-up in the tax basis of goodwill and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. This guidance is effective for annual periods beginning after December 15, 2020, which
was the Company’s first quarter of fiscal year 2021, with early adoption permitted. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or related disclosures.
Recent Accounting Pronouncements
We have reviewed and considered all recent accounting pronouncements that have not yet been adopted and believe there are none that could potentially have a material impact on our business practices, financial condition, results of operations, or disclosures.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment
3 Months Ended
Mar. 31, 2022
Property, Plant and Equipment [Abstract]  
Property and Equipment Property and Equipment
Property and equipment, net consists of the following (in thousands) at:
March 31,December 31,
20222021
Equipment$2,611 $2,429 
Computer hardware and software2,595 2,450 
Tools and molds1,626 1,579 
Leasehold improvements4,449 4,372 
Furniture and fixtures1,515 1,502 
Construction in progress198 127 
12,994 12,459 
Less: accumulated depreciation and amortization(6,087)(5,544)
$6,907 $6,915 
Depreciation and amortization expense of property and equipment was $0.6 million and $0.5 million for the three months ended March 31, 2022 and 2021, respectively.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Operating Leases
In August 2014, the Company entered into a five-year operating lease for approximately 12,215 square feet of office space beginning on November 1, 2014, and expiring on October 31, 2019. In June 2019, the lease was amended to extend the expiration date to October 31, 2020. In September 2020, the lease was amended to extend the expiration date to July 31, 2022, and in December 2021, the lease was amended to extend the expiration date to January 31, 2028. Upon the execution of the amendments, which were deemed to be a lease modification, the Company reassessed the lease liability using the incremental borrowing rate for a collateralized asset of the same remaining term at the modification date and recorded ROU assets for the same amount. The Company also reassessed the lease classification and concluded that the lease continues to be an operating lease. Under the terms of the lease, the Company is responsible for taxes, insurance, and maintenance expense. The lease contains certain scheduled rent increases. Rent expense is recognized on a straight-line basis over the expected lease term.
In November 2017, the Company entered into a seven-year operating lease for approximately 25,548 square feet of office space beginning on August 1, 2018, and expiring on August 31, 2025. In June 2019, the lease was amended to extend the expiration date to October 31, 2027. Upon the execution of the amendments, which were deemed to be a lease modification, the Company reassessed the lease liability using the incremental borrowing rate for a collateralized asset of the same remaining term at the modification date and recorded ROU assets for the same amount. The Company also reassessed the lease classification and concluded that the lease continues to be an operating lease. Under the terms of the lease, the Company is responsible for taxes, insurance, and maintenance expense. The lease contains certain scheduled rent increases. Rent expense is recognized on a straight-line basis over the expected lease term. The Company has a renewal option to extend the term of the lease for a period of five years beyond the initial term. Under the terms of the lease, the base rent payable with respect to each renewal term will be equal to the prevailing market rental rent as of the commencement of the applicable renewal term. In the event of a default of certain of the Company’s obligations under the lease, the Company’s landlord would have the right to
terminate the lease.
In June 2019, the Company entered into an eight-year operating lease for approximately 32,621 square feet of office space beginning on January 15, 2020 and expiring on January 31, 2028. The Company uses these premises as its new principal executive offices and for general office space. The Company intends to utilize its other currently-leased spaces through the lease expiration dates to conduct the training of its sales team and for manufacturing purposes. Under the terms of the lease, the Company is responsible for taxes, insurance, and maintenance expense. The lease contains certain scheduled rent increases. Rent expense is recognized on a straight-line basis over the expected lease term. The Company has a renewal option to extend the term of the lease for a period of five years beyond the initial term. Under the terms of the lease, the base rent payable with respect to each renewal term will be equal to the prevailing market rental rent as of the commencement of the applicable renewal term. In the event of a default of certain of the Company’s obligations under the lease, the Company’s landlord would have the right to terminate the lease.
In August 2020, the Company entered into a 38-month operating lease for approximately 5,693 square feet of warehouse space beginning on October 15, 2020 and expiring on December 31, 2023. The Company uses these premises for general warehouse space.
During the three months ended March 31, 2022 and 2021, ROU assets obtained in exchange for new operating lease liabilities were none and $0.1 million, respectively. As of March 31, 2022 and December 31, 2021, the ROU asset has a balance of $6.8 million and $7.1 million, respectively. The operating lease ROU asset is included within the Company’s non-current other assets, and lease liabilities are included in current or noncurrent liabilities in the Company’s condensed consolidated balance sheets. During the three months ended March 31, 2022 and 2021, cash paid for amounts included in operating lease liabilities was $0.5 million and $0.5 million, respectively. Amortization of the ROU asset was $0.2 million and $0.3 million for the three months ended March 31, 2022 and 2021, respectively.
As of March 31, 2022 and December 31, 2021, the weighted-average remaining lease term for the Company’s operating leases were 5.7 years and 5.9 years, respectively. The weighted-average incremental borrowing rate for a collateralized asset of the same remaining term used to determine the present value of the Company’s operating leases’ future payments was 7.1% and 7.1% as of March 31, 2022 and December 31, 2021, respectively.
Total lease cost for the three months ended March 31, 2022 and 2021 are as follows (in thousands):
Three Months Ended
March 31,
20222021
Lease cost
Operating lease cost$524 $525 
Short-term lease cost21 23 
Variable lease cost35 47 
Total lease cost$580 $595 
License Agreement
In October 2013, the Company entered into the License Agreement, pursuant to which AMF, a Company stockholder, licensed the Company certain patents and know-how (collectively, the AMF IP) relating to, in relevant part, an implantable pulse generator and related system components in development by AMF as of that date, in addition to any peripheral or auxiliary devices, including all components, that when assembled, comprise such device, excluding certain implantable pulse generators (collectively, the AMF Licensed Products). Under the License Agreement, for each calendar year beginning in 2018, the Company is obligated to pay AMF a royalty on an AMF Licensed Product-by-AMF Licensed Product basis if one of the following conditions applies: (i) one or more valid claims within any of the patents licensed to the Company by AMF covers such AMF Licensed Products or the manufacture of such AMF Licensed Products or (ii) for a period of 12 years from the first commercial sale anywhere
in the world of such AMF Licensed Product, in each case. The foregoing royalty is calculated as the greater of (a) 4% of all net revenue derived from the AMF Licensed Products, and (b) the Minimum Royalty, payable quarterly. The Minimum Royalty automatically increases each year after 2018, subject to a maximum amount of $200,000 per year. The Company generated net SNM revenue of $39.1 million and $32.9 million during the three months ended March 31, 2022 and 2021, respectively, and recorded related royalties of $1.6 million and $1.3 million during the three months ended March 31, 2022 and 2021, respectively. Royalty expense is included in operating expenses in the condensed consolidated statements of comprehensive loss. Accrued royalty of $1.6 million and $1.8 million as of March 31, 2022 and December 31, 2021, respectively, is included within accrued liabilities in the Company’s condensed consolidated balance sheets.
Legal Matters
On November 4, 2019, Medtronic, Inc., Medtronic Puerto Rico Operations Co., Medtronic Logistics LLC and Medtronic USA, Inc. (collectively, the Medtronic Affiliates) filed a complaint against the Company in the United States District Court for the Central District of California, Case No. 8:19-cv-2115, and amended the complaint on November 26, 2019. The Company refers to this matter as the Medtronic Litigation. The complaint asserts that the Company’s r-SNM System infringes U.S. Patent Nos. 8,036,756, 8,626,314, 9,463,324 and 9,821,112 held by the Medtronic Affiliates, and the amended complaint further includes the additional patents 8,738,148; 8,457,758; and 7,774,069 (collectively, the Medtronic Patents). The Medtronic Litigation requests customary remedies for patent infringement, including (i) a judgment that the Company has infringed and is infringing the Medtronic Patents, (ii) damages, including treble damages for willful infringement, (iii) a permanent injunction preventing the Company from infringing the Medtronic Patents, (iv) attorneys’ fees, and (v) costs and expenses. The Company believes the allegations are without merit and is vigorously defending itself against them. Given the early stage of the Medtronic Litigation, the Company is unable to predict the likelihood of success of the claims of the Medtronic Affiliates against the Company or to quantify any risk of loss. The Medtronic Litigation could last for an extended period of time and require the Company to dedicate significant financial resources and management resources to its defense. An adverse ruling against the Company could materially and adversely affect its business, financial position, results of operations or cash flows and could also result in reputational harm. Even if the Company is successful in defending against these claims, the Medtronic Litigation could result in significant costs, delays in future product developments, reputational harm or other collateral consequences.
On March 16, 2020, the Company filed seven petitions before the United States Patent and Trademark Office (USPTO) requesting inter partes review (IPR) to contest the validity of each of the Medtronic patents that Medtronic has alleged are being infringed by the Company. In September 2020, the USPTO decided that it will accept or “institute” the IPR process for six of the seven patents, finding that the Company had demonstrated a reasonable likelihood that at least one, if not all, of the claims of these six patents are invalid. The USPTO issued decisions on the IPR petitions in September 2021. The USPTO invalidated several claims in the Medtronic patents but declined to invalidate the majority of asserted claims. The Company appealed the decisions on the claims that were not invalidated. Following these IPR decisions, the judge presiding over the litigation in the United States District Court for the Central District of California lifted the stay on litigation proceedings. The Company is currently engaged in discovery in the Medtronic Litigation.
In addition to the Medtronic Litigation, the Company is and may continue to be involved in claims, legal proceedings, and investigations arising out of its operations in the normal course of business.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Long-Term Debt
3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
Long-Term Debt Long-Term Debt
In June 2021, the principal amount, accrued interest, accrued loan fees, and prepayment fees related to the term loan under the Loan and Security Agreement with Silicon Valley Bank entered into in February 2021, were paid in full. The unamortized debt issuance costs of $4.4 million were expensed and recognized as interest expense.
In January 2021, the principal amount, accrued interest, accrued loan fees, and prepayment fees related to the term loan under the Loan and Security Agreement with Silicon Valley Bank entered into in February 2018, were paid in full. The unamortized debt issuance costs of $0.4 million were expensed and recognized as interest expense.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Stock-based Compensation Stock-based Compensation
Stock-based compensation expense included in the Company’s unaudited condensed consolidated statements of comprehensive loss is allocated as follows (in thousands):
Three Months Ended
March 31,
20222021
Research and development$1,510 $1,329 
General and administrative1,937 1,685 
Sales and marketing3,691 2,289 
$7,138 $5,303 
Stock Option Activity
The option awards issued under the 2014 Stock Option Plan (the 2014 Plan) and the 2018 Omnibus Incentive Plan (the 2018 Plan) were measured based on fair value. The Company’s fair value calculations were made using the Black-Scholes option pricing model with the following assumptions:
Three Months Ended
March 31,
20222021
Expected term (in years)
5.46 - 6.00
Stock volatility
63.49%
Risk-free interest rate
0.53% - 1.16%
Dividend rate
The Company used the simplified method of determining the expected term of stock options as the Company believes this represents the best estimate of the expected term of a new option. The expected stock price volatility assumption was determined by examining the historical volatilities for industry peers, as the Company did not have sufficient trading history for the Company’s common stock. The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical data for the Company’s common stock becomes available. The risk-free interest rate assumption is based on the U.S. Treasury instruments, whose term was consistent with the expected term of the Company’s stock options. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The assumptions regarding the expected term of the options and the expected volatility of the stock price are subjective, and these assumptions have a significant effect on the estimated fair value amounts. There were no stock option grants for the three months ended March 31, 2022. The weighted-average grant date fair value of options granted was $32.89 for the three months ended March 31, 2021.
As of March 31, 2022 and December 31, 2021, there was $5.3 million and $6.7 million, respectively, of total unrecognized compensation cost related to unvested stock options that is expected to be recognized over a weighted-average period of approximately 1.4 years and 1.6 years, respectively.
The following table summarizes stock option activity for the three months ended March 31, 2022 under the 2014 and 2018 Plans (in thousands, except share and per share data):
Number of OptionsWeighted-Average Exercise Price Per ShareAggregate Intrinsic Value
Outstanding at December 31, 2021
1,427,892 $18.13 
Options exercised(91,286)15.53 $3,486 (1)
Options forfeited(8,500)33.88 
Outstanding at March 31, 2022
1,328,106 $18.20 $58,963 (2)
_____________________________________________
(1)    Represents the total difference between the Company’s closing stock price at the time of exercise and the stock option exercise price, multiplied by the number of options exercised.
(2)    Represents the total difference between the Company’s closing stock price on the last trading day of the first quarter of 2022 and the stock option exercise price, multiplied by the number of in-the-money options as of March 31, 2022. The amount of intrinsic value will change based on the fair market value of the Company’s stock.
The weighted-average remaining contractual term of options outstanding and exercisable is 6.8 years and 6.9 years at March 31, 2022 and December 31, 2021, respectively.
Restricted Shares Awards Activity
As of March 31, 2022 and December 31, 2021, there was $52.8 million and $42.5 million, respectively, of total unrecognized compensation cost related to unvested restricted shares awards that is expected to be recognized over a weighted-average period of approximately 2.8 years and 3.0 years, respectively.
The following table summarizes restricted shares awards activity for the three months ended March 31, 2022:
Number of Restricted Shares AwardsWeighted-Average Fair Value Per Share at Grant Date
Outstanding at December 31, 20211,102,034 $46.07 
Restricted shares awards granted352,204 48.14 
Restricted shares awards vested(169,110)37.55 
Restricted shares awards forfeited(39,725)56.85 
Outstanding at March 31, 20221,245,403 $47.47 
Restricted Stock Units Activity
As of March 31, 2022 and December 31, 2021, there was $5.8 million and $1.9 million, respectively, of total unrecognized compensation cost related to unvested restricted stock units that is expected to be recognized over a weighted-average period of approximately 1.1 years and 0.9 years, respectively.
The following table summarizes restricted stock units activity for the three months ended March 31, 2022:
Number of Restricted Stock UnitsWeighted-Average Fair Value Per Share at Grant Date
Outstanding at December 31, 2021250,464 $42.99 
Restricted stock units granted201,884 38.75 
Restricted stock units vested(268,930)35.88 
Outstanding at March 31, 2022183,418 $48.74 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
3 Months Ended
Mar. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The following table presents details of the provision for income taxes and effective tax rates (in thousands, except percentages):
Three Months Ended
March 31,
20222021
Income tax benefit$(1,111)$(555)
Effective tax rate4.67%2.41%
The Company accounts for income taxes according to ASC 740. The Company periodically evaluates whether a portion or all of its deferred tax assets will be recovered. The Company records a valuation allowance against deferred tax assets if and to the extent it is more likely than not that they will not be recovered. In evaluating the need for a valuation allowance, the Company weighs all relevant positive and negative evidence, including among other factors, historical financial performance, forecasts of income over the applicable carryforward periods, and the market environment, with each consideration weighted based on its reliability. The Company continues to maintain a full valuation allowance against its otherwise recognizable U.S. net deferred income tax assets as of March 31, 2022 and December 31, 2021.
The effective tax rate differs from the statutory U.S. income tax rate due to differing tax rates imposed on income earned in foreign jurisdictions, losses in foreign jurisdictions, and certain nondeductible expenses. The effective tax rate could change significantly from quarter to quarter because of recurring and nonrecurring factors.
The provision for income taxes for the three months ended March 31, 2022 was primarily the result of losses benefited in certain foreign jurisdictions.
At December 31, 2021, the Company had U.S. federal and foreign net operating loss (NOL) carryforwards of approximately $258.2 million and $16.4 million, respectively. U.S. federal NOLs in the amount of $51.5 million will expire between 2033 and 2037 while the remainder will carryover indefinitely. The foreign net operating loss carryforwards have an indefinite carryforward period. The Company had U.S. state NOLs of $245.6 million, which will expire between 2033 and 2041.
Pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Internal Revenue Code), use of the Company’s NOL carryforwards may be limited if the Company experiences a cumulative change in ownership of greater than 50% in a rolling three-year period. The Company performed an analysis of changes in ownership for purposes of these Internal Revenue Code sections. Based on the study performed in 2020, the Company determined that an ownership change occurred in 2014, 2018 and 2019. Based on the study performed in 2021, the Company determined that an ownership change did not occur in 2021.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Employee Benefit Plan
3 Months Ended
Mar. 31, 2022
Retirement Benefits [Abstract]  
Employee Benefit Plan Employee Benefit PlanThe Company sponsors a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan covers all employees who meet minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pre- or post-tax basis. Contributions to the plan by the Company may be made at the discretion of the board of directors. During the three months ended March 31, 2022 and 2021, the Company contributions to the plan amounted to $0.5 million and $0.4 million, respectively.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Intangible Assets
3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Goodwill and Intangible Assets
The change in the carrying amount of goodwill during the three months ended March 31, 2022 included the following (in thousands):
December 31, 2021$105,510 
Foreign currency translation adjustment(2,952)
March 31, 2022$102,558 
Intangible assets as of March 31, 2022 included the following (in thousands):
March 31, 2022
Weighted-Average Amortization PeriodGross Carrying AmountAccumulated AmortizationForeign currency translation adjustmentIntangible Assets, Net
Patent license asset8.71 years$1,000 (947)— $53 
Exclusive license asset4 years$3,300 (880)— $2,420 
Technology12 years$81,100 (7,362)(3,490)$70,248 
Trade names and trademarksIndefinite$19,700 — (906)$18,794 
Customer relationships12 years$11,400 (1,320)(416)$9,664 
$116,500 $(10,509)$(4,812)$101,179 
Intangible asset as of December 31, 2021 included the following (in thousands):
December 31, 2021
Weighted-Average Amortization PeriodGross Carrying AmountAccumulated AmortizationForeign currency translation adjustmentIntangible Asset, Net
Patent license asset8.71 years$1,000 (919)— $81 
Exclusive license asset4 years$3,300 (660)— 2,640 
Technology12 years$81,100 (5,668)(1,424)74,008 
Trade names and trademarksIndefinite$19,700 — (365)19,335 
Customer relationships12 years$11,400 (799)(196)10,405 
$116,500 $(8,046)$(1,985)$106,469 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Operations and Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Principles of Consolidation
Principles of Consolidation
The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company; its wholly-owned subsidiaries, Axonics Europe, S.A.S., Axonics Modulation Technologies U.K. Limited, Axonics Modulation Technologies Australia Pty Ltd, Axonics Women’s Health Limited, Bulkamid SARL, Axonics GmbH, and Contura, Inc. Intercompany accounts and transactions have been eliminated in consolidation.
Basis of Presentation
Basis of Presentation and Liquidity
Interim Financial Statements
The interim condensed consolidated financial statements and related footnote disclosures as of and for the three months ended March 31, 2022 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The unaudited interim condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three months ended March 31, 2022 in accordance with United States (U.S.) generally accepted accounting principles (GAAP), however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (SEC) rules and regulations relating to interim financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated
financial statements and notes thereto included within the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (filed with the SEC on March 1, 2022).
Use of Estimates
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses, and related disclosure of contingent assets and liabilities. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. The results of this evaluation then form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates, and such differences may be material to the consolidated financial statements. Significant items subject to such estimates and assumptions include the useful lives of property and equipment and intangible assets, the valuation of deferred income tax assets and liabilities, the valuation of contingent consideration liability, the valuation of stock-based compensation, the product returns reserve, the inventory obsolescence reserve and accounts receivable allowance for credit losses.
Revenue Recognition
Revenue Recognition
Revenue recognized during the three months ended March 31, 2022 and 2021 relates entirely to the sale of the Company’s products to its customers and distributors.
The Company has revenue arrangements that consist of a single performance obligation. The Company recognizes revenue at the point in time when it transfers control of promised goods to its customers. Revenue is measured as the amount of consideration it expects to receive in exchange for transferring goods. The amount of revenue that is recognized is based on the transaction price, which represents the invoiced amount and includes estimates of variable consideration such as discounts, where applicable. The Company also sells to distributors and applies the same policies as its revenue arrangements with customers, specifically that revenue is recognized at the point in time when it transfers control of promised goods to its distributors. The Company does not offer rights of return or price protection. The amount of variable consideration included in the transaction price may be constrained and is included only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Payment terms, typically less than three months, do not include a significant financing component. The Company extends credit to its customers and distributors based upon an evaluation of their financial condition and credit history and generally requires no collateral. The Company does not have any contract balances related to product sales. The Company also does not have significant contract acquisition costs related to product sales.
In accordance with Company policy and based on the Company’s historical experience, the allowance for product returns was $0.1 million and $0.2 million at March 31, 2022 and December 31, 2021, respectively, and is recorded as a reduction of gross revenue in its condensed consolidated statements of comprehensive loss. Damaged or defective products are replaced at no charge under the Company’s standard warranty. For the three months ended March 31, 2022 and 2021, the replacement costs were $0.1 million and $0.1 million, respectively, and are recorded within the sales and marketing expenses in its condensed consolidated statements of comprehensive loss.
The Company offers its standard warranty to all customers. The Company does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to sales and marketing expense. The warranty liability as of March 31, 2022 and December 31, 2021 were $0.1 million and $0.1 million, respectively.
Shipping and handling costs incurred for the delivery of goods to customers and distributors are included in cost of goods sold. Amounts billed to customers and distributors for shipping and handling are included in net revenue.
Allowance for Credit Losses
Allowance for Credit Losses
The Company makes estimates of the collectability of accounts receivable in accordance with Accounting Standards Update (ASU) 2016-13. The Company’s estimate of future credit losses is made by management based upon historical bad debts, customer receivable balances, age of customer receivable balances, customers’ financial conditions and reasonable forecasted economic trends. Despite the Company’s efforts to minimize credit risk exposure, customers could be adversely affected if future economic and industry trends, including those related to COVID-19, change in such a manner as to negatively impact their cash flows. The full effects of COVID-19 on the Company’s customers are highly uncertain and cannot be predicted. As a result, the Company’s future collection experience can differ significantly from historical collection trends. If the Company’s customers experience a negative impact on their cash flows, it could have a material adverse effect on the Company’s results of operations and financial condition.
Cash and Cash Equivalents
Cash and Cash Equivalents
Cash equivalents consist of short-term, highly liquid investments purchased with an original maturity of three months or less. Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. At times, the cash and cash equivalent balances may exceed federally insured limits. The Company does not believe that this results in any significant credit risk as the Company’s policy is to place its cash and cash equivalents in highly-rated financial institutions. The Company also holds cash in foreign banks that are not federally insured. The Company has not experienced any losses on its deposits of cash and cash equivalents.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2: Inputs are quoted prices for similar assets and liabilities in active markets or quoted prices for identical or similar instruments in markets that are not active and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.
Level 3: Inputs are unobservable inputs based on the Company’s assumptions and valuation techniques used to measure assets and liabilities at fair value. The inputs require significant management judgment or estimation.
The Company’s assessment of the significance of an input to the fair value measurement requires judgment, which may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels. The carrying amounts reported in the condensed consolidated financial statements approximate the fair value for cash and cash equivalents, accounts receivable, accounts payables, and accrued expenses due to their short-term nature. The carrying amount of the Company’s term loan, which is described below, approximates fair value, considering the interest rates are based on the prime interest rate.
The purchase price of business acquisitions is primarily allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition date, with the excess recorded as goodwill.
Contingent consideration represents contingent milestone, performance and revenue-sharing payment obligations related to acquisitions and is measured at fair value, based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration is estimated using a binary option-based approach with assumptions the Company believes would be made by a market participant. Significant inputs include projected revenues, discount rates, volatility factors and risk-free rates. The Company assesses these assumptions on an ongoing basis as additional data impacting the assumptions is obtained and any change in fair value of the contingent consideration is recorded within the general and administrative expenses in the consolidated statements of comprehensive loss. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. Generally, a change in the assumption used for the projected revenues would result in a directionally similar change to the overall estimate of the contingent consideration. The fair value of contingent consideration of $10.4 million at
March 31, 2022 is reflected in other long-term liabilities in the Company’s condensed consolidated balance sheets.
The following table summarizes the changes in the fair value of recurring Level 3 fair value measurements during the three months ended March 31, 2022 and 2021 (in thousands):
Three Months Ended
March 31,
20222021
Liabilities
Contingent consideration:
Balance at beginning of period$10,370 $— 
February 25, 2021 Acquisition— 6,750 
Balance at end of period$10,370 $6,750 
There were no transfers between Levels 1, 2 or 3 for the periods presented.
Investment Securities
Investment Securities
Those investments in debt securities with maturities less than 12 months at the date of purchase are considered short-term investments. Those investments in debt securities with maturities greater than 12 months at the date of purchase are considered long-term investments. The Company’s investment securities classified as available-for-sale are recorded at fair value based on the fair value hierarchy (Level 1 and Level 2 inputs in the fair value hierarchy), and consists primarily of commercial paper, corporate notes and U.S. government and agency securities. Unrealized gains or losses, deemed temporary in nature, are reported as other comprehensive income within the condensed consolidated statements of comprehensive loss. There were no unrealized gains or losses during the three months ended March 31, 2022 and 2021.
A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to net income (loss) and the corresponding establishment of a new cost basis for the security. Premiums (discounts) are amortized (accreted) over the life of the related security as an adjustment to yield using the straight-line interest method. Dividend and interest income are recognized when earned. Realized gains or losses are included in net loss and are derived using the specific identification method for determining the cost of securities sold.
Foreign Currency Translation
Foreign Currency Translation
The functional currencies of the Company’s subsidiaries are currencies other than the U.S. dollar. The Company translates assets and liabilities of the foreign subsidiaries into U.S. dollars at the exchange rate in effect on the balance sheet date. Revenue and expenses of the subsidiaries are translated into U.S. dollars at the average exchange rate during the period. Gains or losses from these translation adjustments are reported as a separate component of stockholders’ equity in accumulated other comprehensive gain or loss until there is a sale or complete or substantially complete liquidation of the Company’s investment in the foreign subsidiary at which time the gains or losses will be realized and included in net income (loss). As of March 31, 2022 and December 31, 2021, all foreign currency translation gains (losses) have been unrealized and included in accumulated other comprehensive loss. Accumulated other comprehensive loss consists entirely of losses or gains from translation of foreign subsidiaries at March 31, 2022 and December 31, 2021.
Inventory, Net
Inventory, Net
Inventories are stated at the lower of cost or net realizable value, with cost computed on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors.
The Company capitalizes inventory produced for commercial sale. The Company capitalizes manufacturing costs as inventory following both the receipt of regulatory approval from regulatory bodies and the Company’s
intent to commercialize. Costs associated with developmental products prior to satisfying the Company’s inventory capitalization criteria are charged to research and development expenses as incurred.
Products that have been approved by certain regulatory authorities may also be used in clinical programs to assess the safety and efficacy of the products for usage that have not been approved by the FDA or other regulatory authorities. The form of product utilized for both commercial and certain clinical programs that are identical are included as inventory with an “alternative future use” as defined in authoritative guidance. Component materials and purchased products associated with clinical development programs are included in inventory and charged to research and development expenses when the product enters the research and development process and no longer can be used for commercial purposes and, therefore, does not have an “alternative future use.”
For products that are under development and have not yet been approved by regulatory authorities, purchased component materials are charged to research and development expenses when the inventory ownership transfers to the Company.
The Company analyzes inventory levels to identify inventory that may expire prior to sale, inventory that has a cost basis in excess of its net realizable value, or inventory in excess of expected sales requirements. Although the manufacturing of the r-SNM System is subject to strict quality control, certain batches or units of product may no longer meet quality specifications or may expire, which would require adjustments to the Company’s inventory values. The Company also applies judgment related to the results of quality tests that are performed throughout the production process, as well as the understanding of regulatory guidelines, to determine if it is probable that inventory will be saleable. These quality tests are performed throughout the pre- and post-production processes, and the Company continually gathers information regarding product quality for periods after the manufacturing date. The Company’s products currently have a maximum estimated shelf life range of 12 to 36 months and, based on sales forecasts, the Company expects to realize the carrying value of the product inventory. In the future, reduced demand, quality issues, or excess supply beyond those anticipated by management may result in a material adjustment to inventory levels, which would be recorded as an increase to cost of sales.
The determination of whether inventory costs will be realizable or not requires estimates by the Company’s management. A critical input in this determination is future expected inventory requirements based on internal sales forecasts. Management then compares these requirements to the expiry dates of inventory on hand. To the extent that inventory is expected to expire prior to being sold, management will write down the value of inventory.
Property and Equipment
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and seven years. Leasehold improvements are amortized over the lesser of the life of the lease or the useful life of the improvements. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations.
Goodwill
Goodwill
Goodwill represents the excess purchase price over the fair values of the identifiable assets acquired less the liabilities assumed. Goodwill is tested for impairment at the reporting unit level by comparing the reporting unit’s carrying amount to the fair value of the reporting unit. The fair values are estimated using an income and discounted cash flow approach. The Company evaluates its goodwill on an annual basis in the fourth quarter or more frequently if it believes indicators of impairment exist. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount or performs an annual impairment test. When tested quantitatively, the Company compares the fair value of the applicable reporting unit with its carrying value. In making this assessment, management relies on a number of factors, including expected future operating results, business plans, economic projections, anticipated future cash flows, business trends and declines in the Company’s market capitalization. The Company estimates the fair values of its reporting unit using a combination of the discounted cash flow and income approaches. If the carrying amount of a reporting unit exceeds the reporting unit’s fair value, the amount by which the carrying value exceeds the fair value is recognized as an impairment loss. During the three months ended March 31, 2022, the Company did not record any impairment charges related to goodwill.
Intangible Assets
Intangible Assets
Patent license asset
The intangible asset represents exclusive rights to an additional field-of-use on the patent suite within the License Agreement with AMF. The additional field-of-use was provided in exchange for 50,000 shares of Series A preferred stock, the fair value of which was $1.0 million in 2013. The intangible asset was recorded at its fair value of $1.0 million at the date contributed. In connection with the initial public offering, such shares of Series A preferred stock were converted into common stock. Amortization of this asset is recorded over the shorter of the patent or legal life on a straight-line basis. The weighted-average amortization period is 8.71 years. The Company recorded minimal expenses for the amortization of the patent license asset during the three months ended March 31, 2022 and 2021. The Company will review the intangible asset for impairment whenever an impairment indicator exists. There have been no intangible asset impairment charges to date. For additional information, see Note 8.
Exclusive license asset
The intangible asset represents exclusive rights of existing technologies and development services from MST entered into on March 2, 2021. The agreement was provided in exchange for 65,594 shares of common stock, $0.0001 par value, the fair value of which was $3.6 million upon transfer. The intangible asset was recorded at its fair value of $3.3 million at the date of the agreement, with the difference of $0.3 million recorded as a vendor credit in accounts payable in the condensed consolidated balance sheets. Amortization of this asset is recorded over the four-year term of the agreement on a straight-line basis. The Company recorded expense for the amortization of the exclusive license asset of $0.2 million during the three months ended March 31, 2022. There was no amortization of this intangible asset recorded during the three months ended March 31, 2021. The Company will review the intangible asset for impairment whenever an impairment indicator exists. There have been no intangible asset impairment charges to date. For additional information, see Note 8.
Contura acquisition
The intangible assets represent technology, trade names and trademarks, and customer relationships acquired from Contura on February 25, 2021. The straight-line method over the period of estimated benefit is used to amortize finite-lived intangible assets except for customer relationships. Accounting Standards Codification (ASC) 350-30-35-3 states that customer relationships generally dissipate at a more rapid rate in the earlier periods following a company’s succession to these relationships, with the rate of attrition declining over time. As such, the accelerated method is used to amortize customer relationships. The Company recorded expense for the amortization of Contura acquisition intangible assets of $2.2 million and $0.6 million during the three months ended March 31, 2022 and 2021, respectively. For additional information, see Note 8.
Impairment of Long-Lived Assets Impairment of Long-Lived AssetsThe Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net cash flows that the assets are expected to generate. If said assets are considered to be impaired, the impairment that would be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset.
Leases
Leases
In accordance with ASU No. 2016-02, “Leases (Topic 842)”, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only. Topic 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the bright line thresholds referenced in Topic 842 to assist in evaluating leases for appropriate classification between operating and finance leases. The aforementioned bright lines are applied consistently to the Company’s entire portfolio of leases.
Operating lease ROU asset and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate, which is the rate for a fully collateralized amortizing loan with the same maturity as the lease term, based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
Research and Development
Research and Development
Research and development costs are charged to operations as incurred. Research and development costs include salary and personnel-related costs, costs of clinical studies and testing, supplies and materials, and outside consultant costs.
Advertising Expense Advertising ExpenseThe Company expenses advertising costs as they are incurred.
Income Taxes
Income Taxes
The Company accounts for income taxes using the asset and liability method to compute the difference between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. The Company has net deferred tax assets in certain jurisdictions. The realization of these deferred tax assets is dependent upon the Company’s ability to generate sufficient taxable income in future years. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company evaluates the recoverability of the deferred tax assets annually, and maintains a full valuation allowance on its U.S. net deferred tax assets. The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company is subject to transfer pricing and other tax regulations designed to ensure that appropriate levels of income are reported as earned by the Company’s U.S. and foreign entities and are taxed accordingly. In the normal course of business, the Company is audited by federal, state
and foreign tax authorities, and subject to inquiries from those tax authorities regarding the amount of taxes due. These inquiries may relate to the timing and amount of deductions and the allocation of income among various tax jurisdictions. The Company’s policy is to recognize interest and penalties related to unrecognized tax benefits, if any, in income tax expense.
Stock-Based Compensation
Stock-Based Compensation
The Company measures the cost of employee and non-employee services in exchange for an award of equity instruments based on the grant-date fair value of the award and recognizes compensation cost over the requisite service period (typically the vesting period), generally three or four years. Forfeitures are estimated at the time of the grant and revised in subsequent periods to reflect differences between the estimates and the number of shares that actually become exercisable.
The Company uses the Black-Scholes option pricing model to determine the fair value of stock options (as of the date of grant) that have service conditions for vesting. Stock options and restricted shares awards vest based on service conditions, typically over three or four years.
The Company also grants shares of performance-based restricted stock units that typically vest after one year only if the Company has also achieved certain performance objectives as defined and approved by the Company’s board of directors. The fair value of performance awards are determined based on the Company’s stock price at the date of grant and expensed over the performance period based on the probability of achieving the performance objectives. In addition, the Company also grants market-based restricted stock units that have combined market conditions and service conditions for vesting, for which the Company uses the Monte Carlo valuation model to value equity awards (as of the date of grant).
Net Loss per Share of Common Stock
Net Loss per Share of Common Stock
Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options, unvested RSAs and RSUs are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, diluted net loss per share of common stock is the same as basic net loss per share of common stock for those periods.
Segment Reporting
Segment Reporting
Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company has determined it operates in one segment, the development and commercialization of innovative and minimally invasive products to treat bladder and bowel dysfunction. Geographically, the Company sells over 90% to hospitals in the United States. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance.
Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In December 2019, the Financial Accounting Standards Board (FASB) issued ASU 2019-12, “Income Taxes—Simplifying the Accounting for Income Taxes,” which simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step-up in the tax basis of goodwill and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. This guidance is effective for annual periods beginning after December 15, 2020, which
was the Company’s first quarter of fiscal year 2021, with early adoption permitted. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or related disclosures.
Recent Accounting Pronouncements
We have reviewed and considered all recent accounting pronouncements that have not yet been adopted and believe there are none that could potentially have a material impact on our business practices, financial condition, results of operations, or disclosures.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Operations and Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue Disaggregated by Product and Geographic Market
The following table provides additional information pertaining to net revenue disaggregated by product and geographic market for the three months ended March 31, 2022 and 2021 (in thousands):
Three Months Ended
March 31,
20222021
SNM net revenue
United States$37,715 $31,745 
International markets1,355 1,158 
$39,070 $32,903 
Bulkamid net revenue(1)
United States$6,569 $578 
International markets2,781 892 
$9,350 $1,470 
Total net revenue$48,420 $34,373 
_____________________________________________
(1)    The acquisition of Bulkamid was completed on February 25, 2021. Reported revenue includes sales from February 26, 2021 onwards.
Schedule of Changes in Allowance for Credit Losses
The following table summarizes the changes in our allowance for credit losses (in thousands):
Three Months Ended
March 31,
20222021
Balance at beginning of period$355 $465 
Write-offs— 12 
Bad debt recoveries(39)(65)
Balance at end of period$316 $412 
Schedule of Changes in Fair Value of Liabilities Measured on Recurring Basis
The following table summarizes the changes in the fair value of recurring Level 3 fair value measurements during the three months ended March 31, 2022 and 2021 (in thousands):
Three Months Ended
March 31,
20222021
Liabilities
Contingent consideration:
Balance at beginning of period$10,370 $— 
February 25, 2021 Acquisition— 6,750 
Balance at end of period$10,370 $6,750 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment (Tables)
3 Months Ended
Mar. 31, 2022
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment, Net
Property and equipment, net consists of the following (in thousands) at:
March 31,December 31,
20222021
Equipment$2,611 $2,429 
Computer hardware and software2,595 2,450 
Tools and molds1,626 1,579 
Leasehold improvements4,449 4,372 
Furniture and fixtures1,515 1,502 
Construction in progress198 127 
12,994 12,459 
Less: accumulated depreciation and amortization(6,087)(5,544)
$6,907 $6,915 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Tables)
3 Months Ended
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Total Lease Cost
Total lease cost for the three months ended March 31, 2022 and 2021 are as follows (in thousands):
Three Months Ended
March 31,
20222021
Lease cost
Operating lease cost$524 $525 
Short-term lease cost21 23 
Variable lease cost35 47 
Total lease cost$580 $595 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation (Tables)
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Schedule of Stock-based Compensation Expense
Stock-based compensation expense included in the Company’s unaudited condensed consolidated statements of comprehensive loss is allocated as follows (in thousands):
Three Months Ended
March 31,
20222021
Research and development$1,510 $1,329 
General and administrative1,937 1,685 
Sales and marketing3,691 2,289 
$7,138 $5,303 
Schedule of Option Awards Fair Valuation Assumptions
The option awards issued under the 2014 Stock Option Plan (the 2014 Plan) and the 2018 Omnibus Incentive Plan (the 2018 Plan) were measured based on fair value. The Company’s fair value calculations were made using the Black-Scholes option pricing model with the following assumptions:
Three Months Ended
March 31,
20222021
Expected term (in years)
5.46 - 6.00
Stock volatility
63.49%
Risk-free interest rate
0.53% - 1.16%
Dividend rate
Schedule of Stock Option Activity
The following table summarizes stock option activity for the three months ended March 31, 2022 under the 2014 and 2018 Plans (in thousands, except share and per share data):
Number of OptionsWeighted-Average Exercise Price Per ShareAggregate Intrinsic Value
Outstanding at December 31, 2021
1,427,892 $18.13 
Options exercised(91,286)15.53 $3,486 (1)
Options forfeited(8,500)33.88 
Outstanding at March 31, 2022
1,328,106 $18.20 $58,963 (2)
_____________________________________________
(1)    Represents the total difference between the Company’s closing stock price at the time of exercise and the stock option exercise price, multiplied by the number of options exercised.
(2)    Represents the total difference between the Company’s closing stock price on the last trading day of the first quarter of 2022 and the stock option exercise price, multiplied by the number of in-the-money options as of March 31, 2022. The amount of intrinsic value will change based on the fair market value of the Company’s stock.
Schedule of Restricted Shares Awards Activity
The following table summarizes restricted shares awards activity for the three months ended March 31, 2022:
Number of Restricted Shares AwardsWeighted-Average Fair Value Per Share at Grant Date
Outstanding at December 31, 20211,102,034 $46.07 
Restricted shares awards granted352,204 48.14 
Restricted shares awards vested(169,110)37.55 
Restricted shares awards forfeited(39,725)56.85 
Outstanding at March 31, 20221,245,403 $47.47 
Schedule of Restricted Stock Units Activity
The following table summarizes restricted stock units activity for the three months ended March 31, 2022:
Number of Restricted Stock UnitsWeighted-Average Fair Value Per Share at Grant Date
Outstanding at December 31, 2021250,464 $42.99 
Restricted stock units granted201,884 38.75 
Restricted stock units vested(268,930)35.88 
Outstanding at March 31, 2022183,418 $48.74 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Tables)
3 Months Ended
Mar. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of Provision for Income Taxes and Effective Tax Rates
The following table presents details of the provision for income taxes and effective tax rates (in thousands, except percentages):
Three Months Ended
March 31,
20222021
Income tax benefit$(1,111)$(555)
Effective tax rate4.67%2.41%
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Intangible Assets (Tables)
3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Carrying Amount of Goodwill
The change in the carrying amount of goodwill during the three months ended March 31, 2022 included the following (in thousands):
December 31, 2021$105,510 
Foreign currency translation adjustment(2,952)
March 31, 2022$102,558 
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets
Intangible assets as of March 31, 2022 included the following (in thousands):
March 31, 2022
Weighted-Average Amortization PeriodGross Carrying AmountAccumulated AmortizationForeign currency translation adjustmentIntangible Assets, Net
Patent license asset8.71 years$1,000 (947)— $53 
Exclusive license asset4 years$3,300 (880)— $2,420 
Technology12 years$81,100 (7,362)(3,490)$70,248 
Trade names and trademarksIndefinite$19,700 — (906)$18,794 
Customer relationships12 years$11,400 (1,320)(416)$9,664 
$116,500 $(10,509)$(4,812)$101,179 
Intangible asset as of December 31, 2021 included the following (in thousands):
December 31, 2021
Weighted-Average Amortization PeriodGross Carrying AmountAccumulated AmortizationForeign currency translation adjustmentIntangible Asset, Net
Patent license asset8.71 years$1,000 (919)— $81 
Exclusive license asset4 years$3,300 (660)— 2,640 
Technology12 years$81,100 (5,668)(1,424)74,008 
Trade names and trademarksIndefinite$19,700 — (365)19,335 
Customer relationships12 years$11,400 (799)(196)10,405 
$116,500 $(8,046)$(1,985)$106,469 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details)
3 Months Ended 12 Months Ended
May 14, 2021
USD ($)
$ / shares
shares
Mar. 02, 2021
USD ($)
shares
Mar. 31, 2022
USD ($)
segment
$ / shares
shares
Mar. 31, 2021
USD ($)
shares
Dec. 31, 2013
USD ($)
shares
Dec. 31, 2021
USD ($)
$ / shares
Dec. 31, 2020
USD ($)
Basis of Presentation and Liquidity [Abstract]              
Net loss     $ (22,668,000) $ (22,503,000)      
Accumulated deficit     (337,234,000)     $ (314,566,000)  
Cash and cash equivalents     213,180,000 130,962,000   220,878,000 $ 241,181,000
Outstanding borrowings     0        
Revenue Recognition              
Allowance for product returns     100,000     200,000  
Replacement costs     100,000 100,000      
Warranty liability     100,000     100,000  
Investment Securities:              
Unrealized gain (loss) on investment securities     0 0      
Outstanding investment securities     0     0  
Inventory:              
Finished goods inventory     44,300,000     46,800,000  
Work-in-process inventory     3,000,000     2,800,000  
Raw materials inventory     14,600,000     15,300,000  
Inventory reserves     100,000     $ 200,000  
Goodwill:              
Impairment charges related to goodwill     0        
Intangible Asset:              
Fair value of shares issued for purchase of intangible asset       3,637,000      
Amortization of intangible assets     2,463,000 678,000      
Impairment of finite-lived intangible asset     $ 0        
Common stock, par value (in USD per share) | $ / shares     $ 0.0001     $ 0.0001  
Advertising Expense:              
Advertising expense     $ 3,200,000 $ 1,400,000      
Net Loss per Share of Common Stock:              
Potentially dilutive weighted-average shares not included in computation of diluted weighted average shares (in shares) | shares     2,416,373 2,488,284      
Segment Reporting [Abstract]              
Number of operating segments | segment     1        
Contura              
Intangible Asset:              
Amortization of intangible assets     $ 2,200,000 $ 600,000      
Contingent Consideration Liability | Contura              
Fair Value of Financial Instruments              
Contingent consideration at fair value     $ 10,400,000        
Restricted Stock Units              
Stock-Based Compensation:              
Vesting period     1 year        
Patent license asset              
Intangible Asset:              
Finite-lived intangible asset acquired         $ 1,000,000    
Finite-lived intangible assets, weighted-average amortization period     8 years 8 months 15 days        
Exclusive license asset              
Intangible Asset:              
Finite-lived intangible asset acquired   $ 3,300,000          
Finite-lived intangible assets, weighted-average amortization period     4 years        
Amortization of intangible assets     $ 200,000 $ 0      
Vendor credit in accounts payable   $ 300,000          
Preferred Stock | Patent license asset              
Intangible Asset:              
Stock issued for purchase of intangible asset (in shares) | shares         50,000    
Fair value of shares issued for purchase of intangible asset         $ 1,000,000    
Common Stock              
Intangible Asset:              
Stock issued for purchase of intangible asset (in shares) | shares       65,594      
Common Stock | Exclusive license asset              
Intangible Asset:              
Stock issued for purchase of intangible asset (in shares) | shares   65,594          
Fair value of shares issued for purchase of intangible asset   $ 3,600,000          
Minimum              
Inventory:              
Inventory shelf life     12 months        
Property and Equipment:              
Property and equipment useful life     3 years        
Stock-Based Compensation:              
Requisite service period of recognition of compensation cost     3 years        
Minimum | Stock Option and Restricted Stock-Based Awards              
Stock-Based Compensation:              
Vesting period     3 years        
Maximum              
Inventory:              
Inventory shelf life     36 months        
Property and Equipment:              
Property and equipment useful life     7 years        
Stock-Based Compensation:              
Requisite service period of recognition of compensation cost     4 years        
Maximum | Stock Option and Restricted Stock-Based Awards              
Stock-Based Compensation:              
Vesting period     4 years        
Follow-on Offering              
May 2021 Follow-On Offering:              
Stock issued (in shares) | shares 4,025,000            
Sale of stock, price per share (in USD per share) | $ / shares $ 50.00            
Net proceeds from sale of stock $ 190,000,000            
Exercise of Underwriters Option              
May 2021 Follow-On Offering:              
Stock issued (in shares) | shares 525,000            
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Operations and Summary of Significant Accounting Policies - Schedule of Revenue Disaggregated by Geographic Market (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Disaggregation of Revenue [Line Items]    
Net revenue $ 48,420 $ 34,373
SNM net revenue    
Disaggregation of Revenue [Line Items]    
Net revenue 39,070 32,903
Bulkamid net revenue    
Disaggregation of Revenue [Line Items]    
Net revenue 9,350 1,470
United States | SNM net revenue    
Disaggregation of Revenue [Line Items]    
Net revenue 37,715 31,745
United States | Bulkamid net revenue    
Disaggregation of Revenue [Line Items]    
Net revenue 6,569 578
International markets | SNM net revenue    
Disaggregation of Revenue [Line Items]    
Net revenue 1,355 1,158
International markets | Bulkamid net revenue    
Disaggregation of Revenue [Line Items]    
Net revenue $ 2,781 $ 892
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Operations and Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Doubtful Accounts (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Accounts Receivable, Allowance for Credit Loss [Roll Forward]    
Balance at beginning of period $ 355 $ 465
Write-offs 0 12
Bad debt recoveries (39) (65)
Balance at end of period $ 316 $ 412
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of Operations and Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Liabilities Measured on Recurring Basis (Details) - Level 3 - Contingent Consideration Liability - Fair Value, Recurring - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Contingent consideration:    
Balance at beginning of period $ 10,370 $ 0
February 25, 2021 Acquisition 0 6,750
Balance at end of period $ 10,370 $ 6,750
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment - Schedule of Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 12,994 $ 12,459
Less: accumulated depreciation and amortization (6,087) (5,544)
Property and equipment, net 6,907 6,915
Equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 2,611 2,429
Computer hardware and software    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 2,595 2,450
Tools and molds    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 1,626 1,579
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 4,449 4,372
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 1,515 1,502
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 198 $ 127
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Property, Plant and Equipment [Line Items]    
Depreciation and amortization expense $ 3,029 $ 1,133
Property and Equipment    
Property, Plant and Equipment [Line Items]    
Depreciation and amortization expense $ 600 $ 500
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - Narrative (Details)
3 Months Ended
Sep. 30, 2020
petition
Mar. 16, 2020
petition
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Aug. 31, 2020
ft²
Jun. 30, 2019
ft²
Nov. 30, 2017
ft²
Aug. 31, 2014
ft²
Loss Contingencies [Line Items]                  
Variable lease cost     $ 35,000 $ 47,000          
Right-of-use assets obtained in exchange for operating lease liabilities     0 100,000          
Right-of-use asset     6,800,000   $ 7,100,000        
Cash paid for operating lease liabilities     500,000 500,000          
Amortization of the ROU asset     $ 200,000 300,000          
Weighted-average remaining lease terms for operating leases     5 years 8 months 12 days   5 years 10 months 24 days        
Weighted-average incremental borrowing rate for a collateralized asset of the same remaining term (as a percent)     7.10%   7.10%        
Period after first sale royalty is due     12 years            
Net revenue due as royalty (as a percent)     4.00%            
Revenues     $ 48,420,000 34,373,000          
Royalty expense     1,600,000 1,300,000          
Accrued royalty expense     1,600,000   $ 1,800,000        
Medtronic Litigation                  
Loss Contingencies [Line Items]                  
Number of petitions filed with the United States Patent and Trademark Office | petition 7 7              
Number of petitions accepted by the United States Patent and Trademark Office | petition 6                
Minimum number of claims by Medtronic that are invalid as determined by the United States Patent and Trademark Office | petition 1                
SNM net revenue                  
Loss Contingencies [Line Items]                  
Revenues     39,070,000 $ 32,903,000          
Maximum                  
Loss Contingencies [Line Items]                  
Royalty commitments     $ 200,000            
First Lease                  
Loss Contingencies [Line Items]                  
Term of operating lease contract                 5 years
Net rentable area (square feet) | ft²                 12,215
Second Lease                  
Loss Contingencies [Line Items]                  
Term of operating lease contract               7 years  
Net rentable area (square feet) | ft²               25,548  
Renewal term of operating lease               5 years  
Third Lease                  
Loss Contingencies [Line Items]                  
Term of operating lease contract             8 years    
Net rentable area (square feet) | ft²             32,621    
Renewal term of operating lease             5 years    
Fourth Lease                  
Loss Contingencies [Line Items]                  
Term of operating lease contract           38 months      
Net rentable area (square feet) | ft²           5,693      
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - Schedule of Total Lease Cost (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]    
Operating lease cost $ 524 $ 525
Short-term lease cost 21 23
Variable lease cost 35 47
Total lease cost $ 580 $ 595
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Long-Term Debt - Narrative (Details) - Term Loans - USD ($)
$ in Millions
1 Months Ended
Jun. 30, 2021
Jan. 31, 2021
Term Loan Two    
Debt Instrument [Line Items]    
Unamortized debt issuance costs $ 4.4  
Interest expense $ 4.4  
Term Loan One    
Debt Instrument [Line Items]    
Unamortized debt issuance costs   $ 0.4
Interest expense   $ 0.4
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense $ 7,138 $ 5,303
Research and development    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense 1,510 1,329
General and administrative    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense 1,937 1,685
Sales and marketing    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense $ 3,691 $ 2,289
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation - Schedule of Option Awards Fair Valuation Assumptions (Details)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term (in years) 0 years  
Stock volatility, minimum (as a percent) 0.00% 63.49%
Stock volatility, maximum (as a percent) 0.00% 63.49%
Risk-free interest rate, minimum (as a percent) 0.00% 0.53%
Risk-free interest rate, maximum (as a percent) 0.00% 1.16%
Dividend rate (as a percent) 0.00% 0.00%
Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term (in years)   5 years 5 months 15 days
Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term (in years)   6 years
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Options granted (in shares) 0    
Weighted-average grant date fair value of options granted (in USD per share)   $ 32.89  
Stock Options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized compensation cost related to unvested stock options $ 5.3   $ 6.7
Weighted-average period of recognition of compensation cost 1 year 4 months 24 days   1 year 7 months 6 days
Weighted-average remaining contractual term of options outstanding and exercisable 6 years 9 months 18 days   6 years 10 months 24 days
Restricted Shares Awards      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted-average period of recognition of compensation cost 2 years 9 months 18 days   3 years
Unrecognized compensation cost related to unvested RSAs or RSUs $ 52.8   $ 42.5
Restricted Stock Units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted-average period of recognition of compensation cost 1 year 1 month 6 days   10 months 24 days
Unrecognized compensation cost related to unvested RSAs or RSUs $ 5.8   $ 1.9
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation - Schedule of Stock Option Activity (Details)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2022
USD ($)
$ / shares
shares
Number of Options  
Outstanding at beginning of period (in shares) | shares 1,427,892
Options exercised (in shares) | shares (91,286)
Options forfeited (in shares) | shares (8,500)
Outstanding at end of period (in shares) | shares 1,328,106
Weighted-Average Exercise Price Per Share  
Outstanding at beginning of period (in USD per share) | $ / shares $ 18.13
Options exercised (in USD per share) | $ / shares 15.53
Options forfeited (in USD per share) | $ / shares 33.88
Outstanding at end of period (in USD per share) | $ / shares $ 18.20
Aggregate Intrinsic Value  
Intrinsic value of options exercised | $ $ 3,486
Intrinsic value of options outstanding | $ $ 58,963
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation - Schedule of Restricted Shares Awards Activity (Details) - Restricted Shares Awards
3 Months Ended
Mar. 31, 2022
$ / shares
shares
Number of Restricted Shares Awards  
Outstanding at beginning of period (in shares) | shares 1,102,034
Granted (in shares) | shares 352,204
Vested (in shares) | shares (169,110)
Forfeited (in shares) | shares (39,725)
Outstanding at end of period (in shares) | shares 1,245,403
Weighted-Average Fair Value Per Share at Grant Date  
Outstanding at beginning of period (in USD per share) | $ / shares $ 46.07
Granted (in USD per share) | $ / shares 48.14
Vested (in USD per share) | $ / shares 37.55
Forfeited (in USD per share) | $ / shares 56.85
Outstanding at end of period (in USD per share) | $ / shares $ 47.47
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units
3 Months Ended
Mar. 31, 2022
$ / shares
shares
Number of Restricted Stock Units  
Outstanding at beginning of period (in shares) | shares 250,464
Granted (in shares) | shares 201,884
Vested (in shares) | shares (268,930)
Outstanding at end of period (in shares) | shares 183,418
Weighted-Average Fair Value Per Share at Grant Date  
Outstanding at beginning of period (in USD per share) | $ / shares $ 42.99
Granted (in USD per share) | $ / shares 38.75
Vested (in USD per share) | $ / shares 35.88
Outstanding at end of period (in USD per share) | $ / shares $ 48.74
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes - Schedule of Provision for Income Taxes and Effective Tax Rates (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Tax Disclosure [Abstract]    
Income tax benefit $ (1,111) $ (555)
Effective tax rate (as a percent) 4.67% 2.41%
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes - Narrative (Details)
$ in Millions
Dec. 31, 2021
USD ($)
Domestic Tax Authority  
Operating Loss Carryforwards [Line Items]  
Operating loss carryforwards $ 258.2
Operating loss carryforwards, subject to expiration 51.5
Foreign Tax Authority  
Operating Loss Carryforwards [Line Items]  
Operating loss carryforwards 16.4
State and Local Jurisdiction  
Operating Loss Carryforwards [Line Items]  
Operating loss carryforwards, subject to expiration $ 245.6
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Employee Benefit Plan (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Retirement Benefits [Abstract]    
Contributions by employer $ 0.5 $ 0.4
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Intangible Assets - Schedule of Carrying Amount of Goodwill (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2022
USD ($)
Goodwill [Roll Forward]  
Balance at beginning of period $ 105,510
Foreign currency translation adjustment (2,952)
Balance at end of period $ 102,558
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Intangible Assets - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets, Net:    
Accumulated Amortization $ (10,509) $ (8,046)
Foreign currency translation adjustment (4,812) (1,985)
Intangible Assets, Net (Excluding Goodwill):    
Gross Carrying Amount 116,500 116,500
Accumulated Amortization (10,509) (8,046)
Foreign currency translation adjustment (4,812) (1,985)
Intangible Assets, Net 101,179 106,469
Trade names and trademarks    
Indefinite-lived Intangible Assets:    
Gross Carrying Amount 19,700 19,700
Foreign currency translation adjustment (906) (365)
Intangible Assets, Net $ 18,794 $ 19,335
Patent license asset    
Finite-Lived Intangible Assets [Line Items]    
Weighted-Average Amortization Period 8 years 8 months 15 days 8 years 8 months 15 days
Finite-Lived Intangible Assets, Net:    
Gross Carrying Amount $ 1,000 $ 1,000
Accumulated Amortization (947) (919)
Foreign currency translation adjustment 0 0
Intangible Assets, Net 53 81
Intangible Assets, Net (Excluding Goodwill):    
Accumulated Amortization (947) (919)
Foreign currency translation adjustment $ 0 $ 0
Exclusive license asset    
Finite-Lived Intangible Assets [Line Items]    
Weighted-Average Amortization Period 4 years 4 years
Finite-Lived Intangible Assets, Net:    
Gross Carrying Amount $ 3,300 $ 3,300
Accumulated Amortization (880) (660)
Foreign currency translation adjustment 0 0
Intangible Assets, Net 2,420 2,640
Intangible Assets, Net (Excluding Goodwill):    
Accumulated Amortization (880) (660)
Foreign currency translation adjustment $ 0 $ 0
Technology    
Finite-Lived Intangible Assets [Line Items]    
Weighted-Average Amortization Period 12 years 12 years
Finite-Lived Intangible Assets, Net:    
Gross Carrying Amount $ 81,100 $ 81,100
Accumulated Amortization (7,362) (5,668)
Foreign currency translation adjustment (3,490) (1,424)
Intangible Assets, Net 70,248 74,008
Intangible Assets, Net (Excluding Goodwill):    
Accumulated Amortization (7,362) (5,668)
Foreign currency translation adjustment $ (3,490) $ (1,424)
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Weighted-Average Amortization Period 12 years 12 years
Finite-Lived Intangible Assets, Net:    
Gross Carrying Amount $ 11,400 $ 11,400
Accumulated Amortization (1,320) (799)
Foreign currency translation adjustment (416) (196)
Intangible Assets, Net 9,664 10,405
Intangible Assets, Net (Excluding Goodwill):    
Accumulated Amortization (1,320) (799)
Foreign currency translation adjustment $ (416) $ (196)
XML 52 axnx-20220331_htm.xml IDEA: XBRL DOCUMENT 0001603756 2022-01-01 2022-03-31 0001603756 2022-05-03 0001603756 2022-03-31 0001603756 2021-12-31 0001603756 2021-01-01 2021-03-31 0001603756 us-gaap:CommonStockMember 2021-12-31 0001603756 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001603756 us-gaap:RetainedEarningsMember 2021-12-31 0001603756 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001603756 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001603756 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001603756 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001603756 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001603756 us-gaap:CommonStockMember 2022-03-31 0001603756 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001603756 us-gaap:RetainedEarningsMember 2022-03-31 0001603756 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001603756 us-gaap:CommonStockMember 2020-12-31 0001603756 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001603756 us-gaap:RetainedEarningsMember 2020-12-31 0001603756 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001603756 2020-12-31 0001603756 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001603756 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001603756 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001603756 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001603756 us-gaap:CommonStockMember 2021-03-31 0001603756 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001603756 us-gaap:RetainedEarningsMember 2021-03-31 0001603756 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001603756 2021-03-31 0001603756 axnx:FollowonOfferingMember 2021-05-14 2021-05-14 0001603756 axnx:FollowonOfferingMember 2021-05-14 0001603756 us-gaap:OverAllotmentOptionMember 2021-05-14 2021-05-14 0001603756 axnx:SacralNeuromodulationMember country:US 2022-01-01 2022-03-31 0001603756 axnx:SacralNeuromodulationMember country:US 2021-01-01 2021-03-31 0001603756 axnx:SacralNeuromodulationMember us-gaap:NonUsMember 2022-01-01 2022-03-31 0001603756 axnx:SacralNeuromodulationMember us-gaap:NonUsMember 2021-01-01 2021-03-31 0001603756 axnx:SacralNeuromodulationMember 2022-01-01 2022-03-31 0001603756 axnx:SacralNeuromodulationMember 2021-01-01 2021-03-31 0001603756 axnx:BulkamidMember country:US 2022-01-01 2022-03-31 0001603756 axnx:BulkamidMember country:US 2021-01-01 2021-03-31 0001603756 axnx:BulkamidMember us-gaap:NonUsMember 2022-01-01 2022-03-31 0001603756 axnx:BulkamidMember us-gaap:NonUsMember 2021-01-01 2021-03-31 0001603756 axnx:BulkamidMember 2022-01-01 2022-03-31 0001603756 axnx:BulkamidMember 2021-01-01 2021-03-31 0001603756 axnx:ConturaLimitedMember axnx:ContingentConsiderationLiabilityMember 2022-03-31 0001603756 us-gaap:FairValueInputsLevel3Member axnx:ContingentConsiderationLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001603756 us-gaap:FairValueInputsLevel3Member axnx:ContingentConsiderationLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001603756 us-gaap:FairValueInputsLevel3Member axnx:ContingentConsiderationLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-01-01 2022-03-31 0001603756 us-gaap:FairValueInputsLevel3Member axnx:ContingentConsiderationLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-01-01 2021-03-31 0001603756 us-gaap:FairValueInputsLevel3Member axnx:ContingentConsiderationLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001603756 us-gaap:FairValueInputsLevel3Member axnx:ContingentConsiderationLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001603756 srt:MinimumMember 2022-01-01 2022-03-31 0001603756 srt:MaximumMember 2022-01-01 2022-03-31 0001603756 us-gaap:PatentsMember us-gaap:PreferredStockMember 2013-01-01 2013-12-31 0001603756 us-gaap:PatentsMember 2013-01-01 2013-12-31 0001603756 us-gaap:PatentsMember 2022-01-01 2022-03-31 0001603756 axnx:ExclusiveLicenseAssetMember us-gaap:CommonStockMember 2021-03-02 2021-03-02 0001603756 axnx:ExclusiveLicenseAssetMember 2021-03-02 2021-03-02 0001603756 axnx:ExclusiveLicenseAssetMember 2021-03-02 0001603756 axnx:ExclusiveLicenseAssetMember 2022-01-01 2022-03-31 0001603756 axnx:ExclusiveLicenseAssetMember 2021-01-01 2021-03-31 0001603756 axnx:ConturaLimitedMember 2022-01-01 2022-03-31 0001603756 axnx:ConturaLimitedMember 2021-01-01 2021-03-31 0001603756 srt:MinimumMember axnx:EmployeeStockOptionandRestrictedStockBasedAwardsMember 2022-01-01 2022-03-31 0001603756 srt:MaximumMember axnx:EmployeeStockOptionandRestrictedStockBasedAwardsMember 2022-01-01 2022-03-31 0001603756 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001603756 us-gaap:EquipmentMember 2022-03-31 0001603756 us-gaap:EquipmentMember 2021-12-31 0001603756 us-gaap:ComputerEquipmentMember 2022-03-31 0001603756 us-gaap:ComputerEquipmentMember 2021-12-31 0001603756 us-gaap:ToolsDiesAndMoldsMember 2022-03-31 0001603756 us-gaap:ToolsDiesAndMoldsMember 2021-12-31 0001603756 us-gaap:LeaseholdImprovementsMember 2022-03-31 0001603756 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001603756 us-gaap:FurnitureAndFixturesMember 2022-03-31 0001603756 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001603756 us-gaap:ConstructionInProgressMember 2022-03-31 0001603756 us-gaap:ConstructionInProgressMember 2021-12-31 0001603756 us-gaap:PropertyPlantAndEquipmentMember 2022-01-01 2022-03-31 0001603756 us-gaap:PropertyPlantAndEquipmentMember 2021-01-01 2021-03-31 0001603756 axnx:Lease1Member 2014-08-31 0001603756 axnx:Lease2Member 2017-11-30 0001603756 axnx:Lease3Member 2019-06-30 0001603756 axnx:Lease4Member 2020-08-31 0001603756 srt:MaximumMember 2022-03-31 0001603756 axnx:MedtronicLitigationMember 2020-03-16 2020-03-16 0001603756 axnx:MedtronicLitigationMember 2020-09-30 2020-09-30 0001603756 axnx:TermLoanTwoMember us-gaap:LoansPayableMember 2021-06-30 0001603756 axnx:TermLoanTwoMember us-gaap:LoansPayableMember 2021-06-01 2021-06-30 0001603756 axnx:TermLoanOneMember us-gaap:LoansPayableMember 2021-01-31 0001603756 axnx:TermLoanOneMember us-gaap:LoansPayableMember 2021-01-01 2021-01-31 0001603756 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001603756 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001603756 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001603756 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001603756 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-03-31 0001603756 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-03-31 0001603756 srt:MinimumMember 2021-01-01 2021-03-31 0001603756 srt:MaximumMember 2021-01-01 2021-03-31 0001603756 us-gaap:EmployeeStockOptionMember 2022-03-31 0001603756 us-gaap:EmployeeStockOptionMember 2021-12-31 0001603756 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001603756 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001603756 us-gaap:RestrictedStockMember 2022-03-31 0001603756 us-gaap:RestrictedStockMember 2021-12-31 0001603756 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001603756 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001603756 us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0001603756 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001603756 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001603756 us-gaap:DomesticCountryMember 2021-12-31 0001603756 us-gaap:ForeignCountryMember 2021-12-31 0001603756 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001603756 us-gaap:PatentsMember 2022-03-31 0001603756 axnx:ExclusiveLicenseAssetMember 2022-03-31 0001603756 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-01-01 2022-03-31 0001603756 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-03-31 0001603756 us-gaap:TrademarksAndTradeNamesMember 2022-03-31 0001603756 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-03-31 0001603756 us-gaap:CustomerRelationshipsMember 2022-03-31 0001603756 us-gaap:PatentsMember 2021-01-01 2021-12-31 0001603756 us-gaap:PatentsMember 2021-12-31 0001603756 axnx:ExclusiveLicenseAssetMember 2021-01-01 2021-12-31 0001603756 axnx:ExclusiveLicenseAssetMember 2021-12-31 0001603756 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-01-01 2021-12-31 0001603756 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-12-31 0001603756 us-gaap:TrademarksAndTradeNamesMember 2021-12-31 0001603756 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-12-31 0001603756 us-gaap:CustomerRelationshipsMember 2021-12-31 shares iso4217:USD iso4217:USD shares axnx:segment utr:sqft pure axnx:petition false 2022 Q1 0001603756 --12-31 P3Y P3Y P3Y P0Y 10-Q true 2022-03-31 false 001-38721 Axonics, Inc. DE 45-4744083 26 Technology Drive Irvine, CA 92618 (949) 396-6322 Common stock, par value $0.0001 per share AXNX NASDAQ Yes Yes Large Accelerated Filer false false false 47070097 213180000 220878000 316000 355000 27425000 29044000 61876000 64946000 4952000 6449000 307433000 321317000 6907000 6915000 101179000 106469000 7494000 7734000 102558000 105510000 525571000 547945000 10390000 7654000 6246000 5435000 7480000 12413000 1403000 1366000 25519000 26868000 8686000 9052000 17564000 19217000 10370000 10370000 62139000 65507000 0.0001 0.0001 10000000 10000000 0 0 0 0 0 0 0.0001 0.0001 50000000 50000000 47002862 47002862 46330167 46330167 5000 5000 812141000 803559000 -337234000 -314566000 -11480000 -6560000 463432000 482438000 525571000 547945000 48420000 34373000 15178000 13974000 33242000 20399000 11236000 9369000 10013000 6626000 33063000 20928000 2463000 678000 0 4414000 56775000 42015000 -23533000 -21616000 43000 8000 -289000 -1450000 -246000 -1442000 -23779000 -23058000 -1111000 -555000 -22668000 -22503000 -4920000 -2202000 -27588000 -24705000 -0.50 -0.50 -0.57 -0.57 45139038 45139038 39613964 39613964 46330167 5000 803559000 -314566000 -6560000 482438000 91286 1444000 1444000 312479 5633000 5633000 268930 1505000 1505000 -4920000 -4920000 -22668000 -22668000 47002862 5000 812141000 -337234000 -11480000 463432000 39931030 4000 522296000 -234499000 -431000 287370000 206507 2821000 2821000 358300 3809000 3809000 169054 1494000 1494000 1096583 55728000 55728000 65594 3637000 3637000 -2202000 -2202000 -22503000 -22503000 41827068 4000 589785000 -257002000 -2633000 330154000 -22668000 -22503000 3029000 1133000 7138000 5303000 0 567000 -39000 -65000 -1210000 -577000 -1595000 1480000 -3015000 7193000 -1474000 -860000 25000 100000 2529000 914000 900000 -1569000 -4925000 -915000 20000 42000 -9167000 -25583000 291000 123000 0 140741000 -291000 -140864000 0 106000 0 75000000 0 21500000 1444000 2821000 1444000 56215000 316000 13000 -7698000 -110219000 220878000 241181000 213180000 130962000 1000 170000 0 0 267000 0 0 55728000 0 6750000 0 3637000 0 4500000 Nature of Operations and Summary of Significant Accounting Policies<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axonics, Inc. (the Company) was incorporated in the state of Delaware on March 2, 2012 under the name American Restorative Medicine, Inc. In August 2013, the Company changed its name to Axonics Modulation Technologies, Inc. In March 2021, the Company changed its name to Axonics, Inc. The Company had no operations until October 1, 2013, when the license agreement between Alfred E. Mann Foundation for Scientific Research (AMF) and the Company (the License Agreement) was entered into. The Company is a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction. The Company has designed and developed the rechargeable sacral neuromodulation (SNM) system (r-SNM System), which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The r-SNM System is protected by intellectual property based on Company-generated innovations and patents and other intellectual property licensed from AMF. The Company has </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing approvals in the United States, Europe, Canada, and Australia for all relevant clinical indications. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he premarket approval (PMA) application for the r-SNM System for the treatment of FI was approved by the U.S. Food and Drug Administration (FDA) on September 6, 2019, and the PMA application for the r-SNM System for the treatment of OAB and UR was approved by the FDA on November 13, 2019. Accordingly, the Company began U.S. commercialization of its r-SNM System in the fourth quarter of 2019. Prior to the fourth quarter of 2019, the Company derived revenue only from its international operations in select markets including England, the Netherlands and Canada, and its activities had consisted primarily of developing the r-SNM System, conducting its RELAX-OAB post-market clinical follow-up study in Europe, its ARTISAN-SNM pivotal clinical study in the United States and hiring and training its U.S. commercial team in preparation for the launch of the r-SNM System in the United States. Beginning in February 2021 with the acquisition of Contura Limited, the Company also markets Bulkamid, a urethral bulking agent to treat female stress urinary incontinence (SUI). For more information, see Note 8.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2021 Follow-On Offering</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 14, 2021, the Company completed a follow-on offering by issuing 4,025,000 shares of common stock, at an offering price of $50.00 per share, inclusive of 525,000 shares of the Company’s common stock issued upon the exercise by the underwriters of their option to purchase additional shares. The net proceeds to the Company were approximately $190.0 million, after deducting underwriting discounts, commissions and offering expenses payable by the Company. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company; its wholly-owned subsidiaries, Axonics Europe, S.A.S., Axonics Modulation Technologies U.K. Limited, Axonics Modulation Technologies Australia Pty Ltd, Axonics Women’s Health Limited, Bulkamid SARL, Axonics GmbH, and Contura, Inc. Intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim condensed consolidated financial statements and related footnote disclosures as of and for the three months ended March 31, 2022 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The unaudited interim condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three months ended March 31, 2022 in accordance with United States (U.S.) generally accepted accounting principles (GAAP), however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (SEC) rules and regulations relating to interim financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements and notes thereto included within the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (filed with the SEC on March 1, 2022).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company only began full-scale commercialization of the r-SNM System in late 2019. The Company has expended significant resources on research and development activities, growing its operations organization and building and training its sales organization.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred net losses of $22.7 million and $22.5 million for the three months ended March 31, 2022 and 2021, respectively, and had an accumulated deficit of $337.2 million as of March 31, 2022 compared to $314.6 million at December 31, 2021. The Company expects to continue to spend a significant amount of its existing resources on sales and marketing activities as the Company continues to commercialize and market its products in the United States and internationally.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company had cash and cash equivalents of $213.2 million compared to $220.9 million at December 31, 2021. The Company expects that its cash and cash equivalents on hand will be sufficient to fund its operations through at least the next 12 months. The Company funds its operations through a combination of proceeds from public offerings of its common stock and cash receipts from sales of its products. As of March 31, 2022, the Company had no outstanding borrowings. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may need to raise additional financing in the future to facilitate its business operations. If the Company raises additional funds by issuing equity securities, its stockholders could experience dilution. Debt financing, if available, may involve covenants further restricting its operations or its ability to incur additional debt. Any debt financing or additional equity that the Company raises may contain terms that are not favorable to the Company or its stockholders. Additional financing may not be available at all, or in amounts or on terms acceptable to the Company. If the Company is unable to obtain additional financing when needed to satisfy its liquidity requirements, the Company may be required to scale back its operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent COVID-19 outbreak, and the resulting restrictions intended to slow the spread of COVID-19, including stay-at-home orders, business shutdowns and other restrictions, has adversely affected the Company’s business in several ways. The primary impact on the Company’s business was the cancellation or delay of elective procedures in certain areas to allow health care facilities to prioritize the treatment of COVID-19 patients during the initial stages and resurgence periods of the pandemic or because patients are avoiding health care facilities that they feel are unsafe. These developments materially reduced the number of procedures using the Company’s r-SNM System. If governmental authorities recommend again in the future that it is deemed advisable for health care facilities to not perform outpatient elective procedures, as was the case at various times since the second quarter of 2020, the Company expects it would materially harm the Company’s revenues and potentially increase the Company’s operating loss. Even as efforts to contain the pandemic have made progress and some restrictions have relaxed, new variants of the virus may continue to cause additional outbreaks. These challenges will likely continue for the duration of the pandemic and could reduce our revenue and negatively impact our business, financial condition and results of operations while the pandemic continues. If these delays in procedures occur in the future, the Company may have to scale back its business, including reducing headcount, which could have a negative impact on the Company’s long-term operations. The Company could also experience other negative impacts of the COVID-19 outbreak such as the lack of availability of the Company’s key personnel, temporary closures of the Company’s office or the facilities of the Company’s business partners, customers, third party service providers or other vendors, and the interruption of the Company’s supply chain, distribution channels, liquidity and capital or financial markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any disruption and volatility in the global capital markets as a result of the pandemic may increase the Company’s cost of capital and adversely affect the Company’s ability to access financing when and on terms that the Company desires. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a recession resulting from the spread of COVID-19 could materially affect </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company’s</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> business, especially if a recession results in higher unemployment causing potential patients to not have access to health insurance. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate extent to which the COVID-19 pandemic and its repercussions impact the Company’s business will depend on future developments, which are highly uncertain. However, the foregoing and other continued disruptions to the Company’s business as a result of COVID-19 could result in a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses, and related disclosure of contingent assets and liabilities. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. The results of this evaluation then form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates, and such differences may be material to the consolidated financial statements. Significant items subject to such estimates and assumptions include the useful lives of property and equipment and intangible assets, the valuation of deferred income tax assets and liabilities, the valuation of contingent consideration liability, the valuation of stock-based compensation, the product returns reserve, the inventory obsolescence reserve and accounts receivable allowance for credit losses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized during the three months ended March 31, 2022 and 2021 relates entirely to the sale of the Company’s products to its customers and distributors.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has revenue arrangements that consist of a single performance obligation. The Company recognizes revenue at the point in time when it transfers control of promised goods to its customers. Revenue is measured as the amount of consideration it expects to receive in exchange for transferring goods. The amount of revenue that is recognized is based on the transaction price, which represents the invoiced amount and includes estimates of variable consideration such as discounts, where applicable. The Company also sells to distributors and applies the same policies as its revenue arrangements with customers, specifically that revenue is recognized at the point in time when it transfers control of promised goods to its distributors. The Company does not offer rights of return or price protection. The amount of variable consideration included in the transaction price may be constrained and is included only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Payment terms, typically less than three months, do not include a significant financing component. The Company extends credit to its customers and distributors based upon an evaluation of their financial condition and credit history and generally requires no collateral. The Company does not have any contract balances related to product sales. The Company also does not have significant contract acquisition costs related to product sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Company policy and based on the Company’s historical experience, the allowance for product returns was $0.1 million and $0.2 million at March 31, 2022 and December 31, 2021, respectively, and is recorded as a reduction of gross revenue in its condensed consolidated statements of comprehensive loss. Damaged or defective products are replaced at no charge under the Company’s standard warranty. For the three months ended March 31, 2022 and 2021, the replacement costs were $0.1 million and $0.1 million, respectively, and are recorded within the sales and marketing expenses in its condensed consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers its standard warranty to all customers. The Company does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to sales and marketing expense. The warranty liability as of March 31, 2022 and December 31, 2021 were $0.1 million and $0.1 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred for the delivery of goods to customers and distributors are included in cost of goods sold. Amounts billed to customers and distributors for shipping and handling are included in net revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional information pertaining to net revenue disaggregated by product and geographic market for the three months ended March 31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNM net revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International markets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,070 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,903 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bulkamid net revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International markets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,350 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,420 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,373 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    The acquisition of Bulkamid was completed on February 25, 2021. Reported revenue includes sales from February 26, 2021 onwards.</span></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company makes estimates of the collectability of accounts receivable in accordance with Accounting Standards Update (ASU) 2016-13. The Company’s estimate of future credit losses is made by management based upon historical bad debts, customer receivable balances, age of customer receivable balances, customers’ financial conditions and reasonable forecasted economic trends. Despite the Company’s efforts to minimize credit risk exposure, customers could be adversely affected if future economic and industry trends, including those related to COVID-19, change in such a manner as to negatively impact their cash flows. The full effects of COVID-19 on the Company’s customers are highly uncertain and cannot be predicted. As a result, the Company’s future collection experience can differ significantly from historical collection trends. If the Company’s customers experience a negative impact on their cash flows, it could have a material adverse effect on the Company’s results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the changes in our allowance for credit losses (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of short-term, highly liquid investments purchased with an original maturity of three months or less. Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. At times, the cash and cash equivalent balances may exceed federally insured limits. The Company does not believe that this results in any significant credit risk as the Company’s policy is to place its cash and cash equivalents in highly-rated financial institutions. The Company also holds cash in foreign banks that are not federally insured. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Inputs are quoted prices for similar assets and liabilities in active markets or quoted prices for identical or similar instruments in markets that are not active and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Inputs are unobservable inputs based on the Company’s assumptions and valuation techniques used to measure assets and liabilities at fair value. The inputs require significant management judgment or estimation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s assessment of the significance of an input to the fair value measurement requires judgment, which may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels. The carrying amounts reported in the condensed consolidated financial statements approximate the fair value for cash and cash equivalents, accounts receivable, accounts payables, and accrued expenses due to their short-term nature. The carrying amount of the Company’s term loan, which is described below, approximates fair value, considering the interest rates are based on the prime interest rate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of business acquisitions is primarily allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition date, with the excess recorded as goodwill.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration represents contingent milestone, performance and revenue-sharing payment obligations related to acquisitions and is measured at fair value, based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration is estimated using a binary option-based approach with assumptions the Company believes would be made by a market participant. Significant inputs include projected revenues, discount rates, volatility factors and risk-free rates. The Company assesses these assumptions on an ongoing basis as additional data impacting the assumptions is obtained and any change in fair value of the contingent consideration is recorded within the general and administrative expenses in the consolidated statements of comprehensive loss. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. Generally, a change in the assumption used for the projected revenues would result in a directionally similar change to the overall estimate of the contingent consideration. The fair value of contingent consideration of $10.4 million at </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2022 is reflected in other long-term liabilities in the Company’s condensed consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the changes in the fair value of recurring Level 3 fair value measurements during the three months ended March 31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021 Acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,370 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,750 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Levels 1, 2 or 3 for the periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those investments in debt securities with maturities less than 12 months at the date of purchase are considered short-term investments. Those investments in debt securities with maturities greater than 12 months at the date of purchase are considered long-term investments. The Company’s investment securities classified as available-for-sale are recorded at fair value based on the fair value hierarchy (Level 1 and Level 2 inputs in the fair value hierarchy), and consists primarily of commercial paper, corporate notes and U.S. government and agency securities. Unrealized gains or losses, deemed temporary in nature, are reported as other comprehensive income within the condensed consolidated statements of comprehensive loss. There were no unrealized gains or losses during the three months ended March 31, 2022 and 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to net income (loss) and the corresponding establishment of a new cost basis for the security. Premiums (discounts) are amortized (accreted) over the life of the related security as an adjustment to yield using the straight-line interest method. Dividend and interest income are recognized when earned. Realized gains or losses are included in net loss and are derived using the specific identification method for determining the cost of securities sold.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no outstanding investment securities as of March 31, 2022 and December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currencies of the Company’s subsidiaries are currencies other than the U.S. dollar. The Company translates assets and liabilities of the foreign subsidiaries into U.S. dollars at the exchange rate in effect on the balance sheet date. Revenue and expenses of the subsidiaries are translated into U.S. dollars at the average exchange rate during the period. Gains or losses from these translation adjustments are reported as a separate component of stockholders’ equity in accumulated other comprehensive gain or loss until there is a sale or complete or substantially complete liquidation of the Company’s investment in the foreign subsidiary at which time the gains or losses will be realized and included in net income (loss). As of March 31, 2022 and December 31, 2021, all foreign currency translation gains (losses) have been unrealized and included in accumulated other comprehensive loss. Accumulated other comprehensive loss consists entirely of losses or gains from translation of foreign subsidiaries at March 31, 2022 and December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value, with cost computed on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes inventory produced for commercial sale. The Company capitalizes manufacturing costs as inventory following both the receipt of regulatory approval from regulatory bodies and the Company’s </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intent to commercialize. Costs associated with developmental products prior to satisfying the Company’s inventory capitalization criteria are charged to research and development expenses as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products that have been approved by certain regulatory authorities may also be used in clinical programs to assess the safety and efficacy of the products for usage that have not been approved by the FDA or other regulatory authorities. The form of product utilized for both commercial and certain clinical programs that are identical are included as inventory with an “alternative future use” as defined in authoritative guidance. Component materials and purchased products associated with clinical development programs are included in inventory and charged to research and development expenses when the product enters the research and development process and no longer can be used for commercial purposes and, therefore, does not have an “alternative future use.” </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For products that are under development and have not yet been approved by regulatory authorities, purchased component materials are charged to research and development expenses when the inventory ownership transfers to the Company. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes inventory levels to identify inventory that may expire prior to sale, inventory that has a cost basis in excess of its net realizable value, or inventory in excess of expected sales requirements. Although the manufacturing of the r-SNM System is subject to strict quality control, certain batches or units of product may no longer meet quality specifications or may expire, which would require adjustments to the Company’s inventory values. The Company also applies judgment related to the results of quality tests that are performed throughout the production process, as well as the understanding of regulatory guidelines, to determine if it is probable that inventory will be saleable. These quality tests are performed throughout the pre- and post-production processes, and the Company continually gathers information regarding product quality for periods after the manufacturing date. The Company’s products currently have a maximum estimated shelf life range of 12 to 36 months and, based on sales forecasts, the Company expects to realize the carrying value of the product inventory. In the future, reduced demand, quality issues, or excess supply beyond those anticipated by management may result in a material adjustment to inventory levels, which would be recorded as an increase to cost of sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of whether inventory costs will be realizable or not requires estimates by the Company’s management. A critical input in this determination is future expected inventory requirements based on internal sales forecasts. Management then compares these requirements to the expiry dates of inventory on hand. To the extent that inventory is expected to expire prior to being sold, management will write down the value of inventory.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company had $44.3 million, $3.0 million and $14.6 million of finished goods inventory, work-in-process inventory and raw materials inventory, respectively, net of reserves of $0.1 million. As of December 31, 2021, the Company had $46.8 million, $2.8 million and $15.3 million of finished goods inventory, work-in-process inventory and raw materials inventory, respectively, net of reserves of $0.2 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Customer and Vendor Concentration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, there were no customers who accounted for over 10% of the Company’s consolidated accounts receivable. As of March 31, 2022 and December 31, 2021, there were two vendors and no vendor, respectively, who accounted for over 10% of the Company’s consolidated accounts payable. As of March 31, 2022 and December 31, 2021, there were no customers who accounted for over 10% of the Company’s consolidated net revenue. As of March 31, 2022 and December 31, 2021, there were three vendors and one vendor, respectively, who accounted for over 10% of the Company’s inventory-related purchases.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEyMmYyYzkwYjQyODQ1MzRiY2VmZGJiZGZhNjQ2ZDU3L3NlYzphMjJmMmM5MGI0Mjg0NTM0YmNlZmRiYmRmYTY0NmQ1N180MC9mcmFnOjU0ZDliNWYzZGE1MTQ2YTVhNGYyNTk1YTE5YjNkN2FiL3RleHRyZWdpb246NTRkOWI1ZjNkYTUxNDZhNWE0ZjI1OTVhMTliM2Q3YWJfMjM3ODM_07e157c7-3a38-4472-8210-fac18e90cd5c">three</span> and seven years. Leasehold improvements are amortized over the lesser of the life of the lease or the useful life of the improvements. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess purchase price over the fair values of the identifiable assets acquired less the liabilities assumed. Goodwill is tested for impairment at the reporting unit level by comparing the reporting unit’s carrying amount to the fair value of the reporting unit. The fair values are estimated using an income and discounted cash flow approach. The Company evaluates its goodwill on an annual basis in the fourth quarter or more frequently if it believes indicators of impairment exist. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount or performs an annual impairment test. When tested quantitatively, the Company compares the fair value of the applicable reporting unit with its carrying value. In making this assessment, management relies on a number of factors, including expected future operating results, business plans, economic projections, anticipated future cash flows, business trends and declines in the Company’s market capitalization. The Company estimates the fair values of its reporting unit using a combination of the discounted cash flow and income approaches. If the carrying amount of a reporting unit exceeds the reporting unit’s fair value, the amount by which the carrying value exceeds the fair value is recognized as an impairment loss. During the three months ended March 31, 2022, the Company did not record any impairment charges related to goodwill.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent license asset</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset represents exclusive rights to an additional field-of-use on the patent suite within the License Agreement with AMF. The additional field-of-use was provided in exchange for 50,000 shares of Series A preferred stock, the fair value of which was $1.0 million in 2013. The intangible asset was recorded at its fair value of $1.0 million at the date contributed. In connection with the initial public offering, such shares of Series A preferred stock were converted into common stock. Amortization of this asset is recorded over the shorter of the patent or legal life on a straight-line basis. The weighted-average amortization period is 8.71 years. The Company recorded minimal expenses for the amortization of the patent license asset during the three months ended March 31, 2022 and 2021. The Company will review the intangible asset for impairment whenever an impairment indicator exists. There have been no intangible asset impairment charges to date. For additional information, see Note 8.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exclusive license asset</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset represents exclusive rights of existing technologies and development services from MST entered into on March 2, 2021. The agreement was provided in exchange for 65,594 shares of common stock, $0.0001 par value, the fair value of which was $3.6 million upon transfer. The intangible asset was recorded at its fair value of $3.3 million at the date of the agreement, with the difference of $0.3 million recorded as a vendor credit in accounts payable in the condensed consolidated balance sheets. Amortization of this asset is recorded over the four-year term of the agreement on a straight-line basis. The Company recorded expense for the amortization of the exclusive license asset of $0.2 million during the three months ended March 31, 2022. There was no amortization of this intangible asset recorded during the three months ended March 31, 2021. The Company will review the intangible asset for impairment whenever an impairment indicator exists. There have been no intangible asset impairment charges to date. For additional information, see Note 8.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contura acquisition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets represent technology, trade names and trademarks, and customer relationships acquired from Contura on February 25, 2021. The straight-line method over the period of estimated benefit is used to amortize finite-lived intangible assets except for customer relationships. Accounting Standards Codification (ASC) 350-30-35-3 states that customer relationships generally dissipate at a more rapid rate in the earlier periods following a company’s succession to these relationships, with the rate of attrition declining over time. As such, the accelerated method is used to amortize customer relationships. The Company recorded expense for the amortization of Contura acquisition intangible assets of $2.2 million and $0.6 million during the three months ended March 31, 2022 and 2021, respectively. For additional information, see Note 8.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net cash flows that the assets are expected to generate. If said assets are considered to be impaired, the impairment that would be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There have been minimal impairments of long-lived assets to date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASU No. 2016-02, “Leases (Topic 842)”, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only. Topic 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the bright line thresholds referenced in Topic 842 to assist in evaluating leases for appropriate classification between operating and finance leases. The aforementioned bright lines are applied consistently to the Company’s entire portfolio of leases.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease ROU asset and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate, which is the rate for a fully collateralized amortizing loan with the same maturity as the lease term, based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to operations as incurred. Research and development costs include salary and personnel-related costs, costs of clinical studies and testing, supplies and materials, and outside consultant costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses advertising costs as they are incurred. During the three months ended March 31, 2022 and 2021, advertising expense totaled $3.2 million and $1.4 million, respectively, and are recorded within the sales and marketing expenses in its condensed consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method to compute the difference between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. The Company has net deferred tax assets in certain jurisdictions. The realization of these deferred tax assets is dependent upon the Company’s ability to generate sufficient taxable income in future years. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company evaluates the recoverability of the deferred tax assets annually, and maintains a full valuation allowance on its U.S. net deferred tax assets. The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company is subject to transfer pricing and other tax regulations designed to ensure that appropriate levels of income are reported as earned by the Company’s U.S. and foreign entities and are taxed accordingly. In the normal course of business, the Company is audited by federal, state </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and foreign tax authorities, and subject to inquiries from those tax authorities regarding the amount of taxes due. These inquiries may relate to the timing and amount of deductions and the allocation of income among various tax jurisdictions. The Company’s policy is to recognize interest and penalties related to unrecognized tax benefits, if any, in income tax expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services in exchange for an award of equity instruments based on the grant-date fair value of the award and recognizes compensation cost over the requisite service period (typically the vesting period), generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEyMmYyYzkwYjQyODQ1MzRiY2VmZGJiZGZhNjQ2ZDU3L3NlYzphMjJmMmM5MGI0Mjg0NTM0YmNlZmRiYmRmYTY0NmQ1N180MC9mcmFnOjU0ZDliNWYzZGE1MTQ2YTVhNGYyNTk1YTE5YjNkN2FiL3RleHRyZWdpb246NTRkOWI1ZjNkYTUxNDZhNWE0ZjI1OTVhMTliM2Q3YWJfMTA5OTUxMTY4MzkwNA_ffc30e0a-48e4-4ff7-b28d-28bd00572e9d">three</span> or four years. Forfeitures are estimated at the time of the grant and revised in subsequent periods to reflect differences between the estimates and the number of shares that actually become exercisable. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to determine the fair value of stock options (as of the date of grant) that have service conditions for vesting. Stock options and restricted shares awards vest based on service conditions, typically over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEyMmYyYzkwYjQyODQ1MzRiY2VmZGJiZGZhNjQ2ZDU3L3NlYzphMjJmMmM5MGI0Mjg0NTM0YmNlZmRiYmRmYTY0NmQ1N180MC9mcmFnOjU0ZDliNWYzZGE1MTQ2YTVhNGYyNTk1YTE5YjNkN2FiL3RleHRyZWdpb246NTRkOWI1ZjNkYTUxNDZhNWE0ZjI1OTVhMTliM2Q3YWJfMTA5OTUxMTY4MzkxOQ_d4dfcf68-effe-447e-b3b3-07f5dff83249">three</span> or four years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also grants shares of performance-based restricted stock units that typically vest after one year only if the Company has also achieved certain performance objectives as defined and approved by the Company’s board of directors. The fair value of performance awards are determined based on the Company’s stock price at the date of grant and expensed over the performance period based on the probability of achieving the performance objectives. In addition, the Company also grants market-based restricted stock units that have combined market conditions and service conditions for vesting, for which the Company uses the Monte Carlo valuation model to value equity awards (as of the date of grant). </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share of Common Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options, unvested RSAs and RSUs are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, diluted net loss per share of common stock is the same as basic net loss per share of common stock for those periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022 and 2021, there were 2,416,373 and 2,488,284 potentially dilutive weighted-average shares, respectively, that were not included in the computation of diluted weighted-average shares of common stock and common stock equivalent shares outstanding because their effect would have been antidilutive given the Company’s net loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company has determined it operates in one segment, the development and commercialization of innovative and minimally invasive products to treat bladder and bowel dysfunction. Geographically, the Company sells over 90% to hospitals in the United States. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued ASU 2019-12, “Income Taxes—Simplifying the Accounting for Income Taxes,” which simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step-up in the tax basis of goodwill and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. This guidance is effective for annual periods beginning after December 15, 2020, which </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was the Company’s first quarter of fiscal year 2021, with early adoption permitted. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or related disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed and considered all recent accounting pronouncements that have not yet been adopted and believe there are none that could potentially have a material impact on our business practices, financial condition, results of operations, or disclosures.</span></div> 4025000 50.00 525000 190000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company; its wholly-owned subsidiaries, Axonics Europe, S.A.S., Axonics Modulation Technologies U.K. Limited, Axonics Modulation Technologies Australia Pty Ltd, Axonics Women’s Health Limited, Bulkamid SARL, Axonics GmbH, and Contura, Inc. Intercompany accounts and transactions have been eliminated in consolidation.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim condensed consolidated financial statements and related footnote disclosures as of and for the three months ended March 31, 2022 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The unaudited interim condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three months ended March 31, 2022 in accordance with United States (U.S.) generally accepted accounting principles (GAAP), however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (SEC) rules and regulations relating to interim financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated </span></div>financial statements and notes thereto included within the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (filed with the SEC on March 1, 2022). -22700000 -22500000 -337200000 -314600000 213200000 220900000 0 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses, and related disclosure of contingent assets and liabilities. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. The results of this evaluation then form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates, and such differences may be material to the consolidated financial statements. Significant items subject to such estimates and assumptions include the useful lives of property and equipment and intangible assets, the valuation of deferred income tax assets and liabilities, the valuation of contingent consideration liability, the valuation of stock-based compensation, the product returns reserve, the inventory obsolescence reserve and accounts receivable allowance for credit losses.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized during the three months ended March 31, 2022 and 2021 relates entirely to the sale of the Company’s products to its customers and distributors.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has revenue arrangements that consist of a single performance obligation. The Company recognizes revenue at the point in time when it transfers control of promised goods to its customers. Revenue is measured as the amount of consideration it expects to receive in exchange for transferring goods. The amount of revenue that is recognized is based on the transaction price, which represents the invoiced amount and includes estimates of variable consideration such as discounts, where applicable. The Company also sells to distributors and applies the same policies as its revenue arrangements with customers, specifically that revenue is recognized at the point in time when it transfers control of promised goods to its distributors. The Company does not offer rights of return or price protection. The amount of variable consideration included in the transaction price may be constrained and is included only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Payment terms, typically less than three months, do not include a significant financing component. The Company extends credit to its customers and distributors based upon an evaluation of their financial condition and credit history and generally requires no collateral. The Company does not have any contract balances related to product sales. The Company also does not have significant contract acquisition costs related to product sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Company policy and based on the Company’s historical experience, the allowance for product returns was $0.1 million and $0.2 million at March 31, 2022 and December 31, 2021, respectively, and is recorded as a reduction of gross revenue in its condensed consolidated statements of comprehensive loss. Damaged or defective products are replaced at no charge under the Company’s standard warranty. For the three months ended March 31, 2022 and 2021, the replacement costs were $0.1 million and $0.1 million, respectively, and are recorded within the sales and marketing expenses in its condensed consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers its standard warranty to all customers. The Company does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to sales and marketing expense. The warranty liability as of March 31, 2022 and December 31, 2021 were $0.1 million and $0.1 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred for the delivery of goods to customers and distributors are included in cost of goods sold. Amounts billed to customers and distributors for shipping and handling are included in net revenue.</span></div> 100000 200000 100000 100000 100000 100000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional information pertaining to net revenue disaggregated by product and geographic market for the three months ended March 31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNM net revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International markets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,070 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,903 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bulkamid net revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International markets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,350 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,420 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,373 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    The acquisition of Bulkamid was completed on February 25, 2021. Reported revenue includes sales from February 26, 2021 onwards.</span></div> 37715000 31745000 1355000 1158000 39070000 32903000 6569000 578000 2781000 892000 9350000 1470000 48420000 34373000 <div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company makes estimates of the collectability of accounts receivable in accordance with Accounting Standards Update (ASU) 2016-13. The Company’s estimate of future credit losses is made by management based upon historical bad debts, customer receivable balances, age of customer receivable balances, customers’ financial conditions and reasonable forecasted economic trends. Despite the Company’s efforts to minimize credit risk exposure, customers could be adversely affected if future economic and industry trends, including those related to COVID-19, change in such a manner as to negatively impact their cash flows. The full effects of COVID-19 on the Company’s customers are highly uncertain and cannot be predicted. As a result, the Company’s future collection experience can differ significantly from historical collection trends. If the Company’s customers experience a negative impact on their cash flows, it could have a material adverse effect on the Company’s results of operations and financial condition.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the changes in our allowance for credit losses (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bad debt recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 355000 465000 0 12000 39000 65000 316000 412000 <div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of short-term, highly liquid investments purchased with an original maturity of three months or less. Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. At times, the cash and cash equivalent balances may exceed federally insured limits. The Company does not believe that this results in any significant credit risk as the Company’s policy is to place its cash and cash equivalents in highly-rated financial institutions. The Company also holds cash in foreign banks that are not federally insured. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Inputs are quoted prices for similar assets and liabilities in active markets or quoted prices for identical or similar instruments in markets that are not active and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Inputs are unobservable inputs based on the Company’s assumptions and valuation techniques used to measure assets and liabilities at fair value. The inputs require significant management judgment or estimation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s assessment of the significance of an input to the fair value measurement requires judgment, which may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels. The carrying amounts reported in the condensed consolidated financial statements approximate the fair value for cash and cash equivalents, accounts receivable, accounts payables, and accrued expenses due to their short-term nature. The carrying amount of the Company’s term loan, which is described below, approximates fair value, considering the interest rates are based on the prime interest rate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price of business acquisitions is primarily allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition date, with the excess recorded as goodwill.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration represents contingent milestone, performance and revenue-sharing payment obligations related to acquisitions and is measured at fair value, based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration is estimated using a binary option-based approach with assumptions the Company believes would be made by a market participant. Significant inputs include projected revenues, discount rates, volatility factors and risk-free rates. The Company assesses these assumptions on an ongoing basis as additional data impacting the assumptions is obtained and any change in fair value of the contingent consideration is recorded within the general and administrative expenses in the consolidated statements of comprehensive loss. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. Generally, a change in the assumption used for the projected revenues would result in a directionally similar change to the overall estimate of the contingent consideration. The fair value of contingent consideration of $10.4 million at </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2022 is reflected in other long-term liabilities in the Company’s condensed consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the changes in the fair value of recurring Level 3 fair value measurements during the three months ended March 31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021 Acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,370 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,750 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Levels 1, 2 or 3 for the periods presented.</span></div> 10400000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the changes in the fair value of recurring Level 3 fair value measurements during the three months ended March 31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021 Acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,370 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,750 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 10370000 0 0 6750000 10370000 6750000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those investments in debt securities with maturities less than 12 months at the date of purchase are considered short-term investments. Those investments in debt securities with maturities greater than 12 months at the date of purchase are considered long-term investments. The Company’s investment securities classified as available-for-sale are recorded at fair value based on the fair value hierarchy (Level 1 and Level 2 inputs in the fair value hierarchy), and consists primarily of commercial paper, corporate notes and U.S. government and agency securities. Unrealized gains or losses, deemed temporary in nature, are reported as other comprehensive income within the condensed consolidated statements of comprehensive loss. There were no unrealized gains or losses during the three months ended March 31, 2022 and 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to net income (loss) and the corresponding establishment of a new cost basis for the security. Premiums (discounts) are amortized (accreted) over the life of the related security as an adjustment to yield using the straight-line interest method. Dividend and interest income are recognized when earned. Realized gains or losses are included in net loss and are derived using the specific identification method for determining the cost of securities sold.</span></div> 0 0 0 0 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currencies of the Company’s subsidiaries are currencies other than the U.S. dollar. The Company translates assets and liabilities of the foreign subsidiaries into U.S. dollars at the exchange rate in effect on the balance sheet date. Revenue and expenses of the subsidiaries are translated into U.S. dollars at the average exchange rate during the period. Gains or losses from these translation adjustments are reported as a separate component of stockholders’ equity in accumulated other comprehensive gain or loss until there is a sale or complete or substantially complete liquidation of the Company’s investment in the foreign subsidiary at which time the gains or losses will be realized and included in net income (loss). As of March 31, 2022 and December 31, 2021, all foreign currency translation gains (losses) have been unrealized and included in accumulated other comprehensive loss. Accumulated other comprehensive loss consists entirely of losses or gains from translation of foreign subsidiaries at March 31, 2022 and December 31, 2021.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value, with cost computed on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes inventory produced for commercial sale. The Company capitalizes manufacturing costs as inventory following both the receipt of regulatory approval from regulatory bodies and the Company’s </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intent to commercialize. Costs associated with developmental products prior to satisfying the Company’s inventory capitalization criteria are charged to research and development expenses as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products that have been approved by certain regulatory authorities may also be used in clinical programs to assess the safety and efficacy of the products for usage that have not been approved by the FDA or other regulatory authorities. The form of product utilized for both commercial and certain clinical programs that are identical are included as inventory with an “alternative future use” as defined in authoritative guidance. Component materials and purchased products associated with clinical development programs are included in inventory and charged to research and development expenses when the product enters the research and development process and no longer can be used for commercial purposes and, therefore, does not have an “alternative future use.” </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For products that are under development and have not yet been approved by regulatory authorities, purchased component materials are charged to research and development expenses when the inventory ownership transfers to the Company. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes inventory levels to identify inventory that may expire prior to sale, inventory that has a cost basis in excess of its net realizable value, or inventory in excess of expected sales requirements. Although the manufacturing of the r-SNM System is subject to strict quality control, certain batches or units of product may no longer meet quality specifications or may expire, which would require adjustments to the Company’s inventory values. The Company also applies judgment related to the results of quality tests that are performed throughout the production process, as well as the understanding of regulatory guidelines, to determine if it is probable that inventory will be saleable. These quality tests are performed throughout the pre- and post-production processes, and the Company continually gathers information regarding product quality for periods after the manufacturing date. The Company’s products currently have a maximum estimated shelf life range of 12 to 36 months and, based on sales forecasts, the Company expects to realize the carrying value of the product inventory. In the future, reduced demand, quality issues, or excess supply beyond those anticipated by management may result in a material adjustment to inventory levels, which would be recorded as an increase to cost of sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of whether inventory costs will be realizable or not requires estimates by the Company’s management. A critical input in this determination is future expected inventory requirements based on internal sales forecasts. Management then compares these requirements to the expiry dates of inventory on hand. To the extent that inventory is expected to expire prior to being sold, management will write down the value of inventory.</span></div> P12M P36M 44300000 3000000 14600000 100000 46800000 2800000 15300000 200000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEyMmYyYzkwYjQyODQ1MzRiY2VmZGJiZGZhNjQ2ZDU3L3NlYzphMjJmMmM5MGI0Mjg0NTM0YmNlZmRiYmRmYTY0NmQ1N180MC9mcmFnOjU0ZDliNWYzZGE1MTQ2YTVhNGYyNTk1YTE5YjNkN2FiL3RleHRyZWdpb246NTRkOWI1ZjNkYTUxNDZhNWE0ZjI1OTVhMTliM2Q3YWJfMjM3ODM_07e157c7-3a38-4472-8210-fac18e90cd5c">three</span> and seven years. Leasehold improvements are amortized over the lesser of the life of the lease or the useful life of the improvements. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations.</span></div> P7Y <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess purchase price over the fair values of the identifiable assets acquired less the liabilities assumed. Goodwill is tested for impairment at the reporting unit level by comparing the reporting unit’s carrying amount to the fair value of the reporting unit. The fair values are estimated using an income and discounted cash flow approach. The Company evaluates its goodwill on an annual basis in the fourth quarter or more frequently if it believes indicators of impairment exist. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount or performs an annual impairment test. When tested quantitatively, the Company compares the fair value of the applicable reporting unit with its carrying value. In making this assessment, management relies on a number of factors, including expected future operating results, business plans, economic projections, anticipated future cash flows, business trends and declines in the Company’s market capitalization. The Company estimates the fair values of its reporting unit using a combination of the discounted cash flow and income approaches. If the carrying amount of a reporting unit exceeds the reporting unit’s fair value, the amount by which the carrying value exceeds the fair value is recognized as an impairment loss. During the three months ended March 31, 2022, the Company did not record any impairment charges related to goodwill.</span></div> 0 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent license asset</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset represents exclusive rights to an additional field-of-use on the patent suite within the License Agreement with AMF. The additional field-of-use was provided in exchange for 50,000 shares of Series A preferred stock, the fair value of which was $1.0 million in 2013. The intangible asset was recorded at its fair value of $1.0 million at the date contributed. In connection with the initial public offering, such shares of Series A preferred stock were converted into common stock. Amortization of this asset is recorded over the shorter of the patent or legal life on a straight-line basis. The weighted-average amortization period is 8.71 years. The Company recorded minimal expenses for the amortization of the patent license asset during the three months ended March 31, 2022 and 2021. The Company will review the intangible asset for impairment whenever an impairment indicator exists. There have been no intangible asset impairment charges to date. For additional information, see Note 8.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exclusive license asset</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset represents exclusive rights of existing technologies and development services from MST entered into on March 2, 2021. The agreement was provided in exchange for 65,594 shares of common stock, $0.0001 par value, the fair value of which was $3.6 million upon transfer. The intangible asset was recorded at its fair value of $3.3 million at the date of the agreement, with the difference of $0.3 million recorded as a vendor credit in accounts payable in the condensed consolidated balance sheets. Amortization of this asset is recorded over the four-year term of the agreement on a straight-line basis. The Company recorded expense for the amortization of the exclusive license asset of $0.2 million during the three months ended March 31, 2022. There was no amortization of this intangible asset recorded during the three months ended March 31, 2021. The Company will review the intangible asset for impairment whenever an impairment indicator exists. There have been no intangible asset impairment charges to date. For additional information, see Note 8.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contura acquisition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets represent technology, trade names and trademarks, and customer relationships acquired from Contura on February 25, 2021. The straight-line method over the period of estimated benefit is used to amortize finite-lived intangible assets except for customer relationships. Accounting Standards Codification (ASC) 350-30-35-3 states that customer relationships generally dissipate at a more rapid rate in the earlier periods following a company’s succession to these relationships, with the rate of attrition declining over time. As such, the accelerated method is used to amortize customer relationships. The Company recorded expense for the amortization of Contura acquisition intangible assets of $2.2 million and $0.6 million during the three months ended March 31, 2022 and 2021, respectively. For additional information, see Note 8.</span></div> 50000 1000000 1000000 P8Y8M15D 0 65594 0.0001 3600000 3300000 300000 P4Y 200000 0 0 2200000 600000 Impairment of Long-Lived AssetsThe Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net cash flows that the assets are expected to generate. If said assets are considered to be impaired, the impairment that would be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASU No. 2016-02, “Leases (Topic 842)”, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only. Topic 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the bright line thresholds referenced in Topic 842 to assist in evaluating leases for appropriate classification between operating and finance leases. The aforementioned bright lines are applied consistently to the Company’s entire portfolio of leases.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease ROU asset and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate, which is the rate for a fully collateralized amortizing loan with the same maturity as the lease term, based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to operations as incurred. Research and development costs include salary and personnel-related costs, costs of clinical studies and testing, supplies and materials, and outside consultant costs.</span></div> Advertising ExpenseThe Company expenses advertising costs as they are incurred. 3200000 1400000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method to compute the difference between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. The Company has net deferred tax assets in certain jurisdictions. The realization of these deferred tax assets is dependent upon the Company’s ability to generate sufficient taxable income in future years. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company evaluates the recoverability of the deferred tax assets annually, and maintains a full valuation allowance on its U.S. net deferred tax assets. The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company is subject to transfer pricing and other tax regulations designed to ensure that appropriate levels of income are reported as earned by the Company’s U.S. and foreign entities and are taxed accordingly. In the normal course of business, the Company is audited by federal, state </span></div>and foreign tax authorities, and subject to inquiries from those tax authorities regarding the amount of taxes due. These inquiries may relate to the timing and amount of deductions and the allocation of income among various tax jurisdictions. The Company’s policy is to recognize interest and penalties related to unrecognized tax benefits, if any, in income tax expense. <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services in exchange for an award of equity instruments based on the grant-date fair value of the award and recognizes compensation cost over the requisite service period (typically the vesting period), generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEyMmYyYzkwYjQyODQ1MzRiY2VmZGJiZGZhNjQ2ZDU3L3NlYzphMjJmMmM5MGI0Mjg0NTM0YmNlZmRiYmRmYTY0NmQ1N180MC9mcmFnOjU0ZDliNWYzZGE1MTQ2YTVhNGYyNTk1YTE5YjNkN2FiL3RleHRyZWdpb246NTRkOWI1ZjNkYTUxNDZhNWE0ZjI1OTVhMTliM2Q3YWJfMTA5OTUxMTY4MzkwNA_ffc30e0a-48e4-4ff7-b28d-28bd00572e9d">three</span> or four years. Forfeitures are estimated at the time of the grant and revised in subsequent periods to reflect differences between the estimates and the number of shares that actually become exercisable. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to determine the fair value of stock options (as of the date of grant) that have service conditions for vesting. Stock options and restricted shares awards vest based on service conditions, typically over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEyMmYyYzkwYjQyODQ1MzRiY2VmZGJiZGZhNjQ2ZDU3L3NlYzphMjJmMmM5MGI0Mjg0NTM0YmNlZmRiYmRmYTY0NmQ1N180MC9mcmFnOjU0ZDliNWYzZGE1MTQ2YTVhNGYyNTk1YTE5YjNkN2FiL3RleHRyZWdpb246NTRkOWI1ZjNkYTUxNDZhNWE0ZjI1OTVhMTliM2Q3YWJfMTA5OTUxMTY4MzkxOQ_d4dfcf68-effe-447e-b3b3-07f5dff83249">three</span> or four years.</span></div>The Company also grants shares of performance-based restricted stock units that typically vest after one year only if the Company has also achieved certain performance objectives as defined and approved by the Company’s board of directors. The fair value of performance awards are determined based on the Company’s stock price at the date of grant and expensed over the performance period based on the probability of achieving the performance objectives. In addition, the Company also grants market-based restricted stock units that have combined market conditions and service conditions for vesting, for which the Company uses the Monte Carlo valuation model to value equity awards (as of the date of grant). P4Y P4Y P1Y <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share of Common Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options, unvested RSAs and RSUs are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, diluted net loss per share of common stock is the same as basic net loss per share of common stock for those periods.</span></div> 2416373 2488284 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company has determined it operates in one segment, the development and commercialization of innovative and minimally invasive products to treat bladder and bowel dysfunction. Geographically, the Company sells over 90% to hospitals in the United States. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance.</span></div> 1 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued ASU 2019-12, “Income Taxes—Simplifying the Accounting for Income Taxes,” which simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step-up in the tax basis of goodwill and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. This guidance is effective for annual periods beginning after December 15, 2020, which </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was the Company’s first quarter of fiscal year 2021, with early adoption permitted. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements or related disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed and considered all recent accounting pronouncements that have not yet been adopted and believe there are none that could potentially have a material impact on our business practices, financial condition, results of operations, or disclosures.</span></div> Property and Equipment<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following (in thousands) at:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:68.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,429 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tools and molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,626 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,994 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,087)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,907 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,915 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense of property and equipment was $0.6 million and $0.5 million for the three months ended March 31, 2022 and 2021, respectively.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following (in thousands) at:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:68.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,429 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tools and molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,626 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,994 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,087)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,907 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,915 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2611000 2429000 2595000 2450000 1626000 1579000 4449000 4372000 1515000 1502000 198000 127000 12994000 12459000 6087000 5544000 6907000 6915000 600000 500000 Commitments and Contingencies<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014, the Company entered into a five-year operating lease for approximately 12,215 square feet of office space beginning on November 1, 2014, and expiring on October 31, 2019. In June 2019, the lease was amended to extend the expiration date to October 31, 2020. In September 2020, the lease was amended to extend the expiration date to July 31, 2022, and in December 2021, the lease was amended to extend the expiration date to January 31, 2028. Upon the execution of the amendments, which were deemed to be a lease modification, the Company reassessed the lease liability using the incremental borrowing rate for a collateralized asset of the same remaining term at the modification date and recorded ROU assets for the same amount. The Company also reassessed the lease classification and concluded that the lease continues to be an operating lease. Under the terms of the lease, the Company is responsible for taxes, insurance, and maintenance expense. The lease contains certain scheduled rent increases. Rent expense is recognized on a straight-line basis over the expected lease term. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company entered into a seven-year operating lease for approximately 25,548 square feet of office space beginning on August 1, 2018, and expiring on August 31, 2025. In June 2019, the lease was amended to extend the expiration date to October 31, 2027. Upon the execution of the amendments, which were deemed to be a lease modification, the Company reassessed the lease liability using the incremental borrowing rate for a collateralized asset of the same remaining term at the modification date and recorded ROU assets for the same amount. The Company also reassessed the lease classification and concluded that the lease continues to be an operating lease. Under the terms of the lease, the Company is responsible for taxes, insurance, and maintenance expense. The lease contains certain scheduled rent increases. Rent expense is recognized on a straight-line basis over the expected lease term. The Company has a renewal option to extend the term of the lease for a period of five years beyond the initial term. Under the terms of the lease, the base rent payable with respect to each renewal term will be equal to the prevailing market rental rent as of the commencement of the applicable renewal term. In the event of a default of certain of the Company’s obligations under the lease, the Company’s landlord would have the right to </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terminate the lease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company entered into an eight-year operating lease for approximately 32,621 square feet of office space beginning on January 15, 2020 and expiring on January 31, 2028. The Company uses these premises as its new principal executive offices and for general office space. The Company intends to utilize its other currently-leased spaces through the lease expiration dates to conduct the training of its sales team and for manufacturing purposes. Under the terms of the lease, the Company is responsible for taxes, insurance, and maintenance expense. The lease contains certain scheduled rent increases. Rent expense is recognized on a straight-line basis over the expected lease term. The Company has a renewal option to extend the term of the lease for a period of five years beyond the initial term. Under the terms of the lease, the base rent payable with respect to each renewal term will be equal to the prevailing market rental rent as of the commencement of the applicable renewal term. In the event of a default of certain of the Company’s obligations under the lease, the Company’s landlord would have the right to terminate the lease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into a 38-month operating lease for approximately 5,693 square feet of warehouse space beginning on October 15, 2020 and expiring on December 31, 2023. The Company uses these premises for general warehouse space.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and 2021, ROU assets obtained in exchange for new operating lease liabilities were none and $0.1 million, respectively. As of March 31, 2022 and December 31, 2021, the ROU asset has a balance of $6.8 million and $7.1 million, respectively. The operating lease ROU asset is included within the Company’s non-current other assets, and lease liabilities are included in current or noncurrent liabilities in the Company’s condensed consolidated balance sheets. During the three months ended March 31, 2022 and 2021, cash paid for amounts included in operating lease liabilities was $0.5 million and $0.5 million, respectively. Amortization of the ROU asset was $0.2 million and $0.3 million for the three months ended March 31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, the weighted-average remaining lease term for the Company’s operating leases were 5.7 years and 5.9 years, respectively. The weighted-average incremental borrowing rate for a collateralized asset of the same remaining term used to determine the present value of the Company’s operating leases’ future payments was 7.1% and 7.1% as of March 31, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost for the three months ended March 31, 2022 and 2021 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company entered into the License Agreement, pursuant to which AMF, a Company stockholder, licensed the Company certain patents and know-how (collectively, the AMF IP) relating to, in relevant part, an implantable pulse generator and related system components in development by AMF as of that date, in addition to any peripheral or auxiliary devices, including all components, that when assembled, comprise such device, excluding certain implantable pulse generators (collectively, the AMF Licensed Products). Under the License Agreement, for each calendar year beginning in 2018, the Company is obligated to pay AMF a royalty on an AMF Licensed Product-by-AMF Licensed Product basis if one of the following conditions applies: (i) one or more valid claims within any of the patents licensed to the Company by AMF covers such AMF Licensed Products or the manufacture of such AMF Licensed Products or (ii) for a period of 12 years from the first commercial sale anywhere </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the world of such AMF Licensed Product, in each case. The foregoing royalty is calculated as the greater of (a) 4% of all net revenue derived from the AMF Licensed Products, and (b) the Minimum Royalty, payable quarterly. The Minimum Royalty automatically increases each year after 2018, subject to a maximum amount of $200,000 per year. The Company generated net SNM revenue of $39.1 million and $32.9 million during the three months ended March 31, 2022 and 2021, respectively, and recorded related royalties of $1.6 million and $1.3 million during the three months ended March 31, 2022 and 2021, respectively. Royalty expense is included in operating expenses in the condensed consolidated statements of comprehensive loss. Accrued royalty of $1.6 million and $1.8 million as of March 31, 2022 and December 31, 2021, respectively, is included within accrued liabilities in the Company’s condensed consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2019, Medtronic, Inc., Medtronic Puerto Rico Operations Co., Medtronic Logistics LLC and Medtronic USA, Inc. (collectively, the Medtronic Affiliates) filed a complaint against the Company in the United States District Court for the Central District of California, Case No. 8:19-cv-2115, and amended the complaint on November 26, 2019. The Company refers to this matter as the Medtronic Litigation. The complaint asserts that the Company’s r-SNM System infringes U.S. Patent Nos. 8,036,756, 8,626,314, 9,463,324 and 9,821,112 held by the Medtronic Affiliates, and the amended complaint further includes the additional patents 8,738,148; 8,457,758; and 7,774,069 (collectively, the Medtronic Patents). The Medtronic Litigation requests customary remedies for patent infringement, including (i) a judgment that the Company has infringed and is infringing the Medtronic Patents, (ii) damages, including treble damages for willful infringement, (iii) a permanent injunction preventing the Company from infringing the Medtronic Patents, (iv) attorneys’ fees, and (v) costs and expenses. The Company believes the allegations are without merit and is vigorously defending itself against them. Given the early stage of the Medtronic Litigation, the Company is unable to predict the likelihood of success of the claims of the Medtronic Affiliates against the Company or to quantify any risk of loss. The Medtronic Litigation could last for an extended period of time and require the Company to dedicate significant financial resources and management resources to its defense. An adverse ruling against the Company could materially and adversely affect its business, financial position, results of operations or cash flows and could also result in reputational harm. Even if the Company is successful in defending against these claims, the Medtronic Litigation could result in significant costs, delays in future product developments, reputational harm or other collateral consequences.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 16, 2020, the Company filed seven petitions before the United States Patent and Trademark Office (USPTO) requesting inter partes review (IPR) to contest the validity of each of the Medtronic patents that Medtronic has alleged are being infringed by the Company. In September 2020, the USPTO decided that it will accept or “institute” the IPR process for six of the seven patents, finding that the Company had demonstrated a reasonable likelihood that at least one, if not all, of the claims of these six patents are invalid. The USPTO issued decisions on the IPR petitions in September 2021. The USPTO invalidated several claims in the Medtronic patents but declined to invalidate the majority of asserted claims. The Company appealed the decisions on the claims that were not invalidated. Following these IPR decisions, the judge presiding over the litigation in the United States District Court for the Central District of California lifted the stay on litigation proceedings. The Company is currently engaged in discovery in the Medtronic Litigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Medtronic Litigation, the Company is and may continue to be involved in claims, le</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gal proceedings, and investigations arising out of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> operations in the normal course of business.</span></div> P5Y 12215 P7Y 25548 P5Y P8Y 32621 P5Y P38M 5693 0 100000 6800000 7100000 500000 500000 200000 300000 P5Y8M12D P5Y10M24D 0.071 0.071 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost for the three months ended March 31, 2022 and 2021 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 524000 525000 21000 23000 35000 47000 580000 595000 P12Y 0.04 200000 39100000 32900000 1600000 1300000 1600000 1800000 7 6 7 1 6 Long-Term Debt<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the principal amount, accrued interest, accrued loan fees, and prepayment fees related to the term loan under the Loan and Security Agreement with Silicon Valley Bank entered into in February 2021, were paid in full. The unamortized debt issuance costs of $4.4 million were expensed and recognized as interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the principal amount, accrued interest, accrued loan fees, and prepayment fees related to the term loan under the Loan and Security Agreement with Silicon Valley Bank entered into in February 2018, were paid in full. The unamortized debt issuance costs of $0.4 million were expensed and recognized as interest expense.</span></div> 4400000 4400000 400000 400000 Stock-based Compensation<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in the Company’s unaudited condensed consolidated statements of comprehensive loss is allocated as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,138 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,303 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option awards issued under the 2014 Stock Option Plan (the 2014 Plan) and the 2018 Omnibus Incentive Plan (the 2018 Plan) were measured based on fair value. The Company’s fair value calculations were made using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.803%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.049%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.46 - 6.00</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.49%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.53% - 1.16%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the simplified method of determining the expected term of stock options as the Company believes this represents the best estimate of the expected term of a new option. The expected stock price volatility assumption was determined by examining the historical volatilities for industry peers, as the Company did not have sufficient trading history for the Company’s common stock. The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical data for the Company’s common stock becomes available. The risk-free interest rate assumption is based on the U.S. Treasury instruments, whose term was consistent with the expected term of the Company’s stock options. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The assumptions regarding the expected term of the options and the expected volatility of the stock price are subjective, and these assumptions have a significant effect on the estimated fair value amounts. There were no stock option grants for the three months ended March 31, 2022. The weighted-average grant date fair value of options granted was $32.89 for the three months ended March 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, there was $5.3 million and $6.7 million, respectively, of total unrecognized compensation cost related to unvested stock options that is expected to be recognized over a weighted-average period of approximately 1.4 years and 1.6 years, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the three months ended March 31, 2022 under the 2014 and 2018 Plans (in thousands, except share and per share data):</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:49.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,328,106 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,963 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    Represents the total difference between the Company’s closing stock price at the time of exercise and the stock option exercise price, multiplied by the number of options exercised.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)    Represents the total difference between the Company’s closing stock price on the last trading day of the first quarter of 2022 and the stock option exercise price, multiplied by the number of in-the-money options as of March 31, 2022. The amount of intrinsic value will change based on the fair market value of the Company’s stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining contractual term of options outstanding and exercisable is 6.8 years and 6.9 years at March 31, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Shares Awards Activity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, there was $52.8 million and $42.5 million, respectively, of total unrecognized compensation cost related to unvested restricted shares awards that is expected to be recognized over a weighted-average period of approximately 2.8 years and 3.0 years, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted shares awards activity for the three months ended March 31, 2022:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:68.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Restricted Shares Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Fair Value Per Share at Grant Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102,034 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.07 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted shares awards granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted shares awards vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted shares awards forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,725)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245,403 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.47 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units Activity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022 and December 31, 2021, there was $5.8 million and $1.9 million, respectively, of total unrecognized compensation cost related to unvested restricted stock units that is expected to be recognized over a weighted-average period of approximately 1.1 years and 0.9 years, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock units activity for the three months ended March 31, 2022:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:68.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Fair Value Per Share at Grant Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,464 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.99 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,884 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268,930)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,418 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.74 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in the Company’s unaudited condensed consolidated statements of comprehensive loss is allocated as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,138 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,303 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1510000 1329000 1937000 1685000 3691000 2289000 7138000 5303000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option awards issued under the 2014 Stock Option Plan (the 2014 Plan) and the 2018 Omnibus Incentive Plan (the 2018 Plan) were measured based on fair value. The Company’s fair value calculations were made using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.803%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.049%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.46 - 6.00</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.49%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.53% - 1.16%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> P5Y5M15D P6Y 0 0 0.6349 0.6349 0 0 0.0053 0.0116 0 0 0 32.89 5300000 6700000 P1Y4M24D P1Y7M6D <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the three months ended March 31, 2022 under the 2014 and 2018 Plans (in thousands, except share and per share data):</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:49.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,328,106 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,963 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    Represents the total difference between the Company’s closing stock price at the time of exercise and the stock option exercise price, multiplied by the number of options exercised.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)    Represents the total difference between the Company’s closing stock price on the last trading day of the first quarter of 2022 and the stock option exercise price, multiplied by the number of in-the-money options as of March 31, 2022. The amount of intrinsic value will change based on the fair market value of the Company’s stock.</span></div> 1427892 18.13 91286 15.53 3486000 8500 33.88 1328106 18.20 58963000 P6Y9M18D P6Y10M24D 52800000 42500000 P2Y9M18D P3Y <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted shares awards activity for the three months ended March 31, 2022:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:68.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Restricted Shares Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Fair Value Per Share at Grant Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102,034 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.07 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted shares awards granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted shares awards vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted shares awards forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,725)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245,403 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.47 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1102034 46.07 352204 48.14 169110 37.55 39725 56.85 1245403 47.47 5800000 1900000 P1Y1M6D P0Y10M24D <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock units activity for the three months ended March 31, 2022:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:68.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Fair Value Per Share at Grant Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,464 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.99 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,884 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268,930)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,418 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.74 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 250464 42.99 201884 38.75 268930 35.88 183418 48.74 Income Taxes<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of the provision for income taxes and effective tax rates (in thousands, except percentages):</span></div><div style="margin-bottom:1pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$(1,111)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$(555)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.41%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes according to ASC 740. The Company periodically evaluates whether a portion or all of its deferred tax assets will be recovered. The Company records a valuation allowance against deferred tax assets if and to the extent it is more likely than not that they will not be recovered. In evaluating the need for a valuation allowance, the Company weighs all relevant positive and negative evidence, including among other factors, historical financial performance, forecasts of income over the applicable carryforward periods, and the market environment, with each consideration weighted based on its reliability. The Company continues to maintain a full valuation allowance against its otherwise recognizable U.S. net deferred income tax assets as of March 31, 2022 and December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate differs from the statutory U.S. income tax rate due to differing tax rates imposed on income earned in foreign jurisdictions, losses in foreign jurisdictions, and certain nondeductible expenses. The effective tax rate could change significantly from quarter to quarter because of recurring and nonrecurring factors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the three months ended March 31, 2022 was primarily the result of losses benefited in certain foreign jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the Company had U.S. federal and foreign net operating loss (NOL) carryforwards of approximately $258.2 million and $16.4 million, respectively. U.S. federal NOLs in the amount of $51.5 million will expire between 2033 and 2037 while the remainder will carryover indefinitely. The foreign net operating loss carryforwards have an indefinite carryforward period. The Company had U.S. state NOLs of $245.6 million, which will expire between 2033 and 2041.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Internal Revenue Code), use of the Company’s NOL carryforwards may be limited if the Company experiences a cumulative change in ownership of greater than 50% in a rolling three-year period. The Company performed an analysis of changes in ownership for purposes of these Internal Revenue Code sections. Based on the study performed in 2020, the Company determined that an ownership change occurred in 2014, 2018 and 2019. Based on the study performed in 2021, the Company determined that an ownership change did not occur in 2021.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of the provision for income taxes and effective tax rates (in thousands, except percentages):</span></div><div style="margin-bottom:1pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$(1,111)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$(555)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.41%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> -1111000 -555000 0.0467 0.0241 258200000 16400000 51500000 245600000 Employee Benefit PlanThe Company sponsors a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan covers all employees who meet minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pre- or post-tax basis. Contributions to the plan by the Company may be made at the discretion of the board of directors. During the three months ended March 31, 2022 and 2021, the Company contributions to the plan amounted to $0.5 million and $0.4 million, respectively. 500000 400000 Goodwill and Intangible Assets<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of goodwill during the three months ended March 31, 2022 included the following (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,558 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets as of March 31, 2022 included the following (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:27.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets, Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent license asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.71 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(947)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exclusive license asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(880)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(906)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,794 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,509)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,812)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,179 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset as of December 31, 2021 included the following (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:27.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset, Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent license asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.71 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(919)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exclusive license asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,424)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,046)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,985)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,469 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying amount of goodwill during the three months ended March 31, 2022 included the following (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,510 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,558 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 105510000 -2952000 102558000 <div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets as of March 31, 2022 included the following (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:27.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets, Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent license asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.71 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(947)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exclusive license asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(880)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(906)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,794 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,509)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,812)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,179 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset as of December 31, 2021 included the following (in thousands):</span></div><div style="margin-bottom:1pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:27.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.851%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset, Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent license asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.71 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(919)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exclusive license asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,424)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,046)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,985)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,469 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P8Y8M15D 1000000 947000 0 53000 P4Y 3300000 880000 0 2420000 P12Y 81100000 7362000 -3490000 70248000 19700000 -906000 18794000 P12Y 11400000 1320000 -416000 9664000 116500000 10509000 -4812000 101179000 P8Y8M15D 1000000 919000 0 81000 P4Y 3300000 660000 0 2640000 P12Y 81100000 5668000 -1424000 74008000 19700000 -365000 19335000 P12Y 11400000 799000 -196000 10405000 116500000 8046000 -1985000 106469000 EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 131 270 1 false 47 0 false 7 false false R1.htm 0001001 - Document - Cover Sheet http://axonicsmodulation.com/role/Cover Cover Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101101 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies Sheet http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPolicies Nature of Operations and Summary of Significant Accounting Policies Notes 7 false false R8.htm 2108102 - Disclosure - Property and Equipment Sheet http://axonicsmodulation.com/role/PropertyandEquipment Property and Equipment Notes 8 false false R9.htm 2112103 - Disclosure - Commitments and Contingencies Sheet http://axonicsmodulation.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 9 false false R10.htm 2116104 - Disclosure - Long-Term Debt Sheet http://axonicsmodulation.com/role/LongTermDebt Long-Term Debt Notes 10 false false R11.htm 2118105 - Disclosure - Stock-based Compensation Sheet http://axonicsmodulation.com/role/StockbasedCompensation Stock-based Compensation Notes 11 false false R12.htm 2126106 - Disclosure - Income Taxes Sheet http://axonicsmodulation.com/role/IncomeTaxes Income Taxes Notes 12 false false R13.htm 2130107 - Disclosure - Employee Benefit Plan Sheet http://axonicsmodulation.com/role/EmployeeBenefitPlan Employee Benefit Plan Notes 13 false false R14.htm 2132108 - Disclosure - Goodwill and Intangible Assets Sheet http://axonicsmodulation.com/role/GoodwillandIntangibleAssets Goodwill and Intangible Assets Notes 14 false false R15.htm 2202201 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Policies) Sheet http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies Nature of Operations and Summary of Significant Accounting Policies (Policies) Policies http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPolicies 15 false false R16.htm 2303301 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Tables) Sheet http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables Nature of Operations and Summary of Significant Accounting Policies (Tables) Tables http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPolicies 16 false false R17.htm 2309302 - Disclosure - Property and Equipment (Tables) Sheet http://axonicsmodulation.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://axonicsmodulation.com/role/PropertyandEquipment 17 false false R18.htm 2313303 - Disclosure - Commitments and Contingencies (Tables) Sheet http://axonicsmodulation.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://axonicsmodulation.com/role/CommitmentsandContingencies 18 false false R19.htm 2319304 - Disclosure - Stock-based Compensation (Tables) Sheet http://axonicsmodulation.com/role/StockbasedCompensationTables Stock-based Compensation (Tables) Tables http://axonicsmodulation.com/role/StockbasedCompensation 19 false false R20.htm 2327305 - Disclosure - Income Taxes (Tables) Sheet http://axonicsmodulation.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://axonicsmodulation.com/role/IncomeTaxes 20 false false R21.htm 2333306 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://axonicsmodulation.com/role/GoodwillandIntangibleAssets 21 false false R22.htm 2404401 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details) Sheet http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details) Details http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables 22 false false R23.htm 2405402 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Schedule of Revenue Disaggregated by Geographic Market (Details) Sheet http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofRevenueDisaggregatedbyGeographicMarketDetails Nature of Operations and Summary of Significant Accounting Policies - Schedule of Revenue Disaggregated by Geographic Market (Details) Details 23 false false R24.htm 2406403 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Doubtful Accounts (Details) Sheet http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails Nature of Operations and Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Doubtful Accounts (Details) Details 24 false false R25.htm 2407404 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Liabilities Measured on Recurring Basis (Details) Sheet http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinFairValueofLiabilitiesMeasuredonRecurringBasisDetails Nature of Operations and Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Liabilities Measured on Recurring Basis (Details) Details 25 false false R26.htm 2410405 - Disclosure - Property and Equipment - Schedule of Property and Equipment, Net (Details) Sheet http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails Property and Equipment - Schedule of Property and Equipment, Net (Details) Details 26 false false R27.htm 2411406 - Disclosure - Property and Equipment - Narrative (Details) Sheet http://axonicsmodulation.com/role/PropertyandEquipmentNarrativeDetails Property and Equipment - Narrative (Details) Details 27 false false R28.htm 2414407 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 28 false false R29.htm 2415408 - Disclosure - Commitments and Contingencies - Schedule of Total Lease Cost (Details) Sheet http://axonicsmodulation.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails Commitments and Contingencies - Schedule of Total Lease Cost (Details) Details 29 false false R30.htm 2417409 - Disclosure - Long-Term Debt - Narrative (Details) Sheet http://axonicsmodulation.com/role/LongTermDebtNarrativeDetails Long-Term Debt - Narrative (Details) Details 30 false false R31.htm 2420410 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) Sheet http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) Details 31 false false R32.htm 2421411 - Disclosure - Stock-based Compensation - Schedule of Option Awards Fair Valuation Assumptions (Details) Sheet http://axonicsmodulation.com/role/StockbasedCompensationScheduleofOptionAwardsFairValuationAssumptionsDetails Stock-based Compensation - Schedule of Option Awards Fair Valuation Assumptions (Details) Details 32 false false R33.htm 2422412 - Disclosure - Stock-based Compensation - Narrative (Details) Sheet http://axonicsmodulation.com/role/StockbasedCompensationNarrativeDetails Stock-based Compensation - Narrative (Details) Details 33 false false R34.htm 2423413 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details) Sheet http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails Stock-based Compensation - Schedule of Stock Option Activity (Details) Details 34 false false R35.htm 2424414 - Disclosure - Stock-based Compensation - Schedule of Restricted Shares Awards Activity (Details) Sheet http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails Stock-based Compensation - Schedule of Restricted Shares Awards Activity (Details) Details 35 false false R36.htm 2425415 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units Activity (Details) Sheet http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails Stock-based Compensation - Schedule of Restricted Stock Units Activity (Details) Details 36 false false R37.htm 2428416 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes and Effective Tax Rates (Details) Sheet http://axonicsmodulation.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesandEffectiveTaxRatesDetails Income Taxes - Schedule of Provision for Income Taxes and Effective Tax Rates (Details) Details 37 false false R38.htm 2429417 - Disclosure - Income Taxes - Narrative (Details) Sheet http://axonicsmodulation.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 38 false false R39.htm 2431418 - Disclosure - Employee Benefit Plan (Details) Sheet http://axonicsmodulation.com/role/EmployeeBenefitPlanDetails Employee Benefit Plan (Details) Details http://axonicsmodulation.com/role/EmployeeBenefitPlan 39 false false R40.htm 2434419 - Disclosure - Goodwill and Intangible Assets - Schedule of Carrying Amount of Goodwill (Details) Sheet http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountofGoodwillDetails Goodwill and Intangible Assets - Schedule of Carrying Amount of Goodwill (Details) Details 40 false false R41.htm 2435420 - Disclosure - Goodwill and Intangible Assets - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details) Sheet http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails Goodwill and Intangible Assets - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details) Details 41 false false All Reports Book All Reports axnx-20220331.htm a03312022-exhibit311.htm a03312022-exhibit312.htm a03312022-exhibit321.htm a03312022-exhibit322.htm axnx-20220331.xsd axnx-20220331_cal.xml axnx-20220331_def.xml axnx-20220331_lab.xml axnx-20220331_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "axnx-20220331.htm": { "axisCustom": 0, "axisStandard": 19, "contextCount": 131, "dts": { "calculationLink": { "local": [ "axnx-20220331_cal.xml" ] }, "definitionLink": { "local": [ "axnx-20220331_def.xml" ] }, "inline": { "local": [ "axnx-20220331.htm" ] }, "labelLink": { "local": [ "axnx-20220331_lab.xml" ] }, "presentationLink": { "local": [ "axnx-20220331_pre.xml" ] }, "schema": { "local": [ "axnx-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 425, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 4, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 9 }, "keyCustom": 22, "keyStandard": 248, "memberCustom": 14, "memberStandard": 33, "nsprefix": "axnx", "nsuri": "http://axonicsmodulation.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://axonicsmodulation.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116104 - Disclosure - Long-Term Debt", "role": "http://axonicsmodulation.com/role/LongTermDebt", "shortName": "Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118105 - Disclosure - Stock-based Compensation", "role": "http://axonicsmodulation.com/role/StockbasedCompensation", "shortName": "Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126106 - Disclosure - Income Taxes", "role": "http://axonicsmodulation.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130107 - Disclosure - Employee Benefit Plan", "role": "http://axonicsmodulation.com/role/EmployeeBenefitPlan", "shortName": "Employee Benefit Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2132108 - Disclosure - Goodwill and Intangible Assets", "role": "http://axonicsmodulation.com/role/GoodwillandIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Policies)", "role": "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Nature of Operations and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies (Tables)", "role": "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables", "shortName": "Nature of Operations and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Property and Equipment (Tables)", "role": "http://axonicsmodulation.com/role/PropertyandEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313303 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://axonicsmodulation.com/role/CommitmentsandContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319304 - Disclosure - Stock-based Compensation (Tables)", "role": "http://axonicsmodulation.com/role/StockbasedCompensationTables", "shortName": "Stock-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i8cc402f01eed478ab3b3ce5c6f4421cb_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i8cc402f01eed478ab3b3ce5c6f4421cb_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327305 - Disclosure - Income Taxes (Tables)", "role": "http://axonicsmodulation.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2333306 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details)", "role": "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i8cc402f01eed478ab3b3ce5c6f4421cb_I20220331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Schedule of Revenue Disaggregated by Geographic Market (Details)", "role": "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofRevenueDisaggregatedbyGeographicMarketDetails", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Schedule of Revenue Disaggregated by Geographic Market (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i557f528e051b42f9b60357b01501f7ef_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i7fe9538d4293497abcc4b1cf7b1b0b9d_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Doubtful Accounts (Details)", "role": "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Doubtful Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i7fe9538d4293497abcc4b1cf7b1b0b9d_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i30f0786e8e604eb9afa8755f53ee2df1_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Liabilities Measured on Recurring Basis (Details)", "role": "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinFairValueofLiabilitiesMeasuredonRecurringBasisDetails", "shortName": "Nature of Operations and Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Liabilities Measured on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i30f0786e8e604eb9afa8755f53ee2df1_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i8cc402f01eed478ab3b3ce5c6f4421cb_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Property and Equipment - Schedule of Property and Equipment, Net (Details)", "role": "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails", "shortName": "Property and Equipment - Schedule of Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i8cc402f01eed478ab3b3ce5c6f4421cb_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - Property and Equipment - Narrative (Details)", "role": "http://axonicsmodulation.com/role/PropertyandEquipmentNarrativeDetails", "shortName": "Property and Equipment - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "ibf9b1133c7404e9b871ac6022f9d737d_D20220101-20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:VariableLeaseCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414407 - Disclosure - Commitments and Contingencies - Narrative (Details)", "role": "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415408 - Disclosure - Commitments and Contingencies - Schedule of Total Lease Cost (Details)", "role": "http://axonicsmodulation.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails", "shortName": "Commitments and Contingencies - Schedule of Total Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i8cc402f01eed478ab3b3ce5c6f4421cb_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i8cc402f01eed478ab3b3ce5c6f4421cb_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i2961ab368ac74cbebafcfcd352efb062_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417409 - Disclosure - Long-Term Debt - Narrative (Details)", "role": "http://axonicsmodulation.com/role/LongTermDebtNarrativeDetails", "shortName": "Long-Term Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i2961ab368ac74cbebafcfcd352efb062_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420410 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)", "role": "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails", "shortName": "Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421411 - Disclosure - Stock-based Compensation - Schedule of Option Awards Fair Valuation Assumptions (Details)", "role": "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofOptionAwardsFairValuationAssumptionsDetails", "shortName": "Stock-based Compensation - Schedule of Option Awards Fair Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422412 - Disclosure - Stock-based Compensation - Narrative (Details)", "role": "http://axonicsmodulation.com/role/StockbasedCompensationNarrativeDetails", "shortName": "Stock-based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i7fe9538d4293497abcc4b1cf7b1b0b9d_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423413 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)", "role": "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails", "shortName": "Stock-based Compensation - Schedule of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i7fe9538d4293497abcc4b1cf7b1b0b9d_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i11b67455c3124904b1920b62324b9564_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424414 - Disclosure - Stock-based Compensation - Schedule of Restricted Shares Awards Activity (Details)", "role": "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails", "shortName": "Stock-based Compensation - Schedule of Restricted Shares Awards Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i11b67455c3124904b1920b62324b9564_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "ib7f0614b3b874d348c9f9013e20c5a1d_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425415 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units Activity (Details)", "role": "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails", "shortName": "Stock-based Compensation - Schedule of Restricted Stock Units Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "ib7f0614b3b874d348c9f9013e20c5a1d_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428416 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes and Effective Tax Rates (Details)", "role": "http://axonicsmodulation.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesandEffectiveTaxRatesDetails", "shortName": "Income Taxes - Schedule of Provision for Income Taxes and Effective Tax Rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "4", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i5d4777c0a5044e9eb61b90a647d78cae_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429417 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://axonicsmodulation.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i5d4777c0a5044e9eb61b90a647d78cae_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431418 - Disclosure - Employee Benefit Plan (Details)", "role": "http://axonicsmodulation.com/role/EmployeeBenefitPlanDetails", "shortName": "Employee Benefit Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "role": "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i7fe9538d4293497abcc4b1cf7b1b0b9d_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434419 - Disclosure - Goodwill and Intangible Assets - Schedule of Carrying Amount of Goodwill (Details)", "role": "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountofGoodwillDetails", "shortName": "Goodwill and Intangible Assets - Schedule of Carrying Amount of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "axnx:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i8cc402f01eed478ab3b3ce5c6f4421cb_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435420 - Disclosure - Goodwill and Intangible Assets - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details)", "role": "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "axnx:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i8cc402f01eed478ab3b3ce5c6f4421cb_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "ib4b92375bb1b429da1ce95471cd3d6d2_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "ib4b92375bb1b429da1ce95471cd3d6d2_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Nature of Operations and Summary of Significant Accounting Policies", "role": "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPolicies", "shortName": "Nature of Operations and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108102 - Disclosure - Property and Equipment", "role": "http://axonicsmodulation.com/role/PropertyandEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112103 - Disclosure - Commitments and Contingencies", "role": "http://axonicsmodulation.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axnx-20220331.htm", "contextRef": "i91aea962e5744799a3ac87d9b710ac3d_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 47, "tag": { "axnx_APICShareBasedPaymentArrangementRestrictedStockAwardIncreaseForCostRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "APIC, Share-based Payment Arrangement, Restricted Stock Award, Increase for Cost Recognition", "label": "APIC, Share-based Payment Arrangement, Restricted Stock Award, Increase for Cost Recognition", "terseLabel": "Restricted Shares Award (RSA) issuances and forfeitures for terminations, net and stock-based compensation" } } }, "localname": "APICShareBasedPaymentArrangementRestrictedStockAwardIncreaseForCostRecognition", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "axnx_AccountsPayableVendorCredit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accounts Payable, Vendor Credit", "label": "Accounts Payable, Vendor Credit", "terseLabel": "Vendor credit in accounts payable" } } }, "localname": "AccountsPayableVendorCredit", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "axnx_AccountsReceivableAllowanceforProductReturns": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Allowance for Product Returns", "label": "Accounts Receivable, Allowance for Product Returns", "terseLabel": "Allowance for product returns" } } }, "localname": "AccountsReceivableAllowanceforProductReturns", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "axnx_BasisOfPresentationAndLiquidityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basis Of Presentation And Liquidity", "label": "Basis Of Presentation And Liquidity [Abstract]", "terseLabel": "Basis of Presentation and Liquidity [Abstract]" } } }, "localname": "BasisOfPresentationAndLiquidityAbstract", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "axnx_BulkamidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bulkamid", "label": "Bulkamid [Member]", "terseLabel": "Bulkamid net revenue" } } }, "localname": "BulkamidMember", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofRevenueDisaggregatedbyGeographicMarketDetails" ], "xbrltype": "domainItemType" }, "axnx_BusinessCombinationContingentConsiderationLiabilityAcquiredDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Liability, Acquired During Period", "label": "Business Combination, Contingent Consideration, Liability, Acquired During Period", "terseLabel": "February 25, 2021 Acquisition" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityAcquiredDuringPeriod", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinFairValueofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "axnx_ContingentConsiderationLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration Liability", "label": "Contingent Consideration Liability [Member]", "terseLabel": "Contingent Consideration Liability" } } }, "localname": "ContingentConsiderationLiabilityMember", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinFairValueofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "axnx_ConturaLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contura Limited", "label": "Contura Limited [Member]", "terseLabel": "Contura" } } }, "localname": "ConturaLimitedMember", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "axnx_DeferredIncomeTaxExpenseBenefitAndOtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Income Tax Expense (Benefit) and Other Operating Activities, Cash Flow Statement", "label": "Deferred Income Tax Expense (Benefit) and Other Operating Activities, Cash Flow Statement", "terseLabel": "Deferred income taxes and other items, net" } } }, "localname": "DeferredIncomeTaxExpenseBenefitAndOtherOperatingActivitiesCashFlowStatement", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "axnx_EmployeeStockOptionandRestrictedStockBasedAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Option and Restricted Stock-Based Awards [Member]", "label": "Employee Stock Option and Restricted Stock-Based Awards [Member]", "terseLabel": "Stock Option and Restricted Stock-Based Awards" } } }, "localname": "EmployeeStockOptionandRestrictedStockBasedAwardsMember", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "axnx_ExclusiveLicenseAssetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exclusive License Asset", "label": "Exclusive License Asset [Member]", "terseLabel": "Exclusive license asset" } } }, "localname": "ExclusiveLicenseAssetMember", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "axnx_FiniteLivedIntangibleAssetsForeignExchangeAdjustment": { "auth_ref": [], "calculation": { "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 }, "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails_1": { "order": 3.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite-Lived Intangible Assets, Foreign Exchange Adjustment", "label": "Finite-Lived Intangible Assets, Foreign Exchange Adjustment", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "FiniteLivedIntangibleAssetsForeignExchangeAdjustment", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "axnx_FollowonOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Follow-on Offering [Member]", "label": "Follow-on Offering [Member]", "terseLabel": "Follow-on Offering" } } }, "localname": "FollowonOfferingMember", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "axnx_IncreaseDecreaseinLeaseLiabilities": { "auth_ref": [], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Lease Liabilities", "label": "Increase (Decrease) in Lease Liabilities", "terseLabel": "Lease liability" } } }, "localname": "IncreaseDecreaseinLeaseLiabilities", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "axnx_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationAdjustment": { "auth_ref": [], "calculation": { "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Indefinite-lived Intangible Assets, Foreign Currency Translation Adjustment", "label": "Indefinite-lived Intangible Assets, Foreign Currency Translation Adjustment", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationAdjustment", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "axnx_IndefiniteLivedIntangibleAssetsGross": { "auth_ref": [], "calculation": { "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Indefinite-lived Intangible Assets, Gross", "label": "Indefinite-lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "IndefiniteLivedIntangibleAssetsGross", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "axnx_InventoryShelfLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventory, Shelf Life", "label": "Inventory, Shelf Life", "terseLabel": "Inventory shelf life" } } }, "localname": "InventoryShelfLife", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "axnx_Lease1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease #1 [Member]", "label": "Lease 1 [Member]", "terseLabel": "First Lease" } } }, "localname": "Lease1Member", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "axnx_Lease2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease #2 [Member]", "label": "Lease 2 [Member]", "terseLabel": "Second Lease" } } }, "localname": "Lease2Member", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "axnx_Lease3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease 3 [Member]", "label": "Lease 3 [Member]", "terseLabel": "Third Lease" } } }, "localname": "Lease3Member", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "axnx_Lease4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease 4", "label": "Lease 4 [Member]", "terseLabel": "Fourth Lease" } } }, "localname": "Lease4Member", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "axnx_LiabilityMeasuredAtFairValueRecurringBasisRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liability Measured At Fair Value, Recurring Basis", "label": "Liability Measured At Fair Value, Recurring Basis [Roll Forward]", "terseLabel": "Contingent consideration:" } } }, "localname": "LiabilityMeasuredAtFairValueRecurringBasisRollForward", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinFairValueofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "axnx_LossContingencyNewClaimsFiledMinimumNumberOfPatentClaimsThatAreInvalid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, New Claims Filed, Minimum Number of Patent Claims that are Invalid", "label": "Loss Contingency, New Claims Filed, Minimum Number of Patent Claims that are Invalid", "terseLabel": "Minimum number of claims by Medtronic that are invalid as determined by the United States Patent and Trademark Office" } } }, "localname": "LossContingencyNewClaimsFiledMinimumNumberOfPatentClaimsThatAreInvalid", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "axnx_LossContingencyNewClaimsFiledNumberAcceptedByCourt": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, New Claims Filed, Number Accepted by Court", "label": "Loss Contingency, New Claims Filed, Number Accepted by Court", "terseLabel": "Number of petitions accepted by the United States Patent and Trademark Office" } } }, "localname": "LossContingencyNewClaimsFiledNumberAcceptedByCourt", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "axnx_MedtronicLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medtronic Litigation", "label": "Medtronic Litigation [Member]", "terseLabel": "Medtronic Litigation" } } }, "localname": "MedtronicLitigationMember", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "axnx_NoncashOrPartNoncashAcquisitionContingentConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash or Part Noncash Acquisition, Contingent Consideration", "label": "Noncash or Part Noncash Acquisition, Contingent Consideration", "terseLabel": "Contingent consideration for business acquisition" } } }, "localname": "NoncashOrPartNoncashAcquisitionContingentConsideration", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "axnx_OperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards, Subject To Expiration", "label": "Operating Loss Carryforwards, Subject To Expiration", "terseLabel": "Operating loss carryforwards, subject to expiration" } } }, "localname": "OperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/IncomeTaxesNarrativeDetails", "http://axonicsmodulation.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesandEffectiveTaxRatesDetails" ], "xbrltype": "monetaryItemType" }, "axnx_PercentageofNetRevenueDueAsRoyalty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of Net Revenue Due as Royalty", "label": "Percentage of Net Revenue Due As Royalty", "terseLabel": "Net revenue due as royalty (as a percent)" } } }, "localname": "PercentageofNetRevenueDueAsRoyalty", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "axnx_PeriodAfterFirstSaleRoyaltyIsDue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period After First Sale Royalty Is Due", "label": "Period After First Sale Royalty Is Due", "terseLabel": "Period after first sale royalty is due" } } }, "localname": "PeriodAfterFirstSaleRoyaltyIsDue", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "axnx_ReplacementOfDamagedOrDefectiveProductsCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Replacement of Damaged or Defective Products Cost", "label": "Replacement of Damaged or Defective Products Cost", "terseLabel": "Replacement costs" } } }, "localname": "ReplacementOfDamagedOrDefectiveProductsCost", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "axnx_SacralNeuromodulationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sacral Neuromodulation", "label": "Sacral Neuromodulation [Member]", "terseLabel": "SNM net revenue" } } }, "localname": "SacralNeuromodulationMember", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofRevenueDisaggregatedbyGeographicMarketDetails" ], "xbrltype": "domainItemType" }, "axnx_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Finite-Lived and Indefinite-Lived Intangible Assets", "label": "Schedule of Finite-Lived and Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived and Indefinite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "axnx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisesInPeriodCash": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Exercises In Period, Cash", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Exercises In Period, Cash", "terseLabel": "Issuance of common stock for employee stock option exercises for cash (in shares)" } } }, "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisesInPeriodCash", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "axnx_SharesIssuedRestrictedStockUnitsSharesShareBasedPaymentArrangementAfterForfeiture": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Issued, Restricted Stock Units, Shares, Share-based Payment Arrangement, after Forfeiture", "label": "Shares Issued, Restricted Stock Units, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock for vesting of Restricted Stock Units (RSU) and stock-based compensation (in shares)" } } }, "localname": "SharesIssuedRestrictedStockUnitsSharesShareBasedPaymentArrangementAfterForfeiture", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "axnx_StockIssuedDuringPeriodValueExclusiveLicenseAsset": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Exclusive License Asset", "label": "Stock Issued During Period, Value, Exclusive License Asset", "netLabel": "Common stock issuance for exclusive license asset" } } }, "localname": "StockIssuedDuringPeriodValueExclusiveLicenseAsset", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "axnx_StockIssuedDuringPeriodValueStockOptionsExercisedCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Stock Options Exercised, Cash", "label": "Stock Issued During Period, Value, Stock Options Exercised, Cash", "terseLabel": "Issuance of common stock for employee stock option exercises for cash" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedCash", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "axnx_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "axnx_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "axnx_TermLoanOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan One", "label": "Term Loan One [Member]", "terseLabel": "Term Loan One" } } }, "localname": "TermLoanOneMember", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "axnx_TermLoanTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan Two", "label": "Term Loan Two [Member]", "terseLabel": "Term Loan Two" } } }, "localname": "TermLoanTwoMember", "nsuri": "http://axonicsmodulation.com/20220331", "presentation": [ "http://axonicsmodulation.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofRevenueDisaggregatedbyGeographicMarketDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axonicsmodulation.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r254", "r286", "r332", "r334", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r515", "r518", "r539", "r540" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofOptionAwardsFairValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r254", "r286", "r332", "r334", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r515", "r518", "r539", "r540" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofOptionAwardsFairValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r165", "r303", "r304", "r480", "r514", "r516" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofRevenueDisaggregatedbyGeographicMarketDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r165", "r303", "r304", "r480", "r514", "r516" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofRevenueDisaggregatedbyGeographicMarketDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r254", "r286", "r312", "r332", "r334", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r515", "r518", "r539", "r540" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofOptionAwardsFairValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r254", "r286", "r312", "r332", "r334", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r515", "r518", "r539", "r540" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofOptionAwardsFairValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r166", "r167", "r303", "r305", "r517", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofRevenueDisaggregatedbyGeographicMarketDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r166", "r167", "r303", "r305", "r517", "r525", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofRevenueDisaggregatedbyGeographicMarketDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r38", "r467" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Schedule of Changes in Allowance for Credit Losses" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r19", "r169", "r170" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowance for credit losses of $316 and $355 at March\u00a031, 2022 and December\u00a031, 2021, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r8", "r9", "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalty expense" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r36", "r218" ], "calculation": { "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r22", "r51", "r52", "r53", "r503", "r523", "r524" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r50", "r53", "r60", "r61", "r62", "r108", "r109", "r110", "r416", "r519", "r520", "r548" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Finite-lived intangible assets, weighted-average amortization period" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r20", "r369", "r467" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r108", "r109", "r110", "r366", "r367", "r368", "r422" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition", "terseLabel": "Issuance of common stock for vesting of Restricted Stock Units (RSU) and stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Expense" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r374" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r337", "r362", "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r171", "r179", "r180", "r184" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r26", "r171", "r179" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": { "auth_ref": [ "r183" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.", "label": "Accounts Receivable, Allowance for Credit Loss, Recovery", "negatedLabel": "Bad debt recoveries" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r182" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "terseLabel": "Write-offs" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r70", "r89", "r274", "r448" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r89", "r201", "r211" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive weighted-average shares not included in computation of diluted weighted average shares (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r103", "r148", "r157", "r163", "r177", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r411", "r417", "r436", "r465", "r467", "r486", "r501" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r48", "r103", "r177", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r411", "r417", "r436", "r465", "r467" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r174", "r175", "r186", "r490" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "verboseLabel": "Outstanding investment securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r338", "r364" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://axonicsmodulation.com/role/StockbasedCompensationNarrativeDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r331", "r333" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r331", "r333", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r400" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Acquisition-related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r407", "r408", "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "terseLabel": "Contingent consideration at fair value" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinFairValueofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r94", "r95", "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Change in property and equipment acquired but not yet paid" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r33", "r91" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r92" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r85", "r91", "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of year", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r85", "r437" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock Disclosures [Abstract]", "terseLabel": "May 2021 Follow-On Offering:" } } }, "localname": "ClassOfStockDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r44", "r227", "r491", "r507" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 3)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r224", "r225", "r226", "r235", "r526" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r108", "r109", "r422" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in USD per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r287" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "terseLabel": "Common stock outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18", "r467" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $0.0001, 50,000,000 shares authorized at March\u00a031, 2022 and December\u00a031, 2021; 47,002,862 and 46,330,167 shares issued and outstanding at March\u00a031, 2022 and December\u00a031, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r55", "r57", "r58", "r66", "r494", "r509" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer hardware and software" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r98", "r413" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r72", "r480" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r101", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r268", "r275", "r276", "r278", "r284" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long-Term Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r102", "r106", "r251", "r252", "r253", "r254", "r255", "r256", "r258", "r264", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r280", "r281", "r282", "r283", "r449", "r487", "r488", "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r42", "r102", "r106", "r251", "r252", "r253", "r254", "r255", "r256", "r258", "r264", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r280", "r281", "r282", "r283", "r449" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r42", "r102", "r106", "r251", "r252", "r253", "r254", "r255", "r256", "r258", "r264", "r265", "r266", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r277", "r280", "r281", "r282", "r283", "r288", "r289", "r290", "r291", "r446", "r447", "r449", "r450", "r499" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "auth_ref": [ "r94", "r95", "r96" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.", "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction", "terseLabel": "Accrued loan fees as debt issuance costs" } } }, "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities [Abstract]", "terseLabel": "Investment Securities:" } } }, "localname": "DebtSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesUnrealizedGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Debt Securities, Unrealized Gain (Loss)", "terseLabel": "Unrealized gain (loss) on investment securities" } } }, "localname": "DebtSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r37", "r264", "r448" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r378", "r379" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities, net" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r330" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Contributions by employer" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/EmployeeBenefitPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r89", "r146" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows", "http://axonicsmodulation.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofRevenueDisaggregatedbyGeographicMarketDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofRevenueDisaggregatedbyGeographicMarketDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Revenue Disaggregated by Product and Geographic Market" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net Loss per Share of Common Stock:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r67", "r113", "r114", "r115", "r116", "r117", "r121", "r123", "r125", "r126", "r127", "r130", "r131", "r423", "r424", "r495", "r510" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic (in USD per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r67", "r113", "r114", "r115", "r116", "r117", "r123", "r125", "r126", "r127", "r130", "r131", "r423", "r424", "r495", "r510" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted (in USD per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r128", "r129" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Share of Common Stock" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r437" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesandEffectiveTaxRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r363" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost related to unvested RSAs or RSUs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period of recognition of compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r363" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost related to unvested stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r60", "r61", "r62", "r108", "r109", "r110", "r112", "r118", "r120", "r133", "r178", "r287", "r292", "r366", "r367", "r368", "r391", "r392", "r422", "r438", "r439", "r440", "r441", "r442", "r443", "r519", "r520", "r521", "r548" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinFairValueofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r425", "r426", "r427", "r432" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinFairValueofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r425", "r432" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r266", "r280", "r281", "r313", "r315", "r316", "r317", "r318", "r319", "r320", "r327", "r426", "r468", "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinFairValueofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r431", "r432" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinFairValueofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r425", "r426", "r428", "r429", "r433" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinFairValueofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r266", "r280", "r281", "r313", "r315", "r316", "r317", "r318", "r319", "r320", "r327", "r426", "r470" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinFairValueofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Changes in Fair Value of Liabilities Measured on Recurring Basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinFairValueofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinFairValueofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r266", "r280", "r281", "r313", "r315", "r316", "r317", "r318", "r319", "r320", "r327", "r468", "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinFairValueofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r431", "r433" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofChangesinFairValueofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Weighted-Average Amortization Period" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r210" ], "calculation": { "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 }, "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails_1": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r202", "r206", "r210", "r213", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r210", "r482" ], "calculation": { "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r202", "r209" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r210", "r481" ], "calculation": { "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Intangible Assets, Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Intangible Asset:", "verboseLabel": "Finite-Lived Intangible Assets, Net:" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Finite-lived intangible asset acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r74" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r192", "r194", "r467", "r485" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets", "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r196" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill, Impaired [Abstract]", "terseLabel": "Goodwill:" } } }, "localname": "GoodwillImpairedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r89", "r193", "r195", "r198" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Impairment charges related to goodwill" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r71", "r103", "r148", "r156", "r159", "r162", "r164", "r177", "r240", "r241", "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r436" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r89", "r214" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairment of finite-lived intangible asset" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r216", "r221" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r64", "r148", "r156", "r159", "r162", "r164", "r484", "r492", "r497", "r512" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income tax benefit" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r220", "r223" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r104", "r382", "r384", "r387", "r393", "r395", "r397", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r105", "r119", "r120", "r147", "r380", "r394", "r396", "r513" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax benefit", "verboseLabel": "Income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://axonicsmodulation.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesandEffectiveTaxRatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r59", "r376", "r377", "r384", "r385", "r386", "r390" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r88" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r88" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r88" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r88" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r88" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities, net of business acquisition" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r88" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r88" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r205", "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r212" ], "calculation": { "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "totalLabel": "Intangible Assets, Net" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]", "terseLabel": "Indefinite-lived Intangible Assets:" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r205", "r212" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails_1": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Gross Carrying Amount" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r200", "r208" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Intangible Assets, Net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets", "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]", "terseLabel": "Intangible Assets, Net (Excluding Goodwill):" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r63", "r145", "r445", "r448", "r496" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r83", "r86", "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r28", "r190" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods inventory" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r46", "r467" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventory:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r10", "r47", "r99", "r132", "r187", "r188", "r191", "r478" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory, Net" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r30", "r190" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials inventory" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r46", "r189" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Inventory reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r29", "r190" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process inventory" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNonoperating": { "auth_ref": [ "r75" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.", "label": "Investment Income, Nonoperating", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r176", "r511" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investment Securities" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r463", "r464" ], "calculation": { "http://axonicsmodulation.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Total Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term of operating lease" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of operating lease contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r39", "r103", "r158", "r177", "r240", "r241", "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r412", "r417", "r418", "r436", "r465", "r466" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r103", "r177", "r436", "r467", "r489", "r505" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r41", "r103", "r177", "r240", "r241", "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r412", "r417", "r418", "r436", "r465", "r466", "r467" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowing supported by a written promise to pay an obligation.", "label": "Loans Payable [Member]", "terseLabel": "Term Loans" } } }, "localname": "LoansPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r16", "r265", "r279", "r280", "r281", "r488", "r502" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Outstanding borrowings" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r42", "r239" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r227", "r228", "r229", "r231", "r232", "r233", "r234", "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Number of petitions filed with the United States Patent and Trademark Office" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MarketingAndAdvertisingExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Marketing and Advertising Expense [Abstract]", "terseLabel": "Advertising Expense:" } } }, "localname": "MarketingAndAdvertisingExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r85", "r87", "r90" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r54", "r56", "r62", "r65", "r90", "r103", "r111", "r113", "r114", "r115", "r116", "r119", "r120", "r124", "r148", "r156", "r159", "r162", "r164", "r177", "r240", "r241", "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r424", "r436", "r493", "r508" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetRentableArea": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net rentable area for properties owned.", "label": "Net Rentable Area", "terseLabel": "Net rentable area (square feet)" } } }, "localname": "NetRentableArea", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "areaItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International markets" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofRevenueDisaggregatedbyGeographicMarketDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Noncash Investing and Financing Activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r148", "r156", "r159", "r162", "r164" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r456", "r464" ], "calculation": { "http://axonicsmodulation.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r452" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r452" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r453", "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r451" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Amortization of the ROU asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r462", "r464" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average incremental borrowing rate for a collateralized asset of the same remaining term (as a percent)" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r461", "r464" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease terms for operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r388" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r2", "r107", "r141", "r421" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Nature of Operations and Summary of Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r49" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment", "verboseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r76" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Interest and other expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Exercise of Underwriters Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patent license asset" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r82" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r77" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Acquisition of a business, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r78" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r312", "r314", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r335" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Employee Benefit Plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/EmployeeBenefitPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r17", "r285" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in USD per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r17", "r285" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r17", "r467" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized, no shares issued and outstanding at March\u00a031, 2022 and December\u00a031, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r31", "r32" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r80" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r79", "r365" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r54", "r56", "r62", "r84", "r103", "r111", "r119", "r120", "r148", "r156", "r159", "r162", "r164", "r177", "r240", "r241", "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r410", "r414", "r415", "r419", "r420", "r424", "r436", "r497" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property and Equipment:" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r36", "r219" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails", "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r222", "r527", "r528", "r529" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/PropertyandEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r35", "r217" ], "calculation": { "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "verboseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/PropertyandEquipmentNarrativeDetails", "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r219", "r467", "r498", "r506" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets", "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r34", "r219", "r527", "r528" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r219" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r217" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails", "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property and equipment useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r69", "r181" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Reversal of allowance of credit losses" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r27", "r172" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "terseLabel": "Allowance for Credit Losses" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r81" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedTerseLabel": "Repayment of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r375", "r479", "r541" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Shares Awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationNarrativeDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://axonicsmodulation.com/role/StockbasedCompensationNarrativeDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r21", "r292", "r369", "r467", "r504", "r522", "r524" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r108", "r109", "r110", "r112", "r118", "r120", "r178", "r366", "r367", "r368", "r391", "r392", "r422", "r519", "r521" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r143", "r144", "r155", "r160", "r161", "r165", "r166", "r168", "r302", "r303", "r480" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net revenue", "verboseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails", "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesScheduleofRevenueDisaggregatedbyGeographicMarketDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r100", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r311" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition [Abstract]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r460", "r464" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyGuaranteesCommitmentsAmount": { "auth_ref": [ "r483" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount the entity has committed to make for future royalty guarantees.", "label": "Royalty Guarantees, Commitments, Amount", "terseLabel": "Royalty commitments" } } }, "localname": "RoyaltyGuaranteesCommitmentsAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds from sale of stock" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Stock issued (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "verboseLabel": "Sale of stock, price per share (in USD per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Provision for Income Taxes and Effective Tax Rates" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r337", "r361", "r371" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r202", "r209", "r481" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r197", "r199" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Carrying Amount of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.", "label": "Share-based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]", "terseLabel": "Schedule of Restricted Shares Awards Activity" } } }, "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r36", "r219" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/PropertyandEquipmentNarrativeDetails", "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r347", "r352", "r355" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Activity [Table Text Block]", "terseLabel": "Schedule of Restricted Stock Units Activity" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r338", "r364" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationNarrativeDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofOptionAwardsFairValuationAssumptionsDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r342", "r352", "r355" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Option Awards Fair Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r149", "r150", "r151", "r152", "r153", "r154", "r166" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r88" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]", "terseLabel": "Stock-Based Compensation:" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Requisite service period of recognition of compensation cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding at end of period (in USD per share)", "periodStartLabel": "Outstanding at beginning of period (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Fair Value Per Share at Grant Date", "verboseLabel": "Weighted-Average Fair Value Per Share at Grant Date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend rate (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofOptionAwardsFairValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Stock volatility, maximum (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofOptionAwardsFairValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Stock volatility, minimum (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofOptionAwardsFairValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofOptionAwardsFairValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofOptionAwardsFairValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationNarrativeDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofOptionAwardsFairValuationAssumptionsDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "terseLabel": "Number of Restricted Shares Awards", "verboseLabel": "Number of Restricted Stock Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r354" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Options forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value of options granted (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Intrinsic value of options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r344", "r364" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period (in USD per share)", "periodStartLabel": "Outstanding at beginning of period (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r336", "r340" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://axonicsmodulation.com/role/StockbasedCompensationNarrativeDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedSharesAwardsActivityDetails", "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofRestrictedStockUnitsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options exercised (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Options forfeited (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r338", "r341" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r358", "r370" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofOptionAwardsFairValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual term of options outstanding and exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r293", "r372" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders' Equity and Share-based Payments [Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r457", "r464" ], "calculation": { "http://axonicsmodulation.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrual": { "auth_ref": [ "r238" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.", "label": "Standard Product Warranty Accrual", "terseLabel": "Warranty liability" } } }, "localname": "StandardProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r45", "r60", "r61", "r62", "r108", "r109", "r110", "r112", "r118", "r120", "r133", "r178", "r287", "r292", "r366", "r367", "r368", "r391", "r392", "r422", "r438", "r439", "r440", "r441", "r442", "r443", "r519", "r520", "r521", "r548" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r108", "r109", "r110", "r133", "r480" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r17", "r18", "r292" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance of common stock for acquisition of Contura Limited (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Issuance of common stock for exclusive license asset (in shares)", "verboseLabel": "Stock issued for purchase of intangible asset (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r17", "r18", "r287", "r292" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Restricted Shares Award (RSA) issuances and forfeitures for terminations, net and stock-based compensation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r287", "r292", "r345" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Options exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r45", "r287", "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance of common stock for acquisition of Contura Limited", "verboseLabel": "Common stock issuance for business acquisition" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows", "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Value, Purchase of Assets", "terseLabel": "Issuance of common stock for exclusive license asset", "verboseLabel": "Fair value of shares issued for purchase of intangible asset" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r23", "r24", "r103", "r173", "r177", "r436", "r467" ], "calculation": { "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets", "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental Disclosure of Cash Flow Information" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ToolsDiesAndMoldsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used to cut, shape, and form metal and other materials into goods for sale.", "label": "Tools, Dies and Molds [Member]", "terseLabel": "Tools and molds" } } }, "localname": "ToolsDiesAndMoldsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Trade names and trademarks" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/GoodwillandIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r134", "r135", "r136", "r137", "r138", "r139", "r140" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/NatureofOperationsandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r458", "r464" ], "calculation": { "http://axonicsmodulation.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CommitmentsandContingenciesNarrativeDetails", "http://axonicsmodulation.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r122", "r127" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares used to compute diluted net loss per share (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r121", "r127" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares used to compute basic net loss per share (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://axonicsmodulation.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1),(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r284": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r293": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r335": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r372": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r399": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r421": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r444": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r542": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r543": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r544": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r545": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r546": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r547": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" } }, "version": "2.1" } ZIP 60 0001603756-22-000031-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001603756-22-000031-xbrl.zip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
    IWF<;^PIU,I[&@0M=O_KGG1\[-4Y1;[:

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

    (%>(_O5V59A:8^?>1\I?"!1P8SP31FJ5T6Q M$J_YXO4M^TV-,3YRS9 OQ$M)@HQS#%G-M0D,5GZP*^MR;4ZDRT,SYQZ82UU- M^F(F?>O+GK5)4*TU$IE;BQL*D^ZI1<1X3PQ36&&ZLJ[N@2E9/9Q65RZ!HMG/ M3K4R^"6[)IJ=N<8[O B-?)(C#V6I)95>O5D=*"N\%\^%9U[<V63I#RV"B_I76WZCM MW3,_>>':WM6U]K<]*^+ JD4V?Y$=G< B\S99%:)!AI%,;<6+-!B&L&+2XQ0Q MRP7";DQ(?7&EKIKVNT][8W/C'#941EE*AB;$"):(2Z>040$CJ1/,@0-KTOF; MIWU&7YOD,A@Y2B^Q%:#A_GK7$^/#U%X\V8$/Y6%*)4+7B)#(G+\X*%"/.&+1 M1<1Y"*"3"8\HX6 M8/UD:V//IQ0(8;"I%_0)7'KDB%1($*5C])S)'%LBUM3,L6YQV%L(THT']?

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end